US20230286928A1 - Heterocyclic compounds useful in the treatment of disease - Google Patents
Heterocyclic compounds useful in the treatment of disease Download PDFInfo
- Publication number
- US20230286928A1 US20230286928A1 US18/015,289 US201918015289A US2023286928A1 US 20230286928 A1 US20230286928 A1 US 20230286928A1 US 201918015289 A US201918015289 A US 201918015289A US 2023286928 A1 US2023286928 A1 US 2023286928A1
- Authority
- US
- United States
- Prior art keywords
- pyrazol
- biphenyl
- fluoro
- carbamate
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 60
- 201000010099 disease Diseases 0.000 title claims abstract description 54
- 238000011282 treatment Methods 0.000 title abstract description 6
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract description 3
- 230000001419 dependent effect Effects 0.000 claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims description 247
- 238000000034 method Methods 0.000 claims description 123
- 125000004432 carbon atom Chemical group C* 0.000 claims description 87
- 229910052799 carbon Inorganic materials 0.000 claims description 78
- 125000001424 substituent group Chemical group 0.000 claims description 68
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 claims description 52
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 52
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 39
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 26
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 24
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 23
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 21
- 229910052731 fluorine Inorganic materials 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 16
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 11
- TVXMDWFZWXPQEJ-QGZVFWFLSA-N [(1R)-1-(2-chlorophenyl)ethyl] N-[2-[4-[4-(1-carbamoylcyclopropyl)phenyl]phenyl]-4-fluoropyrazol-3-yl]carbamate Chemical compound C(N)(=O)C1(CC1)C1=CC=C(C=C1)C1=CC=C(C=C1)N1N=CC(=C1NC(O[C@H](C)C1=C(C=CC=C1)Cl)=O)F TVXMDWFZWXPQEJ-QGZVFWFLSA-N 0.000 claims description 10
- QUCZGUDNUFQGRB-QGZVFWFLSA-N [(1R)-1-(2-chlorophenyl)ethyl] N-[2-[4-[4-[1-(cyanocarbamoyl)cyclopropyl]-2-fluorophenyl]phenyl]-4-fluoropyrazol-3-yl]carbamate Chemical compound C(#N)NC(=O)C1(CC1)C1=CC(=C(C=C1)C1=CC=C(C=C1)N1N=CC(=C1NC(O[C@H](C)C1=C(C=CC=C1)Cl)=O)F)F QUCZGUDNUFQGRB-QGZVFWFLSA-N 0.000 claims description 10
- LBWOSLZHUXSUQV-QGZVFWFLSA-N [(1R)-1-(2-chlorophenyl)ethyl] N-[4-chloro-2-[4-[4-[1-(2H-tetrazol-5-yl)cyclopropyl]phenyl]phenyl]pyrazol-3-yl]carbamate Chemical compound N1N=NN=C1C1(CC1)C1=CC=C(C=C1)C1=CC=C(C=C1)N1N=CC(=C1NC(O[C@H](C)C1=C(C=CC=C1)Cl)=O)Cl LBWOSLZHUXSUQV-QGZVFWFLSA-N 0.000 claims description 10
- IENGWLNJRSJGCH-QGZVFWFLSA-N [(1R)-1-(2-chlorophenyl)ethyl] N-[4-fluoro-2-[4-[4-[1-(2H-tetrazol-5-yl)cyclopropyl]phenyl]phenyl]pyrazol-3-yl]carbamate Chemical compound N1N=NN=C1C1(CC1)C1=CC=C(C=C1)C1=CC=C(C=C1)N1N=CC(=C1NC(O[C@H](C)C1=C(C=CC=C1)Cl)=O)F IENGWLNJRSJGCH-QGZVFWFLSA-N 0.000 claims description 10
- ZPHJHGIDTNNEBZ-GOSISDBHSA-N [(1R)-1-phenylethyl] N-[4-chloro-2-[4-[4-[1-(2H-tetrazol-5-yl)cyclopropyl]phenyl]phenyl]pyrazol-3-yl]carbamate Chemical compound N1N=NN=C1C1(CC1)C1=CC=C(C=C1)C1=CC=C(C=C1)N1N=CC(=C1NC(O[C@H](C)C1=CC=CC=C1)=O)Cl ZPHJHGIDTNNEBZ-GOSISDBHSA-N 0.000 claims description 10
- LMSCJYHFCZUSNG-LJQANCHMSA-N [(1R)-1-phenylethyl] N-[4-chloro-2-[4-[4-[1-(methylsulfonylcarbamoyl)cyclopropyl]phenyl]phenyl]pyrazol-3-yl]carbamate Chemical compound C[C@H](C1=CC=CC=C1)OC(=O)NC2=C(C=NN2C3=CC=C(C=C3)C4=CC=C(C=C4)C5(CC5)C(=O)NS(=O)(=O)C)Cl LMSCJYHFCZUSNG-LJQANCHMSA-N 0.000 claims description 10
- YUSQLVXSBDXTTE-QGZVFWFLSA-N [(1R)-1-(2-chlorophenyl)ethyl] N-[4-chloro-2-[4-[2-fluoro-4-[1-(methylsulfonylcarbamoyl)cyclopropyl]phenyl]phenyl]pyrazol-3-yl]carbamate Chemical compound ClC=1C=NN(C=1NC(O[C@H](C)C1=C(C=CC=C1)Cl)=O)C1=CC=C(C=C1)C1=C(C=C(C=C1)C1(CC1)C(NS(=O)(=O)C)=O)F YUSQLVXSBDXTTE-QGZVFWFLSA-N 0.000 claims description 9
- VWOYOAMZHQUJGA-GOSISDBHSA-N [(1R)-1-(2-chlorophenyl)ethyl] N-[4-chloro-2-[4-[4-[1-(cyanocarbamoyl)cyclopropyl]phenyl]phenyl]pyrazol-3-yl]carbamate Chemical compound ClC=1C=NN(C=1NC(O[C@H](C)C1=C(C=CC=C1)Cl)=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C1(CC1)C(NC#N)=O VWOYOAMZHQUJGA-GOSISDBHSA-N 0.000 claims description 9
- NVCRVUNLHMUTRJ-QGZVFWFLSA-N [(1R)-1-(2-chlorophenyl)ethyl] N-[4-fluoro-2-[4-[2-fluoro-4-[1-(methylsulfonylcarbamoyl)cyclopropyl]phenyl]phenyl]pyrazol-3-yl]carbamate Chemical compound FC=1C=NN(C=1NC(O[C@H](C)C1=C(C=CC=C1)Cl)=O)C1=CC=C(C=C1)C1=C(C=C(C=C1)C1(CC1)C(NS(=O)(=O)C)=O)F NVCRVUNLHMUTRJ-QGZVFWFLSA-N 0.000 claims description 9
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 8
- OOYCWKBRJWALRS-GOSISDBHSA-N [(1R)-1-(2-chlorophenyl)ethyl] N-[4-fluoro-2-[4-[4-[1-(methylsulfonylcarbamoyl)cyclopropyl]phenyl]phenyl]pyrazol-3-yl]carbamate Chemical compound FC=1C=NN(C=1NC(O[C@H](C)C1=C(C=CC=C1)Cl)=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C1(CC1)C(NS(=O)(=O)C)=O OOYCWKBRJWALRS-GOSISDBHSA-N 0.000 claims description 8
- APHAOHJRFJHEBP-GOSISDBHSA-N [(1R)-1-phenylethyl] N-[4-fluoro-2-[4-[2-fluoro-4-[1-(methylsulfonylcarbamoyl)cyclopropyl]phenyl]phenyl]pyrazol-3-yl]carbamate Chemical compound FC=1C=NN(C=1NC(O[C@H](C)C1=CC=CC=C1)=O)C1=CC=C(C=C1)C1=C(C=C(C=C1)C1(CC1)C(NS(=O)(=O)C)=O)F APHAOHJRFJHEBP-GOSISDBHSA-N 0.000 claims description 8
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 8
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 8
- BHFSRHOQDDYYKO-LJQANCHMSA-N [(1R)-1-phenylethyl] N-[4-chloro-2-[4-[4-[1-(cyanocarbamoyl)cyclopropyl]phenyl]phenyl]pyrazol-3-yl]carbamate Chemical compound ClC=1C=NN(C=1NC(O[C@H](C)C1=CC=CC=C1)=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C1(CC1)C(NC#N)=O BHFSRHOQDDYYKO-LJQANCHMSA-N 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 229910006069 SO3H Inorganic materials 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 abstract description 13
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 abstract description 13
- 239000003446 ligand Substances 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 252
- 239000000203 mixture Substances 0.000 description 211
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 120
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 96
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 91
- -1 1-propyl (n-propyl) Chemical group 0.000 description 87
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 86
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 81
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 74
- 239000000047 product Substances 0.000 description 65
- 238000006243 chemical reaction Methods 0.000 description 57
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 56
- 239000012044 organic layer Substances 0.000 description 53
- 125000000217 alkyl group Chemical group 0.000 description 50
- 239000011541 reaction mixture Substances 0.000 description 50
- 239000007787 solid Substances 0.000 description 47
- 125000003118 aryl group Chemical group 0.000 description 43
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 43
- 239000000243 solution Substances 0.000 description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 42
- 239000007864 aqueous solution Substances 0.000 description 41
- 239000012267 brine Substances 0.000 description 41
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 41
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 37
- 238000003756 stirring Methods 0.000 description 37
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- 238000012746 preparative thin layer chromatography Methods 0.000 description 32
- 125000001072 heteroaryl group Chemical group 0.000 description 30
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 29
- 125000000623 heterocyclic group Chemical group 0.000 description 29
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 28
- 125000000753 cycloalkyl group Chemical group 0.000 description 28
- 125000004093 cyano group Chemical group *C#N 0.000 description 27
- 229910000029 sodium carbonate Inorganic materials 0.000 description 27
- 238000009472 formulation Methods 0.000 description 26
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 26
- 125000004122 cyclic group Chemical group 0.000 description 25
- 125000004429 atom Chemical group 0.000 description 22
- 239000012043 crude product Substances 0.000 description 22
- 230000001404 mediated effect Effects 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 102100040607 Lysophosphatidic acid receptor 1 Human genes 0.000 description 20
- 125000005842 heteroatom Chemical group 0.000 description 20
- 238000003556 assay Methods 0.000 description 19
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 19
- 229910052760 oxygen Inorganic materials 0.000 description 19
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 18
- 101710149745 Lysophosphatidic acid receptor 1 Proteins 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 125000003342 alkenyl group Chemical group 0.000 description 18
- 229910052796 boron Inorganic materials 0.000 description 18
- 238000010898 silica gel chromatography Methods 0.000 description 16
- 229910052717 sulfur Inorganic materials 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 15
- 125000000547 substituted alkyl group Chemical group 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 14
- 125000000304 alkynyl group Chemical group 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- 229960001866 silicon dioxide Drugs 0.000 description 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 12
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 12
- 125000004474 heteroalkylene group Chemical group 0.000 description 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 12
- 238000004809 thin layer chromatography Methods 0.000 description 12
- 150000002148 esters Chemical class 0.000 description 11
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 239000000556 agonist Substances 0.000 description 10
- 239000005557 antagonist Substances 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 230000009870 specific binding Effects 0.000 description 10
- 239000003039 volatile agent Substances 0.000 description 10
- NLVIETRETNMBPT-GOSISDBHSA-N 1-[4-[4-[4-chloro-5-[[(1R)-1-phenylethoxy]carbonylamino]pyrazol-1-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound ClC=1C=NN(C=1NC(=O)O[C@H](C)C1=CC=CC=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1(CC1)C(=O)O NLVIETRETNMBPT-GOSISDBHSA-N 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- 125000002877 alkyl aryl group Chemical group 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 9
- JXKNHWYELIAHTI-LJQANCHMSA-N 1-[4-[4-[4-cyano-5-[[(1R)-1-phenylethoxy]carbonylamino]pyrazol-1-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound C(#N)C=1C=NN(C=1NC(=O)O[C@H](C)C1=CC=CC=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1(CC1)C(=O)O JXKNHWYELIAHTI-LJQANCHMSA-N 0.000 description 8
- FRRRMPQEWNBTPL-GOSISDBHSA-N 1-[4-[4-[4-fluoro-5-[[(1R)-1-phenylethoxy]carbonylamino]pyrazol-1-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound FC=1C=NN(C=1NC(=O)O[C@H](C)C1=CC=CC=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1(CC1)C(=O)O FRRRMPQEWNBTPL-GOSISDBHSA-N 0.000 description 8
- XWGZRDGRUQXHLE-GOSISDBHSA-N 1-[4-[4-[5-[[(1R)-1-(2-chlorophenyl)ethoxy]carbonylamino]-4-cyanopyrazol-1-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound ClC1=C(C=CC=C1)[C@@H](C)OC(=O)NC1=C(C=NN1C1=CC=C(C=C1)C1=CC=C(C=C1)C1(CC1)C(=O)O)C#N XWGZRDGRUQXHLE-GOSISDBHSA-N 0.000 description 8
- XDMDPYZKKFPYAC-MRXNPFEDSA-N 1-[4-[5-[4-chloro-5-[[(1R)-1-(2-chlorophenyl)ethoxy]carbonylamino]pyrazol-1-yl]pyridin-2-yl]phenyl]cyclopropane-1-carboxylic acid Chemical compound ClC=1C=NN(C=1NC(=O)O[C@H](C)C1=C(C=CC=C1)Cl)C=1C=CC(=NC=1)C1=CC=C(C=C1)C1(CC1)C(=O)O XDMDPYZKKFPYAC-MRXNPFEDSA-N 0.000 description 8
- ZDIJGIHMESWCFF-MRXNPFEDSA-N 1-[4-[5-[5-[[(1R)-1-(2-chlorophenyl)ethoxy]carbonylamino]-4-fluoropyrazol-1-yl]pyridin-2-yl]phenyl]cyclopropane-1-carboxylic acid Chemical compound ClC1=C(C=CC=C1)[C@@H](C)OC(=O)NC1=C(C=NN1C=1C=CC(=NC=1)C1=CC=C(C=C1)C1(CC1)C(=O)O)F ZDIJGIHMESWCFF-MRXNPFEDSA-N 0.000 description 8
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 8
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- LBHLUAHUCJUGBO-GFCCVEGCSA-N [(1R)-1-phenylethyl] N-[2-(4-bromophenyl)-4-chloropyrazol-3-yl]carbamate Chemical compound C1(=CC=CC=C1)[C@@H](C)OC(=O)NC=1N(N=CC=1Cl)C1=CC=C(C=C1)Br LBHLUAHUCJUGBO-GFCCVEGCSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 description 8
- 125000004430 oxygen atom Chemical group O* 0.000 description 8
- 229910052698 phosphorus Inorganic materials 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 7
- BZMSFKQBZWTPIF-QGZVFWFLSA-N 1-[2-fluoro-4-[4-[4-fluoro-5-[[(1R)-1-phenylethoxy]carbonylamino]pyrazol-1-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound FC=1C=C(C=CC=1C1(CC1)C(=O)O)C1=CC=C(C=C1)N1N=CC(=C1NC(=O)O[C@H](C)C1=CC=CC=C1)F BZMSFKQBZWTPIF-QGZVFWFLSA-N 0.000 description 7
- GQABVSVOJJRXED-QGZVFWFLSA-N 1-[3-chloro-4-[4-[4-chloro-5-[[(1R)-1-phenylethoxy]carbonylamino]pyrazol-1-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound ClC1=C(C=CC(=C1)C1(CC1)C(=O)O)C1=CC=C(C=C1)N1N=CC(=C1NC(=O)O[C@H](C)C1=CC=CC=C1)Cl GQABVSVOJJRXED-QGZVFWFLSA-N 0.000 description 7
- DLIQMGMHZXADTM-QGZVFWFLSA-N 1-[3-chloro-4-[4-[4-fluoro-5-[[(1R)-1-phenylethoxy]carbonylamino]pyrazol-1-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound ClC1=C(C=CC(=C1)C1(CC1)C(=O)O)C1=CC=C(C=C1)N1N=CC(=C1NC(=O)O[C@H](C)C1=CC=CC=C1)F DLIQMGMHZXADTM-QGZVFWFLSA-N 0.000 description 7
- BYBREJDTMCSPBO-QGZVFWFLSA-N 1-[4-[4-[4-chloro-5-[[(1R)-1-phenylethoxy]carbonylamino]pyrazol-1-yl]phenyl]-2-fluorophenyl]cyclopropane-1-carboxylic acid Chemical compound ClC=1C=NN(C=1NC(=O)O[C@H](C)C1=CC=CC=C1)C1=CC=C(C=C1)C1=CC(=C(C=C1)C1(CC1)C(=O)O)F BYBREJDTMCSPBO-QGZVFWFLSA-N 0.000 description 7
- KGMFHQGWBBOGMX-LJQANCHMSA-N 1-[4-[4-[4-chloro-5-[[(1R)-1-phenylethoxy]carbonylamino]pyrazol-1-yl]phenyl]-3-methylphenyl]cyclopropane-1-carboxylic acid Chemical compound ClC=1C=NN(C=1NC(=O)O[C@H](C)C1=CC=CC=C1)C1=CC=C(C=C1)C1=C(C=C(C=C1)C1(CC1)C(=O)O)C KGMFHQGWBBOGMX-LJQANCHMSA-N 0.000 description 7
- MFFBTZGSWIPPND-LJQANCHMSA-N 1-[4-[4-[4-fluoro-5-[[(1R)-1-phenylethoxy]carbonylamino]pyrazol-1-yl]phenyl]-3-methylphenyl]cyclopropane-1-carboxylic acid Chemical compound FC=1C=NN(C=1NC(=O)O[C@H](C)C1=CC=CC=C1)C1=CC=C(C=C1)C1=C(C=C(C=C1)C1(CC1)C(=O)O)C MFFBTZGSWIPPND-LJQANCHMSA-N 0.000 description 7
- ZKHHWRLUSUNAFZ-LJQANCHMSA-N 2-[4-[4-[4-cyano-5-[[(1R)-1-phenylethoxy]carbonylamino]pyrazol-1-yl]phenyl]phenyl]-2-methylpropanoic acid Chemical compound C(#N)C=1C=NN(C=1NC(=O)O[C@H](C)C1=CC=CC=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(C(=O)O)(C)C ZKHHWRLUSUNAFZ-LJQANCHMSA-N 0.000 description 7
- PAGVJHPXUMIFBP-GOSISDBHSA-N 2-[4-[4-[5-[[(1R)-1-(2-chlorophenyl)ethoxy]carbonylamino]-4-cyanopyrazol-1-yl]phenyl]phenyl]-2-methylpropanoic acid Chemical compound ClC1=C(C=CC=C1)[C@@H](C)OC(=O)NC1=C(C=NN1C1=CC=C(C=C1)C1=CC=C(C=C1)C(C(=O)O)(C)C)C#N PAGVJHPXUMIFBP-GOSISDBHSA-N 0.000 description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- FPZNNGCDDJSEDO-GFCCVEGCSA-N [(1R)-1-phenylethyl] N-[2-(4-bromophenyl)-4-fluoropyrazol-3-yl]carbamate Chemical compound C1(=CC=CC=C1)[C@@H](C)OC(=O)NC=1N(N=CC=1F)C1=CC=C(C=C1)Br FPZNNGCDDJSEDO-GFCCVEGCSA-N 0.000 description 7
- LHAOZXSEFJNHOF-LLVKDONJSA-N [(1r)-1-(2-chlorophenyl)ethyl] n-[2-(4-bromophenyl)-4-fluoropyrazol-3-yl]carbamate Chemical compound O([C@H](C)C=1C(=CC=CC=1)Cl)C(=O)NC1=C(F)C=NN1C1=CC=C(Br)C=C1 LHAOZXSEFJNHOF-LLVKDONJSA-N 0.000 description 7
- 125000003710 aryl alkyl group Chemical group 0.000 description 7
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 7
- 208000017169 kidney disease Diseases 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- XQQDYMOXTLWTIM-UHFFFAOYSA-N methyl 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropane-1-carboxylate Chemical compound C=1C=C(B2OC(C)(C)C(C)(C)O2)C=CC=1C1(C(=O)OC)CC1 XQQDYMOXTLWTIM-UHFFFAOYSA-N 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000011593 sulfur Substances 0.000 description 7
- FIEYNBQUIDBZII-QGZVFWFLSA-N 1-[3-fluoro-4-[4-[4-fluoro-5-[[(1R)-1-phenylethoxy]carbonylamino]pyrazol-1-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound FC1=C(C=CC(=C1)C1(CC1)C(=O)O)C1=CC=C(C=C1)N1N=CC(=C1NC(=O)O[C@H](C)C1=CC=CC=C1)F FIEYNBQUIDBZII-QGZVFWFLSA-N 0.000 description 6
- PSRAUDUUUYAQQW-QGZVFWFLSA-N 1-[4-[4-[4-chloro-5-[[(1R)-1-phenylethoxy]carbonylamino]pyrazol-1-yl]phenyl]-3-fluorophenyl]cyclopropane-1-carboxylic acid Chemical compound ClC=1C=NN(C=1NC(=O)O[C@H](C)C1=CC=CC=C1)C1=CC=C(C=C1)C1=C(C=C(C=C1)C1(CC1)C(=O)O)F PSRAUDUUUYAQQW-QGZVFWFLSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 6
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 206010038934 Retinopathy proliferative Diseases 0.000 description 6
- 206010064930 age-related macular degeneration Diseases 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 208000019425 cirrhosis of liver Diseases 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 208000002780 macular degeneration Diseases 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 6
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 6
- 239000012363 selectfluor Substances 0.000 description 6
- 229910052710 silicon Inorganic materials 0.000 description 6
- 210000001635 urinary tract Anatomy 0.000 description 6
- YMJLEPMVGQBLHL-UHFFFAOYSA-N 1h-pyrazole-5-carbonitrile Chemical compound N#CC1=CC=NN1 YMJLEPMVGQBLHL-UHFFFAOYSA-N 0.000 description 5
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 5
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000004404 heteroalkyl group Chemical group 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 125000004076 pyridyl group Chemical group 0.000 description 5
- 125000000168 pyrrolyl group Chemical group 0.000 description 5
- 241000894007 species Species 0.000 description 5
- DDUBOVLGCYUYFX-ZCFIWIBFSA-N (1r)-1-(2-chlorophenyl)ethanol Chemical compound C[C@@H](O)C1=CC=CC=C1Cl DDUBOVLGCYUYFX-ZCFIWIBFSA-N 0.000 description 4
- WMPADIXAISNDLG-UHFFFAOYSA-N 1-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-N-methylsulfonylcyclopropane-1-carboxamide Chemical compound FC=1C=C(C=CC=1B1OC(C(O1)(C)C)(C)C)C1(CC1)C(=O)NS(=O)(=O)C WMPADIXAISNDLG-UHFFFAOYSA-N 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 4
- MTOFZIVSDKZBLH-LLVKDONJSA-N [(1R)-1-(2-chlorophenyl)ethyl] N-[2-(4-bromophenyl)-4-chloropyrazol-3-yl]carbamate Chemical compound ClC1=C(C=CC=C1)[C@@H](C)OC(=O)NC=1N(N=CC=1Cl)C1=CC=C(C=C1)Br MTOFZIVSDKZBLH-LLVKDONJSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 150000001241 acetals Chemical class 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000003185 calcium uptake Effects 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 229960001265 ciclosporin Drugs 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- HVCKDQIAOZNULM-UHFFFAOYSA-N ethyl 2-(4-bromophenyl)pyrazole-3-carboxylate Chemical compound CCOC(=O)C1=CC=NN1C1=CC=C(Br)C=C1 HVCKDQIAOZNULM-UHFFFAOYSA-N 0.000 description 4
- 239000003172 expectorant agent Substances 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 125000002541 furyl group Chemical group 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 125000003226 pyrazolyl group Chemical group 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000005017 substituted alkenyl group Chemical group 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 125000000335 thiazolyl group Chemical group 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 3
- BYJIXWOWTNEVFO-UHFFFAOYSA-N 1-(4-bromophenyl)cyclopropane-1-carboxylic acid Chemical compound C=1C=C(Br)C=CC=1C1(C(=O)O)CC1 BYJIXWOWTNEVFO-UHFFFAOYSA-N 0.000 description 3
- RSWZDSGGMFUYMM-UHFFFAOYSA-N 2-(4-bromophenyl)pyrazole-3-carboxylic acid Chemical compound OC(=O)C1=CC=NN1C1=CC=C(Br)C=C1 RSWZDSGGMFUYMM-UHFFFAOYSA-N 0.000 description 3
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical group NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108010006654 Bleomycin Proteins 0.000 description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 3
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 3
- 208000022873 Ocular disease Diseases 0.000 description 3
- 206010034277 Pemphigoid Diseases 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
- 206010039710 Scleroderma Diseases 0.000 description 3
- KKXJONNDLHAERE-GFCCVEGCSA-N [(1R)-1-(2-chlorophenyl)ethyl] N-[2-(4-bromophenyl)-4-cyanopyrazol-3-yl]carbamate Chemical compound ClC1=C(C=CC=C1)[C@@H](C)OC(=O)NC=1N(N=CC=1C#N)C1=CC=C(C=C1)Br KKXJONNDLHAERE-GFCCVEGCSA-N 0.000 description 3
- YSSKMLRHMBAMOI-LLVKDONJSA-N [(1R)-1-(2-chlorophenyl)ethyl] N-[2-(6-chloropyridin-3-yl)pyrazol-3-yl]carbamate Chemical compound ClC1=C(C=CC=C1)[C@@H](C)OC(=O)NC=1N(N=CC=1)C=1C=NC(=CC=1)Cl YSSKMLRHMBAMOI-LLVKDONJSA-N 0.000 description 3
- FKBIBQVMDMLCKB-CYBMUJFWSA-N [(1R)-1-phenylethyl] N-[2-(4-bromophenyl)-4-cyanopyrazol-3-yl]carbamate Chemical compound C1(=CC=CC=C1)[C@@H](C)OC(=O)NC=1N(N=CC=1C#N)C1=CC=C(C=C1)Br FKBIBQVMDMLCKB-CYBMUJFWSA-N 0.000 description 3
- DOZNAISTJWZAJF-CYBMUJFWSA-N [(1R)-1-phenylethyl] N-[2-(4-bromophenyl)pyrazol-3-yl]carbamate Chemical compound C1(=CC=CC=C1)[C@@H](C)OC(=O)NC=1N(N=CC=1)C1=CC=C(C=C1)Br DOZNAISTJWZAJF-CYBMUJFWSA-N 0.000 description 3
- WCYKHIZGPWUOOU-GFCCVEGCSA-N [(1r)-1-(2-chlorophenyl)ethyl] n-[2-(4-bromophenyl)pyrazol-3-yl]carbamate Chemical compound O([C@H](C)C=1C(=CC=CC=1)Cl)C(=O)NC1=CC=NN1C1=CC=C(Br)C=C1 WCYKHIZGPWUOOU-GFCCVEGCSA-N 0.000 description 3
- NOICYZKSQYFZPX-UHFFFAOYSA-N [4-(1-cyanocyclopropyl)phenyl]boronic acid Chemical compound C1=CC(B(O)O)=CC=C1C1(C#N)CC1 NOICYZKSQYFZPX-UHFFFAOYSA-N 0.000 description 3
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 229940125851 compound 27 Drugs 0.000 description 3
- 239000013058 crude material Substances 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- JGFBRKRYDCGYKD-UHFFFAOYSA-N dibutyl(oxo)tin Chemical compound CCCC[Sn](=O)CCCC JGFBRKRYDCGYKD-UHFFFAOYSA-N 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 3
- 125000001033 ether group Chemical group 0.000 description 3
- SGKHYESLCBKUCZ-UHFFFAOYSA-N ethyl 2-(4-bromophenyl)-4-fluoropyrazole-3-carboxylate Chemical compound CCOC(=O)C1=C(F)C=NN1C1=CC=C(Br)C=C1 SGKHYESLCBKUCZ-UHFFFAOYSA-N 0.000 description 3
- 206010016629 fibroma Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- WRGQSWVCFNIUNZ-KTKRTIGZSA-N lysophosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)COP(O)(O)=O WRGQSWVCFNIUNZ-KTKRTIGZSA-N 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 229960001428 mercaptopurine Drugs 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- BJQLTAKNZXYNGA-UHFFFAOYSA-N n-methylsulfonyl-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropane-1-carboxamide Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(C2(CC2)C(=O)NS(C)(=O)=O)C=C1 BJQLTAKNZXYNGA-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 208000007232 portal hypertension Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 229960005328 rupatadine Drugs 0.000 description 3
- WUZYKBABMWJHDL-UHFFFAOYSA-N rupatadine Chemical compound CC1=CN=CC(CN2CCC(CC2)=C2C3=NC=CC=C3CCC3=CC(Cl)=CC=C32)=C1 WUZYKBABMWJHDL-UHFFFAOYSA-N 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- MBEGFNBBAVRKLK-UHFFFAOYSA-N sodium;iminomethylideneazanide Chemical compound [Na+].[NH-]C#N MBEGFNBBAVRKLK-UHFFFAOYSA-N 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 description 3
- 125000001425 triazolyl group Chemical group 0.000 description 3
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 3
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical group C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical group C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical group O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical group C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical group N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical group CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- RGGOWBBBHWTTRE-UHFFFAOYSA-N (4-bromophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=C(Br)C=C1 RGGOWBBBHWTTRE-UHFFFAOYSA-N 0.000 description 2
- OMJKFYKNWZZKTK-POHAHGRESA-N (5z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 2
- WAPNOHKVXSQRPX-SSDOTTSWSA-N (R)-1-phenylethanol Chemical compound C[C@@H](O)C1=CC=CC=C1 WAPNOHKVXSQRPX-SSDOTTSWSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- WZTRQYNCERVOEM-UHFFFAOYSA-N 1-(4-borono-3-chlorophenyl)cyclopropane-1-carboxylic acid Chemical compound C1=C(Cl)C(B(O)O)=CC=C1C1(C(O)=O)CC1 WZTRQYNCERVOEM-UHFFFAOYSA-N 0.000 description 2
- GNYDSCKYOPJKTK-UHFFFAOYSA-N 1-(4-borono-3-methylphenyl)cyclopropane-1-carboxylic acid Chemical compound C1=C(B(O)O)C(C)=CC(C2(CC2)C(O)=O)=C1 GNYDSCKYOPJKTK-UHFFFAOYSA-N 0.000 description 2
- UYGZYLZNIFAXAI-UHFFFAOYSA-N 1-(4-bromo-3-fluorophenyl)-N-methylsulfonylcyclopropane-1-carboxamide Chemical compound BrC1=C(C=C(C=C1)C1(CC1)C(=O)NS(=O)(=O)C)F UYGZYLZNIFAXAI-UHFFFAOYSA-N 0.000 description 2
- NXLMUQRZRCYGCO-UHFFFAOYSA-N 1-(4-bromophenyl)-5-methylpyrazole Chemical compound CC1=CC=NN1C1=CC=C(Br)C=C1 NXLMUQRZRCYGCO-UHFFFAOYSA-N 0.000 description 2
- XHUOEOFQYJPQOZ-UHFFFAOYSA-N 1-(4-bromophenyl)-5-methylpyrazole-4-carboxylic acid Chemical compound CC1=C(C(O)=O)C=NN1C1=CC=C(Br)C=C1 XHUOEOFQYJPQOZ-UHFFFAOYSA-N 0.000 description 2
- QFMHLWUHLMQOQI-UHFFFAOYSA-N 1-(4-bromophenyl)-n-cyanocyclopropane-1-carboxamide Chemical compound C1=CC(Br)=CC=C1C1(C(=O)NC#N)CC1 QFMHLWUHLMQOQI-UHFFFAOYSA-N 0.000 description 2
- MEVAITBPBRVVFM-UHFFFAOYSA-N 1-(4-bromophenyl)-n-methylsulfonylcyclopropane-1-carboxamide Chemical compound C=1C=C(Br)C=CC=1C1(C(=O)NS(=O)(=O)C)CC1 MEVAITBPBRVVFM-UHFFFAOYSA-N 0.000 description 2
- WEBHXXBBDYMULJ-UHFFFAOYSA-N 1-(4-bromophenyl)cyclopropane-1-carboxamide Chemical compound C=1C=C(Br)C=CC=1C1(C(=O)N)CC1 WEBHXXBBDYMULJ-UHFFFAOYSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- WCLUOZCSETWVDM-UHFFFAOYSA-N 1-[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropane-1-carboxylic acid Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(C2(CC2)C(O)=O)C(F)=C1 WCLUOZCSETWVDM-UHFFFAOYSA-N 0.000 description 2
- LHIZEFZZPHIOAV-UHFFFAOYSA-N 1-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropane-1-carboxylic acid Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(C2(CC2)C(O)=O)C=C1F LHIZEFZZPHIOAV-UHFFFAOYSA-N 0.000 description 2
- LPXFLFVANKXSQH-UHFFFAOYSA-N 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropane-1-carboxamide Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(C2(CC2)C(N)=O)C=C1 LPXFLFVANKXSQH-UHFFFAOYSA-N 0.000 description 2
- XVNWTGXJZLFDKA-MRXNPFEDSA-N 1-[4-[4-[5-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-4-fluoropyrazol-1-yl]phenyl]-3-fluorophenyl]cyclopropane-1-carboxylic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)Cl)C(=O)NC1=C(F)C=NN1C(C=C1)=CC=C1C(C(=C1)F)=CC=C1C1(C(O)=O)CC1 XVNWTGXJZLFDKA-MRXNPFEDSA-N 0.000 description 2
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 2
- AKVOQXBQLXOEEF-UHFFFAOYSA-N 2-(4-bromophenyl)-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)C1=CC=C(Br)C=C1 AKVOQXBQLXOEEF-UHFFFAOYSA-N 0.000 description 2
- VUZUKSCCUMLSSL-UHFFFAOYSA-N 2-(4-bromophenyl)-4-fluoropyrazole-3-carboxylic acid Chemical compound OC(=O)C1=C(F)C=NN1C1=CC=C(Br)C=C1 VUZUKSCCUMLSSL-UHFFFAOYSA-N 0.000 description 2
- YHZILNXBIGEKBY-UHFFFAOYSA-N 2-(6-chloropyridin-3-yl)pyrazole-3-carboxylic acid Chemical compound OC(=O)C1=CC=NN1C1=CC=C(Cl)N=C1 YHZILNXBIGEKBY-UHFFFAOYSA-N 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical group NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical group N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- VWTGKVYPKFTDSL-UHFFFAOYSA-N 5-amino-1-(4-bromophenyl)pyrazole-4-carbonitrile Chemical compound NC1=C(C#N)C=NN1C1=CC=C(Br)C=C1 VWTGKVYPKFTDSL-UHFFFAOYSA-N 0.000 description 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical group C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 2
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical group CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 2
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 2
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 2
- UDKCHVLMFQVBAA-UHFFFAOYSA-M Choline salicylate Chemical compound C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O UDKCHVLMFQVBAA-UHFFFAOYSA-M 0.000 description 2
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 2
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 description 2
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical group Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- 101000966782 Homo sapiens Lysophosphatidic acid receptor 1 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 2
- CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- JHOFONMBGUOYKL-UHFFFAOYSA-N N-cyano-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropane-1-carboxamide Chemical compound C(#N)NC(=O)C1(CC1)C1=CC=C(C=C1)B1OC(C(O1)(C)C)(C)C JHOFONMBGUOYKL-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical group S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 2
- 206010029279 Neurogenic bladder Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- OTKJDMGTUTTYMP-ROUUACIJSA-N Safingol ( L-threo-sphinganine) Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ROUUACIJSA-N 0.000 description 2
- 108700012411 TNFSF10 Proteins 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- 208000026723 Urinary tract disease Diseases 0.000 description 2
- 208000012931 Urologic disease Diseases 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- UUVHGDWGJWWBKH-SNVBAGLBSA-N [(1R)-1-(2-chlorophenyl)ethyl] N-[2-(6-chloropyridin-3-yl)-4-fluoropyrazol-3-yl]carbamate Chemical compound ClC1=C(C=CC=C1)[C@@H](C)OC(=O)NC=1N(N=CC=1F)C=1C=NC(=CC=1)Cl UUVHGDWGJWWBKH-SNVBAGLBSA-N 0.000 description 2
- BGFZQFNFLUDBIT-SNVBAGLBSA-N [(1R)-1-(2-chlorophenyl)ethyl] N-[4-chloro-2-(6-chloropyridin-3-yl)pyrazol-3-yl]carbamate Chemical compound ClC1=C(C=CC=C1)[C@@H](C)OC(=O)NC=1N(N=CC=1Cl)C=1C=NC(=CC=1)Cl BGFZQFNFLUDBIT-SNVBAGLBSA-N 0.000 description 2
- ZPGYARMHERYEPO-GOSISDBHSA-N [(1R)-1-(2-chlorophenyl)ethyl] N-[4-chloro-2-[4-[4-(1-cyanocyclopropyl)phenyl]phenyl]pyrazol-3-yl]carbamate Chemical compound ClC1=C(C=CC=C1)[C@@H](C)OC(=O)NC=1N(N=CC=1Cl)C1=CC=C(C=C1)C1=CC=C(C=C1)C1(CC1)C#N ZPGYARMHERYEPO-GOSISDBHSA-N 0.000 description 2
- OIRIHAKLUKIARB-LJQANCHMSA-N [(1R)-1-phenylethyl] N-[4-chloro-2-[4-[4-(1-cyanocyclopropyl)phenyl]phenyl]pyrazol-3-yl]carbamate Chemical compound C1(=CC=CC=C1)[C@@H](C)OC(=O)NC=1N(N=CC=1Cl)C1=CC=C(C=C1)C1=CC=C(C=C1)C1(CC1)C#N OIRIHAKLUKIARB-LJQANCHMSA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical group O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- SMPZPKRDRQOOHT-UHFFFAOYSA-N acronycine Chemical compound CN1C2=CC=CC=C2C(=O)C2=C1C(C=CC(C)(C)O1)=C1C=C2OC SMPZPKRDRQOOHT-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229960003790 alimemazine Drugs 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 125000005360 alkyl sulfoxide group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 108010022198 alkylglycerophosphoethanolamine phosphodiesterase Proteins 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
- 229960003437 aminoglutethimide Drugs 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 239000003434 antitussive agent Substances 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 208000021328 arterial occlusion Diseases 0.000 description 2
- 125000005362 aryl sulfone group Chemical group 0.000 description 2
- 125000005361 aryl sulfoxide group Chemical group 0.000 description 2
- 125000005110 aryl thio group Chemical group 0.000 description 2
- 125000000732 arylene group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical group O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 229960004574 azelastine Drugs 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 description 2
- 229960002071 bepotastine Drugs 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229960004436 budesonide Drugs 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- 125000005587 carbonate group Chemical group 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 229960001803 cetirizine Drugs 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 229960003291 chlorphenamine Drugs 0.000 description 2
- 229960002688 choline salicylate Drugs 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 229960003728 ciclesonide Drugs 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 229960003449 epinastine Drugs 0.000 description 2
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 229950001426 erbulozole Drugs 0.000 description 2
- KLEPCGBEXOCIGS-QPPBQGQZSA-N erbulozole Chemical compound C1=CC(NC(=O)OCC)=CC=C1SC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C=CC(OC)=CC=2)OC1 KLEPCGBEXOCIGS-QPPBQGQZSA-N 0.000 description 2
- LQSOVGAUOHMPLK-SOFGYWHQSA-N ethyl (2e)-2-(dimethylaminomethylidene)-3-oxobutanoate Chemical compound CCOC(=O)C(\C(C)=O)=C\N(C)C LQSOVGAUOHMPLK-SOFGYWHQSA-N 0.000 description 2
- GTCBVGDJIQFBFF-AATRIKPKSA-N ethyl (e)-4-(dimethylamino)-2-oxobut-3-enoate Chemical compound CCOC(=O)C(=O)\C=C\N(C)C GTCBVGDJIQFBFF-AATRIKPKSA-N 0.000 description 2
- LMHJVIOBYOFILY-UHFFFAOYSA-N ethyl 1-(4-bromophenyl)-5-methylpyrazole-4-carboxylate Chemical compound CC1=C(C(=O)OCC)C=NN1C1=CC=C(Br)C=C1 LMHJVIOBYOFILY-UHFFFAOYSA-N 0.000 description 2
- WZMLCZCUOIANEL-UHFFFAOYSA-N ethyl 1-(4-bromophenyl)pyrazole-3-carboxylate Chemical compound N1=C(C(=O)OCC)C=CN1C1=CC=C(Br)C=C1 WZMLCZCUOIANEL-UHFFFAOYSA-N 0.000 description 2
- JPQWEGDRHVSYJJ-UHFFFAOYSA-N ethyl 2-(6-chloropyridin-3-yl)pyrazole-3-carboxylate Chemical compound CCOC(=O)C1=CC=NN1C1=CC=C(Cl)N=C1 JPQWEGDRHVSYJJ-UHFFFAOYSA-N 0.000 description 2
- 229940117360 ethyl pyruvate Drugs 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 229940066493 expectorants Drugs 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- IKIBJHWXDSKRKV-UHFFFAOYSA-N fijianolide B Natural products CC1CC(=C)CC(O)C2OC2CC(OC(=O)C=C/CC3OC(C)(CC=C3)C1)C(O)C=CC4CC(=CCO4)C IKIBJHWXDSKRKV-UHFFFAOYSA-N 0.000 description 2
- 229960000676 flunisolide Drugs 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 125000003838 furazanyl group Chemical group 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical group OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 229960004958 ketotifen Drugs 0.000 description 2
- MSBQEQDLFWWWMV-XZZGLLCESA-N laulimalide Chemical compound C(/[C@H](O)[C@H]1OC(=O)\C=C/C[C@@H]2C=CC[C@H](O2)C[C@H](CC(=C)C[C@H](O)[C@@H]2O[C@H]2C1)C)=C\[C@@H]1CC(C)=CCO1 MSBQEQDLFWWWMV-XZZGLLCESA-N 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 229960004338 leuprorelin Drugs 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960004296 megestrol acetate Drugs 0.000 description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
- 229960000582 mepyramine Drugs 0.000 description 2
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 2
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- UGQIRBNJSFRFQL-LJQANCHMSA-N methyl 1-[4-[4-[4-chloro-5-[[(1R)-1-phenylethoxy]carbonylamino]pyrazol-1-yl]phenyl]phenyl]cyclopropane-1-carboxylate Chemical compound C1(=CC=CC=C1)[C@@H](C)OC(=O)NC1=C(C=NN1C1=CC=C(C=C1)C1=CC=C(C=C1)C1(CC1)C(=O)OC)Cl UGQIRBNJSFRFQL-LJQANCHMSA-N 0.000 description 2
- NQTRBNXHIOPLAC-HXUWFJFHSA-N methyl 1-[4-[4-[4-cyano-5-[[(1R)-1-phenylethoxy]carbonylamino]pyrazol-1-yl]phenyl]phenyl]cyclopropane-1-carboxylate Chemical compound C1(=CC=CC=C1)[C@@H](C)OC(=O)NC1=C(C=NN1C1=CC=C(C=C1)C1=CC=C(C=C1)C1(CC1)C(=O)OC)C#N NQTRBNXHIOPLAC-HXUWFJFHSA-N 0.000 description 2
- HUPHTLWRVONXLB-LJQANCHMSA-N methyl 1-[4-[4-[5-[[(1R)-1-(2-chlorophenyl)ethoxy]carbonylamino]-4-cyanopyrazol-1-yl]phenyl]phenyl]cyclopropane-1-carboxylate Chemical compound ClC1=C(C=CC=C1)[C@@H](C)OC(=O)NC1=C(C=NN1C1=CC=C(C=C1)C1=CC=C(C=C1)C1(CC1)C(=O)OC)C#N HUPHTLWRVONXLB-LJQANCHMSA-N 0.000 description 2
- HPQWWISTPHFPHF-HXUWFJFHSA-N methyl 2-[4-[4-[4-cyano-5-[[(1R)-1-phenylethoxy]carbonylamino]pyrazol-1-yl]phenyl]phenyl]-2-methylpropanoate Chemical compound C1(=CC=CC=C1)[C@@H](C)OC(=O)NC1=C(C=NN1C1=CC=C(C=C1)C1=CC=C(C=C1)C(C(=O)OC)(C)C)C#N HPQWWISTPHFPHF-HXUWFJFHSA-N 0.000 description 2
- RAGWTXRTMGSMRC-UHFFFAOYSA-N methyl 2-methyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propanoate Chemical compound C1=CC(C(C)(C)C(=O)OC)=CC=C1B1OC(C)(C)C(C)(C)O1 RAGWTXRTMGSMRC-UHFFFAOYSA-N 0.000 description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 229960000350 mitotane Drugs 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 230000000510 mucolytic effect Effects 0.000 description 2
- 229940066491 mucolytics Drugs 0.000 description 2
- 229960000951 mycophenolic acid Drugs 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 229960004114 olopatadine Drugs 0.000 description 2
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 description 2
- 229960002657 orciprenaline Drugs 0.000 description 2
- 125000000962 organic group Chemical group 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 208000024691 pancreas disease Diseases 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000012286 potassium permanganate Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229960003440 semustine Drugs 0.000 description 2
- 108010047846 soblidotin Proteins 0.000 description 2
- DZMVCVHATYROOS-ZBFGKEHZSA-N soblidotin Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCC1=CC=CC=C1 DZMVCVHATYROOS-ZBFGKEHZSA-N 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 206010062261 spinal cord neoplasm Diseases 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 125000004426 substituted alkynyl group Chemical group 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 2
- 229950007866 tanespimycin Drugs 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 2
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 150000003555 thioacetals Chemical class 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- 239000003848 thrombocyte activating factor antagonist Substances 0.000 description 2
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- FQCQGOZEWWPOKI-UHFFFAOYSA-K trisalicylate-choline Chemical compound [Mg+2].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O FQCQGOZEWWPOKI-UHFFFAOYSA-K 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 208000014001 urinary system disease Diseases 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- FCCNKYGSMOSYPV-DEDISHTHSA-N (-)-Epothilone E Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C FCCNKYGSMOSYPV-DEDISHTHSA-N 0.000 description 1
- UKIMCRYGLFQEOE-RLHMMOOASA-N (-)-Epothilone F Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C UKIMCRYGLFQEOE-RLHMMOOASA-N 0.000 description 1
- KQODQNJLJQHFQV-UHFFFAOYSA-N (-)-hemiasterlin Natural products C1=CC=C2C(C(C)(C)C(C(=O)NC(C(=O)N(C)C(C=C(C)C(O)=O)C(C)C)C(C)(C)C)NC)=CN(C)C2=C1 KQODQNJLJQHFQV-UHFFFAOYSA-N 0.000 description 1
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- HZSBSRAVNBUZRA-RQDPQJJXSA-J (1r,2r)-cyclohexane-1,2-diamine;tetrachloroplatinum(2+) Chemical compound Cl[Pt+2](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N HZSBSRAVNBUZRA-RQDPQJJXSA-J 0.000 description 1
- PFJFPBDHCFMQPN-RGJAOAFDSA-N (1s,3s,7s,10r,11s,12s,16r)-3-[(e)-1-[2-(aminomethyl)-1,3-thiazol-4-yl]prop-1-en-2-yl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CN)=N1 PFJFPBDHCFMQPN-RGJAOAFDSA-N 0.000 description 1
- VCQURUZYYSOUHP-UHFFFAOYSA-N (2,3,4,5,6-pentafluorophenyl) 2,2,2-trifluoroacetate Chemical compound FC1=C(F)C(F)=C(OC(=O)C(F)(F)F)C(F)=C1F VCQURUZYYSOUHP-UHFFFAOYSA-N 0.000 description 1
- MRJQTLJSMQOFTP-JGTKTWDESA-N (2S)-N-benzyl-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide hydrochloride Chemical compound Cl.CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC=2C=CC=CC=2)CCC1 MRJQTLJSMQOFTP-JGTKTWDESA-N 0.000 description 1
- YCYMCMYLORLIJX-SNVBAGLBSA-N (2r)-2-propyloctanoic acid Chemical compound CCCCCC[C@H](C(O)=O)CCC YCYMCMYLORLIJX-SNVBAGLBSA-N 0.000 description 1
- PAYBYKKERMGTSS-MNCSTQPFSA-N (2r,3r,3as,9ar)-7-fluoro-2-(hydroxymethyl)-6-imino-2,3,3a,9a-tetrahydrofuro[1,2][1,3]oxazolo[3,4-a]pyrimidin-3-ol Chemical compound N=C1C(F)=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 PAYBYKKERMGTSS-MNCSTQPFSA-N 0.000 description 1
- CXHDSLQCNYLQND-XQRIHRDZSA-N (2r,5s)-3,5-dimethyl-2-pyridin-3-yl-1,3-thiazolidin-4-one;hydrochloride Chemical compound Cl.CN1C(=O)[C@H](C)S[C@@H]1C1=CC=CN=C1 CXHDSLQCNYLQND-XQRIHRDZSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- RPEPXOHTYVXVMA-CIUDSAMLSA-N (2s)-2-amino-5-[[(2s)-1-[[(1s)-1-carboxy-4-(3h-diazirin-3-yl)-4-oxobutyl]amino]-5-(3h-diazirin-3-yl)-1,5-dioxopentan-2-yl]amino]-5-oxopentanoic acid Chemical compound C([C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](CCC(=O)C1N=N1)C(O)=O)CC(=O)C1N=N1 RPEPXOHTYVXVMA-CIUDSAMLSA-N 0.000 description 1
- QKDRXGFQVGOQKS-CRSSMBPESA-N (2s,3r,4r,5s,6r)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](SC)O2)O)=CC=C1Cl QKDRXGFQVGOQKS-CRSSMBPESA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 description 1
- KJTPWUVVLPCPJD-AUWJEWJLSA-N (2z)-7-amino-2-[(4-hydroxy-3,5-dimethylphenyl)methylidene]-5,6-dimethoxy-3h-inden-1-one Chemical compound O=C1C=2C(N)=C(OC)C(OC)=CC=2C\C1=C\C1=CC(C)=C(O)C(C)=C1 KJTPWUVVLPCPJD-AUWJEWJLSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- LSXOBYNBRKOTIQ-RQUBOUMQSA-N (3s,10r,13e,16s)-10-[(3-chloro-4-methoxyphenyl)methyl]-6,6-dimethyl-3-(2-methylpropyl)-16-[(1s)-1-[(2r,3r)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NCC(C)(C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 LSXOBYNBRKOTIQ-RQUBOUMQSA-N 0.000 description 1
- GWMHBVLPNWHWGW-CNYBTUBUSA-N (3s,6z)-3-benzyl-6-[[5-(2-methylbut-3-en-2-yl)-1h-imidazol-4-yl]methylidene]piperazine-2,5-dione Chemical compound N1C=NC(\C=C/2C(N[C@@H](CC=3C=CC=CC=3)C(=O)N\2)=O)=C1C(C)(C=C)C GWMHBVLPNWHWGW-CNYBTUBUSA-N 0.000 description 1
- SWXOGPJRIDTIRL-DOUNNPEJSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s)-1-amino-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-DOUNNPEJSA-N 0.000 description 1
- RAHQINWMWXFOIA-UHFFFAOYSA-N (6-chloropyridin-3-yl)hydrazine;hydrochloride Chemical compound Cl.NNC1=CC=C(Cl)N=C1 RAHQINWMWXFOIA-UHFFFAOYSA-N 0.000 description 1
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 1
- RCFNNLSZHVHCEK-YGCMNLPTSA-N (7s,9s)-7-[(2s,4r,6s)-4-amino-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 RCFNNLSZHVHCEK-YGCMNLPTSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 1
- 125000006747 (C2-C10) heterocycloalkyl group Chemical group 0.000 description 1
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 description 1
- DOEWDSDBFRHVAP-KRXBUXKQSA-N (E)-3-tosylacrylonitrile Chemical compound CC1=CC=C(S(=O)(=O)\C=C\C#N)C=C1 DOEWDSDBFRHVAP-KRXBUXKQSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- UWPBQLKEHGGKKD-GZTJUZNOSA-N (e)-7-phenyl-7-pyridin-3-ylhept-6-enoic acid Chemical compound C=1C=CN=CC=1C(=C/CCCCC(=O)O)/C1=CC=CC=C1 UWPBQLKEHGGKKD-GZTJUZNOSA-N 0.000 description 1
- KQODQNJLJQHFQV-MKWZWQCGSA-N (e,4s)-4-[[(2s)-3,3-dimethyl-2-[[(2s)-3-methyl-2-(methylamino)-3-(1-methylindol-3-yl)butanoyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid Chemical compound C1=CC=C2C(C(C)(C)[C@@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)NC)=CN(C)C2=C1 KQODQNJLJQHFQV-MKWZWQCGSA-N 0.000 description 1
- POILWHVDKZOXJZ-ARJAWSKDSA-M (z)-4-oxopent-2-en-2-olate Chemical compound C\C([O-])=C\C(C)=O POILWHVDKZOXJZ-ARJAWSKDSA-M 0.000 description 1
- OJRZEKJECRTBPJ-NGAMADIESA-N (z,5s)-5-acetamido-1-diazonio-6-hydroxy-6-oxohex-1-en-2-olate Chemical compound CC(=O)N[C@H](C(O)=O)CC\C([O-])=C\[N+]#N OJRZEKJECRTBPJ-NGAMADIESA-N 0.000 description 1
- OWQPOVKKUWUEKE-UHFFFAOYSA-N 1,2,3-benzotriazine Chemical compound N1=NN=CC2=CC=CC=C21 OWQPOVKKUWUEKE-UHFFFAOYSA-N 0.000 description 1
- FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8s)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3h-pyrrolo[3,2-e]indole-6-carbonyl]-1h-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- OUPZKGBUJRBPGC-HLTSFMKQSA-N 1,5-bis[[(2r)-oxiran-2-yl]methyl]-3-[[(2s)-oxiran-2-yl]methyl]-1,3,5-triazinane-2,4,6-trione Chemical compound O=C1N(C[C@H]2OC2)C(=O)N(C[C@H]2OC2)C(=O)N1C[C@H]1CO1 OUPZKGBUJRBPGC-HLTSFMKQSA-N 0.000 description 1
- UOAFGUOASVSLPK-UHFFFAOYSA-N 1-(2-chloroethyl)-3-(2,2-dimethylpropyl)-1-nitrosourea Chemical compound CC(C)(C)CNC(=O)N(N=O)CCCl UOAFGUOASVSLPK-UHFFFAOYSA-N 0.000 description 1
- ZJKFGOYSWXSOAH-UHFFFAOYSA-N 1-(4-borono-3-fluorophenyl)cyclopropane-1-carboxylic acid Chemical compound C1=C(F)C(B(O)O)=CC=C1C1(C(O)=O)CC1 ZJKFGOYSWXSOAH-UHFFFAOYSA-N 0.000 description 1
- WKVFGGQPVGDERD-UHFFFAOYSA-N 1-(4-bromo-3-fluorophenyl)cyclopropane-1-carboxylic acid Chemical compound C=1C=C(Br)C(F)=CC=1C1(C(=O)O)CC1 WKVFGGQPVGDERD-UHFFFAOYSA-N 0.000 description 1
- BWPZBXQENXGRQV-UHFFFAOYSA-N 1-(4-bromophenyl)cyclopropane-1-carbonitrile Chemical compound C1=CC(Br)=CC=C1C1(C#N)CC1 BWPZBXQENXGRQV-UHFFFAOYSA-N 0.000 description 1
- JQJSFAJISYZPER-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-(2,3-dihydro-1h-inden-5-ylsulfonyl)urea Chemical compound C1=CC(Cl)=CC=C1NC(=O)NS(=O)(=O)C1=CC=C(CCC2)C2=C1 JQJSFAJISYZPER-UHFFFAOYSA-N 0.000 description 1
- SNYUHPPZINRDSG-UHFFFAOYSA-N 1-(oxiran-2-ylmethyl)-4-[1-(oxiran-2-ylmethyl)piperidin-4-yl]piperidine Chemical compound C1CC(C2CCN(CC3OC3)CC2)CCN1CC1CO1 SNYUHPPZINRDSG-UHFFFAOYSA-N 0.000 description 1
- QEMSVZNTSXPFJA-HNAYVOBHSA-N 1-[(1s,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol Chemical compound C1([C@H](O)[C@H](C)N2CCC(O)(CC2)C=2C=CC=CC=2)=CC=C(O)C=C1 QEMSVZNTSXPFJA-HNAYVOBHSA-N 0.000 description 1
- WFNAKBGANONZEQ-UHFFFAOYSA-N 1-[(4-chlorophenyl)-phenylmethyl]-4-methylpiperazine Chemical compound C1CN(C)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 WFNAKBGANONZEQ-UHFFFAOYSA-N 0.000 description 1
- KMUVLVUJMAYIOL-QGZVFWFLSA-N 1-[3-fluoro-4-[4-[5-[[(1r)-1-phenylethoxy]carbonylamino]-4-(trifluoromethyl)pyrazol-1-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound O([C@H](C)C=1C=CC=CC=1)C(=O)NC1=C(C(F)(F)F)C=NN1C(C=C1)=CC=C1C(C(=C1)F)=CC=C1C1(C(O)=O)CC1 KMUVLVUJMAYIOL-QGZVFWFLSA-N 0.000 description 1
- NXDMYFBKUGPDMK-GOSISDBHSA-N 1-[4-[4-[5-[[(1r)-1-phenylethoxy]carbonylamino]-4-(trifluoromethyl)pyrazol-1-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound O([C@H](C)C=1C=CC=CC=1)C(=O)NC1=C(C(F)(F)F)C=NN1C(C=C1)=CC=C1C(C=C1)=CC=C1C1(C(O)=O)CC1 NXDMYFBKUGPDMK-GOSISDBHSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- ZKFNOUUKULVDOB-UHFFFAOYSA-N 1-amino-1-phenylmethyl phosphonic acid Chemical compound OP(=O)(O)C(N)C1=CC=CC=C1 ZKFNOUUKULVDOB-UHFFFAOYSA-N 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- OOMDVERDMZLRFX-UHFFFAOYSA-N 2,2-bis(aminomethyl)propane-1,3-diol;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound [Pt].NCC(CN)(CO)CO.OC(=O)C1(C(O)=O)CCC1 OOMDVERDMZLRFX-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- VKDGNNYJFSHYKD-UHFFFAOYSA-N 2,5-diamino-2-(difluoromethyl)pentanoic acid;hydron;chloride Chemical compound Cl.NCCCC(N)(C(F)F)C(O)=O VKDGNNYJFSHYKD-UHFFFAOYSA-N 0.000 description 1
- NJWBUDCAWGTQAS-UHFFFAOYSA-N 2-(chrysen-6-ylmethylamino)-2-methylpropane-1,3-diol;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 NJWBUDCAWGTQAS-UHFFFAOYSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- KPRFMAZESAKTEJ-UHFFFAOYSA-N 2-[1-amino-4-[2,5-dioxo-4-(1-phenylethyl)pyrrolidin-3-yl]-1-oxobutan-2-yl]-5-carbamoylheptanedioic acid;azane Chemical compound [NH4+].[NH4+].C=1C=CC=CC=1C(C)C1C(CCC(C(CCC(CC([O-])=O)C(N)=O)C([O-])=O)C(N)=O)C(=O)NC1=O KPRFMAZESAKTEJ-UHFFFAOYSA-N 0.000 description 1
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- DSWLRNLRVBAVFC-UHFFFAOYSA-N 2-methylsulfinyl-1-pyridin-2-ylethanone Chemical compound CS(=O)CC(=O)C1=CC=CC=N1 DSWLRNLRVBAVFC-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- ONJRTQUWKRDCTA-UHFFFAOYSA-N 2h-thiochromene Chemical compound C1=CC=C2C=CCSC2=C1 ONJRTQUWKRDCTA-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- PYSICVOJSJMFKP-UHFFFAOYSA-N 3,5-dibromo-2-chloropyridine Chemical compound ClC1=NC=C(Br)C=C1Br PYSICVOJSJMFKP-UHFFFAOYSA-N 0.000 description 1
- GRLUHXSUZYFZCW-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine;dihydrochloride Chemical compound Cl.Cl.C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 GRLUHXSUZYFZCW-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- GTJXPMSTODOYNP-BTKVJIOYSA-N 3-[(e)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 GTJXPMSTODOYNP-BTKVJIOYSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- QNKJFXARIMSDBR-UHFFFAOYSA-N 3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(CCN(CCCl)CCCl)C(=O)NC11CCCCC1 QNKJFXARIMSDBR-UHFFFAOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- PXLPCZJACKUXGP-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)-6-ethylpyrimidine-2,4-diamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C(Cl)=C1 PXLPCZJACKUXGP-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- DQOGWKZQQBYYMW-LQGIGNHCSA-N 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine;(2s,3s,4s,5r,6s)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O.COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 DQOGWKZQQBYYMW-LQGIGNHCSA-N 0.000 description 1
- OTSZCHORPMQCBZ-UHFFFAOYSA-N 6-[(3-chlorophenyl)-imidazol-1-ylmethyl]-1h-benzimidazole;hydron;chloride Chemical compound Cl.ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 OTSZCHORPMQCBZ-UHFFFAOYSA-N 0.000 description 1
- ZNTIXVYOBQDFFV-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.O=C1NC(N)=CC2=C1N=CN2 ZNTIXVYOBQDFFV-UHFFFAOYSA-N 0.000 description 1
- KABRXLINDSPGDF-UHFFFAOYSA-N 7-bromoisoquinoline Chemical compound C1=CN=CC2=CC(Br)=CC=C21 KABRXLINDSPGDF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- LPDLEICKXUVJHW-QJILNLRNSA-N 78nz2pmp25 Chemical compound OS(O)(=O)=O.O([C@]12[C@H](OC(C)=O)[C@]3(CC)C=CCN4CC[C@@]5([C@H]34)[C@H]1N(C)C1=C5C=C(C(=C1)OC)[C@]1(C(=O)OC)C3=C(C4=CC=CC=C4N3)CCN3C[C@H](C1)C[C@@](C3)(O)CC)C(=O)N(CCCl)C2=O LPDLEICKXUVJHW-QJILNLRNSA-N 0.000 description 1
- ZUZXYJOSNSTJMU-UHFFFAOYSA-N 9-cyclohexyl-2-n,6-n-bis[(4-methoxyphenyl)methyl]purine-2,6-diamine Chemical compound C1=CC(OC)=CC=C1CNC1=NC(NCC=2C=CC(OC)=CC=2)=C(N=CN2C3CCCCC3)C2=N1 ZUZXYJOSNSTJMU-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 108700032558 Aspergillus restrictus MITF Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- CIUUIPMOFZIWIZ-UHFFFAOYSA-N Bropirimine Chemical compound NC1=NC(O)=C(Br)C(C=2C=CC=CC=2)=N1 CIUUIPMOFZIWIZ-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 description 1
- 229940122444 Chemokine receptor antagonist Drugs 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 206010064190 Cholestatic pruritus Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- PPASFTRHCXASPY-UHFFFAOYSA-N Cl.Cl.NCCCNc1ccc2c3c(nn2CCNCCO)c4c(O)ccc(O)c4C(=O)c13 Chemical compound Cl.Cl.NCCCNc1ccc2c3c(nn2CCNCCO)c4c(O)ccc(O)c4C(=O)c13 PPASFTRHCXASPY-UHFFFAOYSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- SPKNARKFCOPTSY-UHFFFAOYSA-N D-asperlin Natural products CC1OC1C1C(OC(C)=O)C=CC(=O)O1 SPKNARKFCOPTSY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- OALVLUFFPXEHFO-UHFFFAOYSA-N Diazonamide A Natural products O1C=2C34C(O)OC5=C3C=CC=C5C(C3=5)=CC=CC=5NC(Cl)=C3C(=C(N=3)Cl)OC=3C=2N=C1C(C(C)C)NC(=O)C(NC(=O)C(N)C(C)C)CC1=CC=C(O)C4=C1 OALVLUFFPXEHFO-UHFFFAOYSA-N 0.000 description 1
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 1
- OFDNQWIFNXBECV-UHFFFAOYSA-N Dolastatin 10 Natural products CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)CC)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-UHFFFAOYSA-N 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- 102100021977 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Human genes 0.000 description 1
- 108050004000 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- NBEALWAVEGMZQY-UHFFFAOYSA-N Enpromate Chemical compound C=1C=CC=CC=1C(C#C)(C=1C=CC=CC=1)OC(=O)NC1CCCCC1 NBEALWAVEGMZQY-UHFFFAOYSA-N 0.000 description 1
- BEFZAMRWPCMWFJ-JRBBLYSQSA-N Epothilone C Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C BEFZAMRWPCMWFJ-JRBBLYSQSA-N 0.000 description 1
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 description 1
- UKIMCRYGLFQEOE-UHFFFAOYSA-N Epothilone F Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2(C)OC2CC1C(C)=CC1=CSC(CO)=N1 UKIMCRYGLFQEOE-UHFFFAOYSA-N 0.000 description 1
- MCIACXAZCBVDEE-CUUWFGFTSA-N Ertugliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@@]23O[C@@](CO)(CO2)[C@@H](O)[C@H](O)[C@H]3O)=CC=C1Cl MCIACXAZCBVDEE-CUUWFGFTSA-N 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- PUWHHWCHAVXSIG-NCLPIGKXSA-N Fluocortin Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)C(O)=O)[C@@]2(C)C[C@@H]1O PUWHHWCHAVXSIG-NCLPIGKXSA-N 0.000 description 1
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- ZBLLGPUWGCOJNG-UHFFFAOYSA-N Halichondrin B Natural products CC1CC2(CC(C)C3OC4(CC5OC6C(CC5O4)OC7CC8OC9CCC%10OC(CC(C(C9)C8=C)C%11%12CC%13OC%14C(OC%15CCC(CC(=O)OC7C6C)OC%15C%14O%11)C%13O%12)CC%10=C)CC3O2)OC%16OC(CC1%16)C(O)CC(O)CO ZBLLGPUWGCOJNG-UHFFFAOYSA-N 0.000 description 1
- FOGXJPFPZOHSQS-AYVLZSQQSA-N Hydrocortisone butyrate propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O FOGXJPFPZOHSQS-AYVLZSQQSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010054698 Interferon Alfa-n3 Proteins 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 101150036626 LSR gene Proteins 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- WHSOLWOTCHFFBK-ZQGJOIPISA-N Luseogliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)S2)O)=C(OC)C=C1C WHSOLWOTCHFFBK-ZQGJOIPISA-N 0.000 description 1
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- GZENKSODFLBBHQ-ILSZZQPISA-N Medrysone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 GZENKSODFLBBHQ-ILSZZQPISA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 1
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- USVMJSALORZVDV-SDBHATRESA-N N(6)-(Delta(2)-isopentenyl)adenosine Chemical compound C1=NC=2C(NCC=C(C)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O USVMJSALORZVDV-SDBHATRESA-N 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
- WQLDJUQUFZDTSD-XXODBJNXSA-N O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(C)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(C)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 WQLDJUQUFZDTSD-XXODBJNXSA-N 0.000 description 1
- UMDBGTRUNWFBPE-UHFFFAOYSA-N O.Cl.Cl.CNCCNc1ccc2c3c(nn2CCNCCO)c4c(O)ccc(O)c4C(=O)c13 Chemical compound O.Cl.Cl.CNCCNc1ccc2c3c(nn2CCNCCO)c4c(O)ccc(O)c4C(=O)c13 UMDBGTRUNWFBPE-UHFFFAOYSA-N 0.000 description 1
- 239000005480 Olmesartan Substances 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108700023400 Platelet-activating factor receptors Proteins 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- XESARGFCSKSFID-UHFFFAOYSA-N Pyrazofurin Natural products OC1=C(C(=O)N)NN=C1C1C(O)C(O)C(CO)O1 XESARGFCSKSFID-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- PTTJLTMUKRRHAT-VJAKQJMOSA-N Taccalonolide A Chemical compound C([C@@H]1C(=O)[C@@H]2O)[C@@H]3O[C@@H]3[C@H](OC(C)=O)[C@]1(C)[C@@H]1[C@@H]2[C@@H]2[C@@H](OC(C)=O)[C@H]3[C@@]4(C)[C@](C)(O)C(=O)OC4=C[C@@H](C)[C@@H]3[C@@]2(C)[C@@H](OC(C)=O)[C@H]1OC(C)=O PTTJLTMUKRRHAT-VJAKQJMOSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 1
- ZXOCGDDVNPDRIW-NHFZGCSJSA-N Tofogliflozin Chemical compound O.C1=CC(CC)=CC=C1CC1=CC=C(CO[C@@]23[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C2=C1 ZXOCGDDVNPDRIW-NHFZGCSJSA-N 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- IBEDDHUHZBDXGB-OEJISELMSA-N Tubulysin A Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N(COC(=O)CC(C)C)[C@H](C[C@@H](OC(C)=O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(O)=O)CC=1C=CC(O)=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C IBEDDHUHZBDXGB-OEJISELMSA-N 0.000 description 1
- IBEDDHUHZBDXGB-UHFFFAOYSA-N Tubulysin A Natural products N=1C(C(=O)NC(CC(C)C(O)=O)CC=2C=CC(O)=CC=2)=CSC=1C(OC(C)=O)CC(C(C)C)N(COC(=O)CC(C)C)C(=O)C(C(C)CC)NC(=O)C1CCCCN1C IBEDDHUHZBDXGB-UHFFFAOYSA-N 0.000 description 1
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 1
- 206010060875 Uraemic pruritus Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- VPXXPAWIDFVFPF-GOSISDBHSA-N [(1R)-1-(2-chlorophenyl)ethyl] N-[2-[4-[4-(1-cyanocyclopropyl)phenyl]phenyl]-4-fluoropyrazol-3-yl]carbamate Chemical compound ClC1=C(C=CC=C1)[C@@H](C)OC(=O)NC=1N(N=CC=1F)C1=CC=C(C=C1)C1=CC=C(C=C1)C1(CC1)C#N VPXXPAWIDFVFPF-GOSISDBHSA-N 0.000 description 1
- PGZKOHSLBTXCSD-QGZVFWFLSA-N [(1R)-1-(2-chlorophenyl)ethyl] N-[2-[6-[4-(1-cyanocyclopropyl)phenyl]pyridin-3-yl]-4-fluoropyrazol-3-yl]carbamate Chemical compound ClC1=C(C=CC=C1)[C@@H](C)OC(=O)NC=1N(N=CC=1F)C=1C=NC(=CC=1)C1=CC=C(C=C1)C1(CC1)C#N PGZKOHSLBTXCSD-QGZVFWFLSA-N 0.000 description 1
- VUPBDWQPEOWRQP-RTUCOMKBSA-N [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1S,2S)-3-[[(2R,3S)-5-[[(2S,3R)-1-[[2-[4-[4-[[4-amino-6-[3-(4-aminobutylamino)propylamino]-6-oxohexyl]carbamoyl]-1,3-thiazol-2-yl]-1,3-thiazol-2-yl]-1-[(2S,3R,4R,5S,6S)-5-amino-3,4-dihydroxy-6-methyloxan-2-yl]oxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-5-oxopentan-2-yl]amino]-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-1-(1H-imidazol-5-yl)-3-oxopropoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] carbamate Chemical compound C[C@@H](O)[C@H](NC(=O)C[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1nc(nc(N)c1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1cnc[nH]1)C(=O)NC(O[C@@H]1O[C@@H](C)[C@@H](N)[C@@H](O)[C@H]1O)C(O)c1nc(cs1)-c1nc(cs1)C(=O)NCCCC(N)CC(=O)NCCCNCCCCN VUPBDWQPEOWRQP-RTUCOMKBSA-N 0.000 description 1
- SPKNARKFCOPTSY-XWPZMVOTSA-N [(2r,3s)-2-[(2s,3r)-3-methyloxiran-2-yl]-6-oxo-2,3-dihydropyran-3-yl] acetate Chemical compound C[C@H]1O[C@@H]1[C@H]1[C@@H](OC(C)=O)C=CC(=O)O1 SPKNARKFCOPTSY-XWPZMVOTSA-N 0.000 description 1
- ZHHIHQFAUZZMTG-BSVJBJGJSA-N [(2r,3s,4s,5r,6r)-2-[(2r,3s,4s,5s,6s)-2-[(1r,2s)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[[(2r,3s,4s)-3-hydroxy-5-[[(2s,3r)-3-hydroxy-1-oxo-1-[2-[4-[4-[3-[[(1s)-1-phenylethyl] Chemical compound OS(O)(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C ZHHIHQFAUZZMTG-BSVJBJGJSA-N 0.000 description 1
- VQSGYKUTGGRSPK-SIOACEIBSA-N [(3s,4s,7s)-2-[3-[(2s,5s,8s,11s,14r,17r,20s,23r,26r)-11,14-bis(2-amino-2-oxoethyl)-5,20-bis[(1r)-1-hydroxyethyl]-8-methyl-17,23-bis(2-methylpropyl)-26-octyl-3,6,9,12,15,18,21,24,27-nonaoxo-1,4,7,10,13,16,19,22,25-nonazacycloheptacos-2-yl]propyl]-5-chloro- Chemical compound N1C(=O)[C@@H](CCCCCCCC)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]1CCCN1[C@@]2(OCCC2)[C@@H](O)C2=C(Cl)C(=O)[C@@](C)(OC(=O)CCC)C(=O)C2=C1 VQSGYKUTGGRSPK-SIOACEIBSA-N 0.000 description 1
- IVCRCPJOLWECJU-XQVQQVTHSA-N [(7r,8r,9s,10r,13s,14s,17s)-7,13-dimethyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1C[C@]2(C)[C@@H](OC(C)=O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 IVCRCPJOLWECJU-XQVQQVTHSA-N 0.000 description 1
- KMLCRELJHYKIIL-UHFFFAOYSA-N [1-(azanidylmethyl)cyclohexyl]methylazanide;platinum(2+);sulfuric acid Chemical compound [Pt+2].OS(O)(=O)=O.[NH-]CC1(C[NH-])CCCCC1 KMLCRELJHYKIIL-UHFFFAOYSA-N 0.000 description 1
- NMHKTASGTFXJPL-UHFFFAOYSA-N [2-methoxy-3-(octadecylcarbamoyloxy)propyl] 2-(1,3-thiazol-3-ium-3-yl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCNC(=O)OCC(OC)COP([O-])(=O)OCC[N+]=1C=CSC=1 NMHKTASGTFXJPL-UHFFFAOYSA-N 0.000 description 1
- NAFFDQVVNWTDJD-UHFFFAOYSA-L [4-(azanidylmethyl)oxan-4-yl]methylazanide;cyclobutane-1,1-dicarboxylate;platinum(4+) Chemical compound [Pt+4].[NH-]CC1(C[NH-])CCOCC1.[O-]C(=O)C1(C([O-])=O)CCC1 NAFFDQVVNWTDJD-UHFFFAOYSA-L 0.000 description 1
- JURAJLFHWXNPHG-UHFFFAOYSA-N [acetyl(methylcarbamoyl)amino] n-methylcarbamate Chemical compound CNC(=O)ON(C(C)=O)C(=O)NC JURAJLFHWXNPHG-UHFFFAOYSA-N 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- RUGAHXUZHWYHNG-NLGNTGLNSA-N acetic acid;(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5, Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 RUGAHXUZHWYHNG-NLGNTGLNSA-N 0.000 description 1
- IGCAUIJHGNYDKE-UHFFFAOYSA-N acetic acid;1,4-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione Chemical compound CC([O-])=O.CC([O-])=O.O=C1C2=CC=CC=C2C(=O)C2=C1C(NCC[NH2+]CCO)=CC=C2NCC[NH2+]CCO IGCAUIJHGNYDKE-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- QAWIHIJWNYOLBE-OKKQSCSOSA-N acivicin Chemical compound OC(=O)[C@@H](N)[C@@H]1CC(Cl)=NO1 QAWIHIJWNYOLBE-OKKQSCSOSA-N 0.000 description 1
- 229950008427 acivicin Drugs 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 229960003792 acrivastine Drugs 0.000 description 1
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 1
- 229950000616 acronine Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 108010016133 acylglycerol kinase Proteins 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 229950004955 adozelesin Drugs 0.000 description 1
- BYRVKDUQDLJUBX-JJCDCTGGSA-N adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-JJCDCTGGSA-N 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 229960004733 albiglutide Drugs 0.000 description 1
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229960000552 alclometasone Drugs 0.000 description 1
- FJXOGVLKCZQRDN-PHCHRAKRSA-N alclometasone Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O FJXOGVLKCZQRDN-PHCHRAKRSA-N 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229950010817 alvocidib Drugs 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 229950004821 ambomycin Drugs 0.000 description 1
- 229960002414 ambrisentan Drugs 0.000 description 1
- OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 description 1
- 229960003099 amcinonide Drugs 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229960002469 antazoline Drugs 0.000 description 1
- REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- 229960001372 aprepitant Drugs 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229940092117 atgam Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 229960000383 azatadine Drugs 0.000 description 1
- SEBMTIQKRHYNIT-UHFFFAOYSA-N azatadine Chemical compound C1CN(C)CCC1=C1C2=NC=CC=C2CCC2=CC=CC=C21 SEBMTIQKRHYNIT-UHFFFAOYSA-N 0.000 description 1
- HRXVDDOKERXBEY-UHFFFAOYSA-N azatepa Chemical compound C1CN1P(=O)(N1CC1)N(CC)C1=NN=CS1 HRXVDDOKERXBEY-UHFFFAOYSA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 229950004295 azotomycin Drugs 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
- 229950001858 batimastat Drugs 0.000 description 1
- 229960004495 beclometasone Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229950005567 benzodepa Drugs 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- MMIMIFULGMZVPO-UHFFFAOYSA-N benzyl 3-bromo-2,6-dinitro-5-phenylmethoxybenzoate Chemical compound [O-][N+](=O)C1=C(C(=O)OCC=2C=CC=CC=2)C([N+](=O)[O-])=C(Br)C=C1OCC1=CC=CC=C1 MMIMIFULGMZVPO-UHFFFAOYSA-N 0.000 description 1
- VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl n-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
- FWYVRZOREBYLCY-UHFFFAOYSA-N bepafant Chemical compound C1C=2SC=3N4C(C)=NN=C4CN=C(C=4C(=CC=CC=4)Cl)C=3C=2CC1C(=O)N1CCOCC1 FWYVRZOREBYLCY-UHFFFAOYSA-N 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- 229950006844 bizelesin Drugs 0.000 description 1
- 229960004395 bleomycin sulfate Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 229960003065 bosentan Drugs 0.000 description 1
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- PZOHOALJQOFNTB-UHFFFAOYSA-M brequinar sodium Chemical compound [Na+].N1=C2C=CC(F)=CC2=C(C([O-])=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PZOHOALJQOFNTB-UHFFFAOYSA-M 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- AOJDZKCUAATBGE-UHFFFAOYSA-N bromomethane Chemical compound Br[CH2] AOJDZKCUAATBGE-UHFFFAOYSA-N 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- 229960000725 brompheniramine Drugs 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229950009494 bropirimine Drugs 0.000 description 1
- 229960005520 bryostatin Drugs 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- 229960001713 canagliflozin Drugs 0.000 description 1
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229950009338 caracemide Drugs 0.000 description 1
- 229950005155 carbetimer Drugs 0.000 description 1
- 229960000428 carbinoxamine Drugs 0.000 description 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001721 carbon Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000006244 carboxylic acid protecting group Chemical group 0.000 description 1
- WIUSFZNUZWLLDZ-UHFFFAOYSA-N caribaeolin Natural products C1=CC(OC)(C(=CC2C(C(C=CC2C(C)C)(C)O)C2)COC(C)=O)OC1(C)C2OC(=O)C=CC1=CN(C)C=N1 WIUSFZNUZWLLDZ-UHFFFAOYSA-N 0.000 description 1
- KGOMYXIKIJGWKS-UHFFFAOYSA-N caribaeoside Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(C=CC1C(C)C)(C)O)C1C=C2COC1OCC(O)C(O)C1OC(C)=O KGOMYXIKIJGWKS-UHFFFAOYSA-N 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- BBZDXMBRAFTCAA-AREMUKBSSA-N carzelesin Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 1
- 229950007509 carzelesin Drugs 0.000 description 1
- 229950010667 cedefingol Drugs 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- BZXULYMZYPRZOG-UHFFFAOYSA-N centaureidin Chemical compound C1=C(O)C(OC)=CC=C1C1=C(OC)C(=O)C2=C(O)C(OC)=C(O)C=C2O1 BZXULYMZYPRZOG-UHFFFAOYSA-N 0.000 description 1
- CCWSQXBMKLEALQ-WMZOPIPTSA-N centaureidin Natural products CO[C@@H]1[C@@H](Oc2cc(O)c(OC)c(O)c2C1=O)c3ccc(OC)c(O)c3 CCWSQXBMKLEALQ-WMZOPIPTSA-N 0.000 description 1
- KGOMYXIKIJGWKS-DKNGGRFKSA-N chembl1916173 Chemical compound C(/[C@H]1[C@H]([C@](C=C[C@@H]1C(C)C)(C)O)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O KGOMYXIKIJGWKS-DKNGGRFKSA-N 0.000 description 1
- OWSKEUBOCMEJMI-KPXOXKRLSA-N chembl2105946 Chemical compound [N-]=[N+]=CC(=O)CC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CCC(=O)C=[N+]=[N-])C(O)=O OWSKEUBOCMEJMI-KPXOXKRLSA-N 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000002559 chemokine receptor antagonist Substances 0.000 description 1
- 229960004831 chlorcyclizine Drugs 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- VQSGYKUTGGRSPK-UHFFFAOYSA-N chlorofusin Natural products N1C(=O)C(CCCCCCCC)NC(=O)C(CC(C)C)NC(=O)C(C(C)O)NC(=O)C(CC(C)C)NC(=O)C(CC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(C)NC(=O)C(C(C)O)NC(=O)C1CCCN1C2(OCCC2)C(O)C2=C(Cl)C(=O)C(C)(OC(=O)CCC)C(=O)C2=C1 VQSGYKUTGGRSPK-UHFFFAOYSA-N 0.000 description 1
- 108010076060 chlorofusin Proteins 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229950011359 cirolemycin Drugs 0.000 description 1
- 229960001284 citicoline Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 229960001146 clobetasone Drugs 0.000 description 1
- XXIFVOHLGBURIG-OZCCCYNHSA-N clobetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)CC2=O XXIFVOHLGBURIG-OZCCCYNHSA-N 0.000 description 1
- 229960004299 clocortolone Drugs 0.000 description 1
- YMTMADLUXIRMGX-RFPWEZLHSA-N clocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O YMTMADLUXIRMGX-RFPWEZLHSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 229960002219 cloprednol Drugs 0.000 description 1
- YTJIBEDMAQUYSZ-FDNPDPBUSA-N cloprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C=C(Cl)C2=C1 YTJIBEDMAQUYSZ-FDNPDPBUSA-N 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229960003840 cortivazol Drugs 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 108010083340 cryptophycin 52 Proteins 0.000 description 1
- YFGZFQNBPSCWPN-UHFFFAOYSA-N cryptophycin 52 Natural products C1=CC(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 YFGZFQNBPSCWPN-UHFFFAOYSA-N 0.000 description 1
- 229960000729 cyclandelate Drugs 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 229960003564 cyclizine Drugs 0.000 description 1
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- SSMHAKGTYOYXHN-UHFFFAOYSA-N cyclobutan-1,1-diyl Chemical group [C]1CCC1 SSMHAKGTYOYXHN-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- YXQWGVLNDXNSJJ-UHFFFAOYSA-N cyclopenta-1,3-diene;vanadium(2+) Chemical compound [V+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 YXQWGVLNDXNSJJ-UHFFFAOYSA-N 0.000 description 1
- CYKDRLQDTUXOBO-UHFFFAOYSA-N cyclopropan-1,1-diyl Chemical group [C]1CC1 CYKDRLQDTUXOBO-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- YCWXIQRLONXJLF-PFFGJIDWSA-N d06307 Chemical compound OS(O)(=O)=O.C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC.C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC YCWXIQRLONXJLF-PFFGJIDWSA-N 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- 229960003109 daunorubicin hydrochloride Drugs 0.000 description 1
- XQGZSYKGWHUSDH-UHFFFAOYSA-N dazoxiben Chemical compound C1=CC(C(=O)O)=CC=C1OCCN1C=NC=C1 XQGZSYKGWHUSDH-UHFFFAOYSA-N 0.000 description 1
- 229950008000 dazoxiben Drugs 0.000 description 1
- ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 229940119740 deoxycorticosterone Drugs 0.000 description 1
- NFDRTHOLSNXDNN-UHFFFAOYSA-N desacetyleleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1O NFDRTHOLSNXDNN-UHFFFAOYSA-N 0.000 description 1
- WRPLJTYNAMMOEE-TXILBGFKSA-N desmethyleleutherobin Chemical compound O([C@H]1C[C@H]2C(C)=CC[C@@H]([C@H]2\C=C(CO[C@H]2[C@H]([C@H](O)[C@H](O)CO2)OC(C)=O)/[C@]2(O)O[C@@]1(C)C=C2)C(C)C)C(=O)\C=C\C1=CN(C)C=N1 WRPLJTYNAMMOEE-TXILBGFKSA-N 0.000 description 1
- WRPLJTYNAMMOEE-UHFFFAOYSA-N desmethyleleutherobin Natural products C1=CC2(C)OC1(O)C(COC1C(C(O)C(O)CO1)OC(C)=O)=CC1C(C(C)C)CC=C(C)C1CC2OC(=O)C=CC1=CN(C)C=N1 WRPLJTYNAMMOEE-UHFFFAOYSA-N 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960002593 desoximetasone Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- 229960003654 desoxycortone Drugs 0.000 description 1
- BEFZAMRWPCMWFJ-UHFFFAOYSA-N desoxyepothilone A Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC=CCC1C(C)=CC1=CSC(C)=N1 BEFZAMRWPCMWFJ-UHFFFAOYSA-N 0.000 description 1
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 description 1
- SOYKEARSMXGVTM-HNNXBMFYSA-N dexchlorpheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 SOYKEARSMXGVTM-HNNXBMFYSA-N 0.000 description 1
- 229960001882 dexchlorpheniramine Drugs 0.000 description 1
- VPOCYEOOFRNHNL-RQDPQJJXSA-J dexormaplatin Chemical compound Cl[Pt](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N VPOCYEOOFRNHNL-RQDPQJJXSA-J 0.000 description 1
- 229950001640 dexormaplatin Drugs 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- YKBUODYYSZSEIY-PLSHLZFXSA-N diazonamide a Chemical compound N([C@H]([C@]12C=3O4)O5)C6=C2C=CC=C6C(C2=6)=CC=CC=6NC(Cl)=C2C(=C(N=2)Cl)OC=2C=3N=C4[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)C)CC2=CC=C5C1=C2 YKBUODYYSZSEIY-PLSHLZFXSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229960004154 diflorasone Drugs 0.000 description 1
- WXURHACBFYSXBI-XHIJKXOTSA-N diflorasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-XHIJKXOTSA-N 0.000 description 1
- 229960004091 diflucortolone Drugs 0.000 description 1
- OGPWIDANBSLJPC-RFPWEZLHSA-N diflucortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O OGPWIDANBSLJPC-RFPWEZLHSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 229960004875 difluprednate Drugs 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical group [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- CZLKTMHQYXYHOO-QTNFYWBSSA-L disodium;(2s)-2-[(2-phosphonatoacetyl)amino]butanedioic acid Chemical compound [Na+].[Na+].OC(=O)C[C@@H](C(O)=O)NC(=O)CP([O-])([O-])=O CZLKTMHQYXYHOO-QTNFYWBSSA-L 0.000 description 1
- SVJSWELRJWVPQD-KJWOGLQMSA-L disodium;(2s)-2-[[4-[2-[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 SVJSWELRJWVPQD-KJWOGLQMSA-L 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 1
- 108010045524 dolastatin 10 Proteins 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 229960005178 doxylamine Drugs 0.000 description 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229950005133 duazomycin Drugs 0.000 description 1
- 229930192837 duazomycin Natural products 0.000 description 1
- 229960005175 dulaglutide Drugs 0.000 description 1
- 108010005794 dulaglutide Proteins 0.000 description 1
- 229950009041 edaravone Drugs 0.000 description 1
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- 229960002046 eflornithine hydrochloride Drugs 0.000 description 1
- XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 description 1
- MGQRRMONVLMKJL-KWJIQSIXSA-N elsamitrucin Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](N)[C@H]1O[C@@H]1[C@](O)(C)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 MGQRRMONVLMKJL-KWJIQSIXSA-N 0.000 description 1
- 229950002339 elsamitrucin Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229960003345 empagliflozin Drugs 0.000 description 1
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229950010625 enloplatin Drugs 0.000 description 1
- 229950001022 enpromate Drugs 0.000 description 1
- GLCKXJLCYIJMRB-UPRLRBBYSA-N enrasentan Chemical compound C1([C@H]2[C@@H]([C@H](C3=CC=C(C=C32)OCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1OCCO GLCKXJLCYIJMRB-UPRLRBBYSA-N 0.000 description 1
- 229950006561 enrasentan Drugs 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229950004926 epipropidine Drugs 0.000 description 1
- 229960003265 epirubicin hydrochloride Drugs 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
- BEFZAMRWPCMWFJ-QJKGZULSSA-N epothilone C Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QJKGZULSSA-N 0.000 description 1
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 1
- FCCNKYGSMOSYPV-UHFFFAOYSA-N epothilone E Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2OC2CC1C(C)=CC1=CSC(CO)=N1 FCCNKYGSMOSYPV-UHFFFAOYSA-N 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- FCCNKYGSMOSYPV-OKOHHBBGSA-N epothilone e Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 FCCNKYGSMOSYPV-OKOHHBBGSA-N 0.000 description 1
- UKIMCRYGLFQEOE-RGJAOAFDSA-N epothilone f Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 UKIMCRYGLFQEOE-RGJAOAFDSA-N 0.000 description 1
- 229950006535 ertugliflozin Drugs 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
- 229960003745 esmolol Drugs 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960001766 estramustine phosphate sodium Drugs 0.000 description 1
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N etanidazole Chemical compound OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 description 1
- 229950006566 etanidazole Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- GTCBVGDJIQFBFF-UHFFFAOYSA-N ethyl 4-(dimethylamino)-2-oxobut-3-enoate Chemical compound CCOC(=O)C(=O)C=CN(C)C GTCBVGDJIQFBFF-UHFFFAOYSA-N 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- JEFPWOBULVSOTM-PPHPATTJSA-N ethyl n-[(2s)-5-amino-2-methyl-3-phenyl-1,2-dihydropyrido[3,4-b]pyrazin-7-yl]carbamate;2-hydroxyethanesulfonic acid Chemical compound OCCS(O)(=O)=O.C=1([C@H](C)NC=2C=C(N=C(N)C=2N=1)NC(=O)OCC)C1=CC=CC=C1 JEFPWOBULVSOTM-PPHPATTJSA-N 0.000 description 1
- HZQPPNNARUQMJA-IMIWJGOWSA-N ethyl n-[4-[[(2r,4r)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methylsulfanyl]phenyl]carbamate;hydrochloride Chemical compound Cl.C1=CC(NC(=O)OCC)=CC=C1SC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 HZQPPNNARUQMJA-IMIWJGOWSA-N 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- NMUSYJAQQFHJEW-ARQDHWQXSA-N fazarabine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-ARQDHWQXSA-N 0.000 description 1
- 229950005096 fazarabine Drugs 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960005341 fenoprofen calcium Drugs 0.000 description 1
- VHUXSAWXWSTUOD-UHFFFAOYSA-L fenoprofen calcium (anhydrous) Chemical compound [Ca+2].[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1.[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 VHUXSAWXWSTUOD-UHFFFAOYSA-L 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960001440 fluclorolone Drugs 0.000 description 1
- VTWKPILBIUBMDS-OTJLYDAYSA-N fluclorolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(Cl)[C@@H](Cl)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 VTWKPILBIUBMDS-OTJLYDAYSA-N 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960002011 fludrocortisone Drugs 0.000 description 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
- 229960004511 fludroxycortide Drugs 0.000 description 1
- 229960003469 flumetasone Drugs 0.000 description 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 229960005355 fluocortin Drugs 0.000 description 1
- 229960003973 fluocortolone Drugs 0.000 description 1
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 description 1
- 229960001048 fluorometholone Drugs 0.000 description 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960003590 fluperolone Drugs 0.000 description 1
- HHPZZKDXAFJLOH-QZIXMDIESA-N fluperolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](OC(C)=O)C)(O)[C@@]1(C)C[C@@H]2O HHPZZKDXAFJLOH-QZIXMDIESA-N 0.000 description 1
- 229960003238 fluprednidene Drugs 0.000 description 1
- YVHXHNGGPURVOS-SBTDHBFYSA-N fluprednidene Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](C(=C)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 YVHXHNGGPURVOS-SBTDHBFYSA-N 0.000 description 1
- 229950005682 flurocitabine Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- UXTSQCOOUJTIAC-UHFFFAOYSA-N fosquidone Chemical compound C=1N2CC3=CC=CC=C3C(C)C2=C(C(C2=CC=C3)=O)C=1C(=O)C2=C3OP(O)(=O)OCC1=CC=CC=C1 UXTSQCOOUJTIAC-UHFFFAOYSA-N 0.000 description 1
- 229950005611 fosquidone Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 229960005144 gemcitabine hydrochloride Drugs 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 229930000755 gossypol Natural products 0.000 description 1
- 229950005277 gossypol Drugs 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- FXNFULJVOQMBCW-VZBLNRDYSA-N halichondrin b Chemical compound O([C@@H]1[C@@H](C)[C@@H]2O[C@@H]3C[C@@]4(O[C@H]5[C@@H](C)C[C@@]6(C[C@@H]([C@@H]7O[C@@H](C[C@@H]7O6)[C@@H](O)C[C@@H](O)CO)C)O[C@H]5C4)O[C@@H]3C[C@@H]2O[C@H]1C[C@@H]1C(=C)[C@H](C)C[C@@H](O1)CC[C@H]1C(=C)C[C@@H](O1)CC1)C(=O)C[C@H](O2)CC[C@H]3[C@H]2[C@H](O2)[C@@H]4O[C@@H]5C[C@@]21O[C@@H]5[C@@H]4O3 FXNFULJVOQMBCW-VZBLNRDYSA-N 0.000 description 1
- 229960002475 halometasone Drugs 0.000 description 1
- GGXMRPUKBWXVHE-MIHLVHIWSA-N halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 108010057806 hemiasterlin Proteins 0.000 description 1
- 229930187626 hemiasterlin Natural products 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229960002453 hydrocortisone aceponate Drugs 0.000 description 1
- MFBMYAOAMQLLPK-FZNHGJLXSA-N hydrocortisone aceponate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(C)=O)(OC(=O)CC)[C@@]1(C)C[C@@H]2O MFBMYAOAMQLLPK-FZNHGJLXSA-N 0.000 description 1
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 1
- 229960002846 hydrocortisone probutate Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- SOCGJDYHNGLZEC-UHFFFAOYSA-N hydron;n-methyl-n-[4-[(7-methyl-3h-imidazo[4,5-f]quinolin-9-yl)amino]phenyl]acetamide;chloride Chemical compound Cl.C1=CC(N(C(C)=O)C)=CC=C1NC1=CC(C)=NC2=CC=C(NC=N3)C3=C12 SOCGJDYHNGLZEC-UHFFFAOYSA-N 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- SKOWZLGOFVSKLB-UHFFFAOYSA-N hypodiboric acid Chemical compound OB(O)B(O)O SKOWZLGOFVSKLB-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960001176 idarubicin hydrochloride Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960002240 iloprost Drugs 0.000 description 1
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004926 indolenyl group Chemical group 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 229960003507 interferon alfa-2b Drugs 0.000 description 1
- 229960004061 interferon alfa-n1 Drugs 0.000 description 1
- 108010006088 interferon alfa-n1 Proteins 0.000 description 1
- 229940109242 interferon alfa-n3 Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229950000991 ipragliflozin Drugs 0.000 description 1
- AHFWIQIYAXSLBA-RQXATKFSSA-N ipragliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(F)C(CC=2SC3=CC=CC=C3C=2)=C1 AHFWIQIYAXSLBA-RQXATKFSSA-N 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 229950010897 iproplatin Drugs 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 229960000779 irinotecan hydrochloride Drugs 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 229950003690 isbogrel Drugs 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- DWOIXRLFJBZDSB-MLLHTCFKSA-N isoeleutherobin a Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](OC(C)=O)[C@@H]1O DWOIXRLFJBZDSB-MLLHTCFKSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- FABUFPQFXZVHFB-PVYNADRNSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-PVYNADRNSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004384 ketorolac tromethamine Drugs 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- FPKOGTAFKSLZLD-FQEVSTJZSA-N lamifiban Chemical compound C1=CC(C(=N)N)=CC=C1C(=O)N[C@H](C(=O)N1CCC(CC1)OCC(O)=O)CC1=CC=C(O)C=C1 FPKOGTAFKSLZLD-FQEVSTJZSA-N 0.000 description 1
- 229950003178 lamifiban Drugs 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960001739 lanreotide acetate Drugs 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- KDQAABAKXDWYSZ-SDCRJXSCSA-N leurosidine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-SDCRJXSCSA-N 0.000 description 1
- 229960001120 levocabastine Drugs 0.000 description 1
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 description 1
- 229960001508 levocetirizine Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- XDMHALQMTPSGEA-UHFFFAOYSA-N losoxantrone hydrochloride Chemical compound Cl.Cl.OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO XDMHALQMTPSGEA-UHFFFAOYSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 229960000994 lumiracoxib Drugs 0.000 description 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
- 229950004397 luseogliflozin Drugs 0.000 description 1
- 229940072082 magnesium salicylate Drugs 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 229940099262 marinol Drugs 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
- 229960002868 mechlorethamine hydrochloride Drugs 0.000 description 1
- 229940013798 meclofenamate Drugs 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-M meclofenamic acid(1-) Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C([O-])=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-M 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960001011 medrysone Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960003846 melengestrol acetate Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- LWYJUZBXGAFFLP-OCNCTQISSA-N menogaril Chemical compound O1[C@@]2(C)[C@H](O)[C@@H](N(C)C)[C@H](O)[C@@H]1OC1=C3C(=O)C(C=C4C[C@@](C)(O)C[C@H](C4=C4O)OC)=C4C(=O)C3=C(O)C=C12 LWYJUZBXGAFFLP-OCNCTQISSA-N 0.000 description 1
- 229950002676 menogaril Drugs 0.000 description 1
- 229960001810 meprednisone Drugs 0.000 description 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- KPQJSSLKKBKWEW-RKDOVGOJSA-N methanesulfonic acid;5-nitro-2-[(2r)-1-[2-[[(2r)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.[O-][N+](=O)C1=CC(C(N([C@@H](CNCCNC[C@@H](C)N2C(C=3C=C(C=C4C=CC=C(C=34)C2=O)[N+]([O-])=O)=O)C)C2=O)=O)=C3C2=CC=CC3=C1 KPQJSSLKKBKWEW-RKDOVGOJSA-N 0.000 description 1
- BKBBTCORRZMASO-ZOWNYOTGSA-M methotrexate monosodium Chemical compound [Na+].C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C([O-])=O)C=C1 BKBBTCORRZMASO-ZOWNYOTGSA-M 0.000 description 1
- 229960003058 methotrexate sodium Drugs 0.000 description 1
- HNTJWMPUBJHPLD-UHFFFAOYSA-N methyl 1-(4-bromophenyl)cyclopropane-1-carboxylate Chemical compound C=1C=C(Br)C=CC=1C1(C(=O)OC)CC1 HNTJWMPUBJHPLD-UHFFFAOYSA-N 0.000 description 1
- JTYDXPPFLQSEAQ-UHFFFAOYSA-N methyl 2-(4-bromophenyl)-2-methylpropanoate Chemical compound COC(=O)C(C)(C)C1=CC=C(Br)C=C1 JTYDXPPFLQSEAQ-UHFFFAOYSA-N 0.000 description 1
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960002037 methylprednisolone aceponate Drugs 0.000 description 1
- DALKLAYLIPSCQL-YPYQNWSCSA-N methylprednisolone aceponate Chemical compound C1([C@@H](C)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CC)[C@@]2(C)C[C@@H]1O DALKLAYLIPSCQL-YPYQNWSCSA-N 0.000 description 1
- VQJHOPSWBGJHQS-UHFFFAOYSA-N metoprine, methodichlorophen Chemical compound CC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C(Cl)=C1 VQJHOPSWBGJHQS-UHFFFAOYSA-N 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- QTFKTBRIGWJQQL-UHFFFAOYSA-N meturedepa Chemical compound C1C(C)(C)N1P(=O)(NC(=O)OCC)N1CC1(C)C QTFKTBRIGWJQQL-UHFFFAOYSA-N 0.000 description 1
- 229950009847 meturedepa Drugs 0.000 description 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
- 229950010895 midostaurin Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- DRCJGCOYHLTVNR-ZUIZSQJWSA-N mitindomide Chemical compound C1=C[C@@H]2[C@@H]3[C@H]4C(=O)NC(=O)[C@H]4[C@@H]3[C@H]1[C@@H]1C(=O)NC(=O)[C@H]21 DRCJGCOYHLTVNR-ZUIZSQJWSA-N 0.000 description 1
- 229950001314 mitindomide Drugs 0.000 description 1
- 229950002137 mitocarcin Drugs 0.000 description 1
- 229950000911 mitogillin Drugs 0.000 description 1
- 108010026677 mitomalcin Proteins 0.000 description 1
- 229950007612 mitomalcin Drugs 0.000 description 1
- 229950005715 mitosper Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004169 mitoxantrone hydrochloride Drugs 0.000 description 1
- 229960001144 mizolastine Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- CRJGESKKUOMBCT-PMACEKPBSA-N n-[(2s,3s)-1,3-dihydroxyoctadecan-2-yl]acetamide Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-PMACEKPBSA-N 0.000 description 1
- NKFHKYQGZDAKMX-PPRKPIOESA-N n-[(e)-1-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]ethylideneamino]benzamide;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 NKFHKYQGZDAKMX-PPRKPIOESA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- KWQWWUXRGIIBAS-UHFFFAOYSA-N n-[2-(4-hydroxyanilino)pyridin-3-yl]-4-methoxybenzenesulfonamide;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=CN=C1NC1=CC=C(O)C=C1 KWQWWUXRGIIBAS-UHFFFAOYSA-N 0.000 description 1
- TUYWTLTWNJOZNY-UHFFFAOYSA-N n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2h-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-propan-2-ylpyridine-2-sulfonamide Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2C=C(N=CC=2)C2=NNN=N2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)C)C=N1 TUYWTLTWNJOZNY-UHFFFAOYSA-N 0.000 description 1
- JNGQUJZDVFZPEN-UHFFFAOYSA-N n-[[4-(5-bromopyrimidin-2-yl)oxy-3-methylphenyl]carbamoyl]-2-(dimethylamino)benzamide Chemical compound CN(C)C1=CC=CC=C1C(=O)NC(=O)NC(C=C1C)=CC=C1OC1=NC=C(Br)C=N1 JNGQUJZDVFZPEN-UHFFFAOYSA-N 0.000 description 1
- WRINSSLBPNLASA-FOCLMDBBSA-N n-methyl-n-[(e)-(n-methylanilino)diazenyl]aniline Chemical compound C=1C=CC=CC=1N(C)\N=N\N(C)C1=CC=CC=C1 WRINSSLBPNLASA-FOCLMDBBSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- 230000006959 non-competitive inhibition Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- 229960000435 oblimersen Drugs 0.000 description 1
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229960005117 olmesartan Drugs 0.000 description 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 229950008017 ormaplatin Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229950000370 oxisuran Drugs 0.000 description 1
- 229950003837 ozagrel Drugs 0.000 description 1
- SHZKQBHERIJWAO-AATRIKPKSA-N ozagrel Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1CN1C=NC=C1 SHZKQBHERIJWAO-AATRIKPKSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 229960002858 paramethasone Drugs 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 229950006960 peliomycin Drugs 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- VPAWVRUHMJVRHU-VGDKGRGNSA-N perfosfamide Chemical compound OO[C@@H]1CCO[P@@](=O)(N(CCCl)CCCl)N1 VPAWVRUHMJVRHU-VGDKGRGNSA-N 0.000 description 1
- 229950009351 perfosfamide Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 239000003358 phospholipase A2 inhibitor Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- XESARGFCSKSFID-FLLFQEBCSA-N pirazofurin Chemical compound OC1=C(C(=O)N)NN=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XESARGFCSKSFID-FLLFQEBCSA-N 0.000 description 1
- 229960003073 pirfenidone Drugs 0.000 description 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 description 1
- 102000030769 platelet activating factor receptor Human genes 0.000 description 1
- JKPDEYAOCSQBSZ-OEUJLIAZSA-N plomestane Chemical compound O=C1CC[C@]2(CC#C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKPDEYAOCSQBSZ-OEUJLIAZSA-N 0.000 description 1
- 229950004541 plomestane Drugs 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229960004293 porfimer sodium Drugs 0.000 description 1
- 229950004406 porfiromycin Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960002794 prednicarbate Drugs 0.000 description 1
- FNPXMHRZILFCKX-KAJVQRHHSA-N prednicarbate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O FNPXMHRZILFCKX-KAJVQRHHSA-N 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 229960001586 procarbazine hydrochloride Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- MKSVFGKWZLUTTO-FZFAUISWSA-N puromycin dihydrochloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO MKSVFGKWZLUTTO-FZFAUISWSA-N 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000004292 pyrrolin-2-yl group Chemical group [H]C1([H])N=C(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004363 pyrrolin-3-yl group Chemical group [H]C1=NC([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 108700027806 rGLP-1 Proteins 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229950011516 remogliflozin etabonate Drugs 0.000 description 1
- UAOCLDQAQNNEAX-ABMICEGHSA-N remogliflozin etabonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=NN(C(C)C)C(C)=C1CC1=CC=C(OC(C)C)C=C1 UAOCLDQAQNNEAX-ABMICEGHSA-N 0.000 description 1
- 229960004356 riboprine Drugs 0.000 description 1
- 229950006674 ridogrel Drugs 0.000 description 1
- GLLPUTYLZIKEGF-HAVVHWLPSA-N ridogrel Chemical compound C=1C=CC(C(F)(F)F)=CC=1C(=N/OCCCCC(=O)O)\C1=CC=CN=C1 GLLPUTYLZIKEGF-HAVVHWLPSA-N 0.000 description 1
- 229960001487 rimexolone Drugs 0.000 description 1
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- QXKJWHWUDVQATH-UHFFFAOYSA-N rogletimide Chemical compound C=1C=NC=CC=1C1(CC)CCC(=O)NC1=O QXKJWHWUDVQATH-UHFFFAOYSA-N 0.000 description 1
- 229950005230 rogletimide Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 102220009258 rs193922583 Human genes 0.000 description 1
- 229950008902 safingol Drugs 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 229950011186 semaglutide Drugs 0.000 description 1
- 108010060325 semaglutide Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229950009089 simtrazene Drugs 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- PHWXUGHIIBDVKD-UHFFFAOYSA-N sitaxentan Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC=2C(=CC=3OCOC=3C=2)C)=C1Cl PHWXUGHIIBDVKD-UHFFFAOYSA-N 0.000 description 1
- 229960002578 sitaxentan Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229950004296 soblidotin Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- XBUIKNRVGYFSHL-IAVQPKKASA-M sodium;[(1e,3r,4r,6r,7z,9z,11e)-3,6,13-trihydroxy-3-methyl-1-[(2r)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] hydrogen phosphate Chemical compound [Na+].OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)([O-])=O)[C@@](O)(C)\C=C\[C@H]1CC=CC(=O)O1 XBUIKNRVGYFSHL-IAVQPKKASA-M 0.000 description 1
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 229950005268 sotagliflozin Drugs 0.000 description 1
- 229950009641 sparsomycin Drugs 0.000 description 1
- XKLZIVIOZDNKEQ-CLQLPEFOSA-N sparsomycin Chemical compound CSC[S@](=O)C[C@H](CO)NC(=O)\C=C\C1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-CLQLPEFOSA-N 0.000 description 1
- XKLZIVIOZDNKEQ-UHFFFAOYSA-N sparsomycin Natural products CSCS(=O)CC(CO)NC(=O)C=CC1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-UHFFFAOYSA-N 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 229950006050 spiromustine Drugs 0.000 description 1
- 229950004330 spiroplatin Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229950007841 sulofenur Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- PTTJLTMUKRRHAT-KYDPQNDISA-N taccalonolide A Natural products O=C(O[C@@H]1[C@H](OC(=O)C)[C@@H]2[C@]3(C)[C@H](OC(=O)C)[C@H]4O[C@H]4C[C@@H]3C(=O)[C@H](O)[C@H]2[C@@H]2[C@@H](OC(=O)C)[C@H]3[C@@]4(C)[C@@](O)(C)C(=O)OC4=C[C@@H](C)[C@@H]3[C@@]12C)C PTTJLTMUKRRHAT-KYDPQNDISA-N 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 108700003774 talisomycin Proteins 0.000 description 1
- 229950002687 talisomycin Drugs 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- URLYINUFLXOMHP-HTVVRFAVSA-N tcn-p Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O URLYINUFLXOMHP-HTVVRFAVSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 229950008703 teroxirone Drugs 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 229950000584 tezosentan Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000005503 thioxanyl group Chemical group 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- 229960003723 tiazofurine Drugs 0.000 description 1
- FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229950002376 tirapazamine Drugs 0.000 description 1
- ORYDPOVDJJZGHQ-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=CC2=[N+]([O-])C(N)=N[N+]([O-])=C21 ORYDPOVDJJZGHQ-UHFFFAOYSA-N 0.000 description 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
- 229960003425 tirofiban Drugs 0.000 description 1
- 229960004631 tixocortol Drugs 0.000 description 1
- YWDBSCORAARPPF-VWUMJDOOSA-N tixocortol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CS)[C@@H]4[C@@H]3CCC2=C1 YWDBSCORAARPPF-VWUMJDOOSA-N 0.000 description 1
- 229950006667 tofogliflozin Drugs 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- MWYHLEQJTQJHSS-UHFFFAOYSA-N tomelukast Chemical compound C1=CC(C(C)=O)=C(O)C(CCC)=C1OCCCCC1=NNN=N1 MWYHLEQJTQJHSS-UHFFFAOYSA-N 0.000 description 1
- 229950010953 tomelukast Drugs 0.000 description 1
- 229960004167 toremifene citrate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229950005135 traxoprodil Drugs 0.000 description 1
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 description 1
- 229960005032 treprostinil Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- 238000006692 trifluoromethylation reaction Methods 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- 229960000538 trimetrexate glucuronate Drugs 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 229960001128 triprolidine Drugs 0.000 description 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 108010061145 tubulysin A Proteins 0.000 description 1
- 229960002249 ulobetasol Drugs 0.000 description 1
- LEHFPXVYPMWYQD-XHIJKXOTSA-N ulobetasol Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]2(C)C[C@@H]1O LEHFPXVYPMWYQD-XHIJKXOTSA-N 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- SPDZFJLQFWSJGA-UHFFFAOYSA-N uredepa Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 1
- 229950006929 uredepa Drugs 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 229960002730 vapreotide Drugs 0.000 description 1
- 108700029852 vapreotide Proteins 0.000 description 1
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 1
- 229960003895 verteporfin Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
- 229960004982 vinblastine sulfate Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
- 229960002110 vincristine sulfate Drugs 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960005212 vindesine sulfate Drugs 0.000 description 1
- BCXOZISMDZTYHW-IFQBWSDRSA-N vinepidine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@H](C2)CC)N2CCC2=C1NC1=CC=CC=C21 BCXOZISMDZTYHW-IFQBWSDRSA-N 0.000 description 1
- 229960002166 vinorelbine tartrate Drugs 0.000 description 1
- GBABOYUKABKIAF-IWWDSPBFSA-N vinorelbinetartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- UFOVYHGILLJGLP-UHFFFAOYSA-N vitilevuamide Chemical compound N1C(=O)C(NC(=O)CCC(O)=O)CSCC(C(NC(C(=O)NC(=C)C(=O)NC(CC(C)CC)C(=O)NC(C(=O)N(C)C(C(O)COC)C(=O)NC(CO)C(=O)OC2C)C(C)C)C(C)CC)=O)NC(=O)C3CCCN3C(=O)C(CC=3C=CC=CC=3)NC(=O)C2NC(=O)C(CC(C)CC)NC(=O)C(C)NC(=O)C1CC1=CC=CC=C1 UFOVYHGILLJGLP-UHFFFAOYSA-N 0.000 description 1
- 108010079700 vitilevuamide Proteins 0.000 description 1
- 229960001771 vorozole Drugs 0.000 description 1
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 1
- DVPVGSLIUJPOCJ-XXRQFBABSA-N x1j761618a Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(=O)CN(C)C)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(=O)CN(C)C)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 DVPVGSLIUJPOCJ-XXRQFBABSA-N 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
- 229950003017 zeniplatin Drugs 0.000 description 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
- 229960005332 zileuton Drugs 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/52—Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to compounds having pharmacological activity, to processes for preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and prophylaxis of disease in a subject in need thereof, in particular for human and veterinarian treatments of pain, pruritus, cancer, inflammation and fibrotic diseases.
- Lysophospholipids affect fundamental cellular functions that include proliferation, differentiation, survival, migration, adhesion, invasion, and morphogensis. Abnormal functions influence many biological processes leading to disease that include, but are not limited to fibrotic disease, inflammation, cancer and peripheral nerve injury.
- Lysophosphatidic acid (LPA) is a lysophospholipid that has been shown to act through specific G protein-coupled receptors (GPCRs) in an autocrine and paracrine fashion. Antagonists of the LPA receptors find use in the treatment of diseases, disorders or conditions in which LPA plays a role.
- GPCRs G protein-coupled receptors
- LPAs lysophosphatidic acid receptors
- LPA1R lysophosphatidic acid receptor subtype 1
- LPA lysophosphatidic acid
- those compounds are useful for the treatment of fibrosis of organs (e.g., liver, kidney, lung, heart and the like), liver diseases (e.g., acute hepatatis, chronic hepatitis, liver fibrosis, liver cirrhosis, portal hypertension, regenerative failure, nonalcoholic steatohepatitis (NASH), liver hypofunction, hepatic blood flow disorder, and the like), cell proliferative disease such as cancers (including but not limited to solid tumor, solid tumor metastasis, vascular fibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia, chronic lymphocytic leukemia (CLL), invasive metastasis of cancer cell, and the like), inflammatory diseases (including but not limited to psoriasis, nephropathy, pneumonia and the like), gastrointestinal tract disease (including but not limited to (irritable bowel syndrome (IBS), inflammatory bowel disease (IBD
- the compounds of the invention include compounds of Formula I that have the structure:
- compositions, devices, articles of manufacture or methods that “comprise” a component or step are open and they include or read on those compositions or methods plus an additional component(s) or step(s).
- disclosed compositions, devices, articles of manufacture or methods that “consist of” a component or step are closed and they would not include or read on those compositions or methods having appreciable amounts of an additional component(s) or an additional step(s).
- use of the term “including” as well as other forms, such as “include”, “includes,” and “included,” is not limiting.
- the section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. Unless otherwise indicated, conventional methods of mass spectroscopy, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA techniques and pharmacology are employed.
- “Bond” or “single bond” as used herein means a chemical bond between two atoms, or two moieties when the atoms joined by the bond are considered to be part of larger substructure.
- the referenced group is absent thereby allowing a bond to be formed between the remaining identified groups.
- Manganesed ring as used herein means any cyclic structure.
- the term “membered” is meant to denote the number of skeletal atoms that constitute the ring.
- those membered rings include cyclohexyl, pyridinyl, pyranyl and thiopyranyl, which are 6-membered rings and cyclopentyl, pyrrolyl, furanyl, and thienyl, which are 5-membered rings.
- “Moiety” as used herein means a specific segment, fragment or functional group of a molecule or compound. Chemical moieties are sometimes indicated as chemical entities that are embedded in or appended (i.e., a substituent or variable group) to a molecule or compound.
- Alkyl as used herein is a collection of carbon atoms that are covalently linked together in normal, secondary, tertiary or cyclic arrangements, i.e., in a linear, branched, cyclic arrangement or some combination thereof.
- An alkyl substituent to a structure is that chain of carbon atoms that is covalently attached to the structure through a sp 3 carbon of the substituent.
- alkyl substituents contains one or more saturated moieties or groups and may additionally contain unsaturated alkyl moieties or groups, i.e., the substituent may comprise one, two, three or more independently selected double bonds or triple bonds of a combination thereof, typically one double or one triple bond if such unsaturated alkyl moieties or groups are present.
- Unsaturated alkyl moieties or groups include moieties or groups as described below for alkenyl, alkynyl, cycloalkyl, and aryl moieties. Saturated alkyl moieties contain saturated carbon atoms (sp 3 ) and no aromatic, sp 2 or sp carbon atoms.
- the number of carbon atoms in an alkyl moiety or group can vary and typically is 1 to about 50, e.g., about 1-30 or about 1-20, unless otherwise specified, e.g., C 1-8 alkyl or C1-C8 alkyl means an alkyl moiety containing 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms and C 1-6 alkyl or C1-C6 means an alkyl moiety containing 1, 2, 3, 4, 5 or 6 carbon atoms.
- species may include methyl, ethyl, 1-propyl (n-propyl), 2-propyl (iso-propyl, —CH(CH 3 ) 2 ), 1-butyl (n-butyl), 2-methyl-1-propyl (iso-butyl, —CH 2 CH(CH 3 ) 2 ), 2-butyl (sec-butyl, —CH(CH 3 )CH 2 CH 3 ), 2-methyl-2-propyl (t-butyl, —C(CH 3 ) 3 ), amyl, isoamyl, sec-amyl and other linear, cyclic and branch chain alkyl moieties.
- alkyl groups can contain species and groups described below for cycloalkyl, alkenyl, alkynyl groups, aryl groups, arylalkyl groups, alkylaryl groups and the like.
- Cycloalkyl as used here is a monocyclic, bicyclic or tricyclic ring system composed of only carbon atoms.
- the term “cycloalkyl” encompasses a monocyclic or polycyclic aliphatic, non-aromatic radical, wherein each of the atoms forming the ring (i.e. skeletal atoms) is a carbon atom.
- the number of carbon atoms in an cycloalkyl substituent, moiety or group can vary and typically is 3 to about 50, e.g., about 1-30 or about 1-20, unless otherwise specified, e.g., C 3-8 alkyl or C3-C8 alkyl means an cycloalkyl substituent, moiety or group containing 3, 4, 5, 6, 7 or 8 carbon atoms and C 3-6 alkyl or C3-C6 means an cycloalkyl substituent, moiety or group containing 3, 4, 5 or 6 carbon atoms.
- Cycloalkyl substituents, moieties or groups will typically have 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms and may contain exo or endo-cyclic double bonds or endo-cyclic triple bonds or a combination of both wherein the endo-cyclic double or triple bonds, or the combination of both, do not form a cyclic conjugated system of 4n+2 electrons; wherein the bicyclic ring system may share one (i.e., spiro ring system) or two carbon atoms and the tricyclic ring system may share a total of 2, 3 or 4 carbon atoms, typically 2 or 3.
- cycloalkyl substituents, moieties or groups can contain moieties and groups described for alkenyl, alkynyl, aryl, arylalkyl, alkylaryl and the like and can contain one or more other cycloalkyl moieties.
- cycloalkyls may be saturated, or partially unsaturated.
- Cycloalkyls may be fused with an aromatic ring, and the points of attachment to the aromatic ring are at a carbon or carbons of the cycloalkyl substituent, moiety or group that is not an aromatic ring carbon atom.
- Cycloalkyl groups include groups having from 3 to 10 ring atoms.
- Cycloalkyl substituents, moieties or groups include cyclopropyl, cyclopentyl, cyclohexyl, adamantly or other cyclic all carbon containing moieties. Cycloalkyls further include cyclobutyl, cyclopentenyl, cyclohexenyl, cycloheptyl and cyclooctyl. Cycloalkyl groups may be substituted or unsubstituted.
- a cycloalkyl substituent can be a monoradical or a diradical (i.e., an cycloalkylene, such as, but not limited to, cyclopropan-1,1-diyl, cyclobutan-1,1-diyl, cyclopentan-1,1-diyl, cyclohexan-1,1-diyl, cyclohexan-1,4-diyl, cycloheptan-1,1-diyl, and the like).
- an cycloalkylene such as, but not limited to, cyclopropan-1,1-diyl, cyclobutan-1,1-diyl, cyclopentan-1,1-diyl, cyclohexan-1,1-diyl, cyclohexan-1,4-diyl, cycloheptan-1,1-diyl, and the like).
- cycloalkyl When cycloalkyl is used as a Markush group (i.e., a substituent) the cycloalkyl is attached to a Markush formula with which it is associated through a carbon involved in a cyclic carbon ring system carbon of the cycloalkyl group that is not an aromatic carbon.
- Heteroalkylene as used herein means an alkylene (i.e. alkanediyl) group, moiety or substituent in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorus or combinations thereof. Heteroalkylene includes C 1 -C 6 heteroalkylene or C 1 -C 4 heteroalkylene.
- heteroalkylenes include, but are not limited to, —OCH 2 —, —OCH(CH 3 )—, —OC(CH 3 ) 2 —, —OCH 2 CH 2 —, —CH 2 O—, —CH(CH 3 )O—, C(CH 3 ) 2 O—, —CH 2 CH 2 O—, —CH 2 OCH 2 —, —CH 2 OCH 2 CH 2 —, —CH 2 CH 2 OCH 2 —, —SCH 2 —, —SCH(CH 3 )—, —SC(CH 3 ) 2 —, —SCH 2 CH 2 —, —CH 2 S—, —CH(CH 3 )S—, —C(CH 3 ) 2 S—, —CH 2 CH 2 S—, —CH 2 SCH 2 —, —CH 2 SCH 2 CH 2 —, —CH 2 CH 2 SCH 2 —, —S( ⁇ O) 2 CH 2 —, —S( ⁇
- Carboxylic acid bioisostere as used herein means a functional group, moiety or substituent that exhibits similar physical, biological and/or chemical properties as a carboxylic acid moiety.
- carboxylic acid bioisosteres include,
- Alkenyl as used herein means a substituent, moiety or group that comprises one or more double bond moieties (e.g., —CH ⁇ CH—) or 1, 2, 3, 4, 5 or 6 or more, typically 1, 2 or 3 such moieties and can include an aryl moiety or group such as benzene, and additionally comprises linked normal, secondary, tertiary or cyclic carbon atoms, i.e., linear, branched, cyclic or any combination thereof unless the alkenyl moiety is a vinyl moiety (e.g., —CH ⁇ CH 2 ).
- An alkenyl moiety, group or substituent with multiple double bonds may have the double bonds arranged contiguously (i.e.
- a 1,3 butadienyl moiety or non-contiguously with one or more intervening saturated carbon atoms or a combination thereof, provided that a cyclic, contiguous arrangement of double bonds do not form a cyclically conjugated system of 4n+2 electrons (i.e., aromatic).
- the number of carbon atoms in an alkenyl group or moiety can vary and typically is 2 to about 50, e.g., about 2-30 or about 2-20, unless otherwise specified, e.g., C 2-8 alkenyl or C2-8 alkenyl means an alkenyl moiety containing 2, 3, 4, 5, 6, 7 or 8 carbon atoms and C 2-6 alkenyl or C2-6 alkenyl means an alkenyl moiety containing 2, 3, 4, 5 or 6 carbon atoms.
- Alkenyl moieties or groups will typically have 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms.
- species include, by way of example and not limitation, any of the alkyl or cycloalkyl, groups moieties or substituents described herein that has one or more double bonds, methylene ( ⁇ CH 2 ), methylmethylene ( ⁇ CH—CH 3 ), ethylmethylene ( ⁇ CH—CH 2 —CH 3 ), ⁇ CH—CH 2 —CH 2 —CH 3 , vinyl (—CH ⁇ CH 2 ), allyl, 1-methylvinyl, butenyl, iso-butenyl, 3-methyl-2-butenyl, 1-pentenyl, cyclopentenyl, 1-methyl-cyclopentenyl, 1-hexenyl, 3-hexenyl, cyclohexenyl and other linear, cyclic and branched chained all carbon containing moieties containing at least one double bond.
- alkenyl When alkenyl is used as a Markush group (i.e., a substituent) the alkenyl is attached to a Markush formula with which it is associated through an unsaturated carbon of a double bond of the alkenyl moiety or group unless specified otherwise.
- Alkynyl as used herein means a substituent, moiety or group that comprises one or more triple bond moieties (i.e., —C ⁇ C—), e.g., 1, 2, 3, 4, 5, 6 or more, typically 1 or 2 triple bonds, optionally comprising 1, 2, 3, 4, 5, 6 or more double bonds, with the remaining bonds (if present) being single bonds and comprising linked normal, secondary, tertiary or cyclic carbon atoms, i.e., linear, branched, cyclic or any combination thereof, unless the alkynyl moiety is ethynyl.
- triple bond moieties i.e., —C ⁇ C—
- the number of carbon atoms in an alkenyl moiety or group can vary and typically is 2 to about 50, e.g., about 2-30 or about 2-20, unless otherwise specified, e.g., C 2-8 alkynyl or C2-8 alkynyl means an alkynyl moiety containing 2, 3, 4, 5, 6, 7 or 8 carbon atoms.
- Alkynyl groups will typically have 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms.
- species include, by way of example and not limitation, any of the alkyl moieties, groups or substituents described herein that has one or more double bonds, ethynyl, propynyl, butynyl, iso-butynyl, 3-methyl-2-butynyl, 1-pentynyl, cyclopentynyl, 1-methyl-cyclopentynyl, 1-hexynyl, 3-hexynyl, cyclohexynyl and other linear, cyclic and branched chained all carbon containing moieties containing at least one triple bond.
- alkynyl When an alkynyl is used as a Markush group (i.e., a substituent) the alkynyl is attached to a Markush formula with which it is associated through one of the unsaturated carbons of the alkynyl functional group.
- Aromatic refers to a planar ring having a delocalized pi-electron system containing 4n+2 pi electrons, where n is a positive integer. Aromatic rings can be formed from five, six, seven, eight, nine, ten, or more than ten atoms. Aromatics are optionally substituted.
- aromatic includes both carboxcylic aryl (“aryl”, e.g., phenyl) and heterocyclic aryl (or “heteroaryl” or “heteroaromatic”) groups (e.g., pyridine).
- aryl e.g., phenyl
- heterocyclic aryl or “heteroaryl” or “heteroaromatic” groups
- the term includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of carbon atoms) groups.
- Aryl as used here means an aromatic ring system or a fused ring system with no ring heteroatoms comprising 1, 2, 3 or 4 to 6 rings, typically 1 to 3 rings, wherein the rings are composed of only carbon atoms; and refers to a cyclically conjugated system of 4n+2 electrons (Huckel rule), typically 6, 10 or 14 electrons some of which may additionally participate in exocyclic conjugation (cross-conjugated (e.g., quinone).
- Aryl substituents, moieties or groups are typically formed by five, six, seven, eight, nine, or more than nine, carbon atoms.
- Aryl substituents, moieties or groups are optionally substituted.
- Exemplary aryls include C 6 -C 10 aryls such as phenyl and naphthalenyl and phenanthryl.
- an aryl group can be a monoradical or a diradical (i.e., an arylene group).
- Exemplary arylenes include, but are not limited to, phenyl-1,2-ene, phenyl-1,3-ene, and phenyl-1,4-ene.
- aryl is used as a Markush group (i.e., a substituent) the aryl is attached to a Markush formula with which it is associated through an aromatic carbon of the aryl group.
- Arylalkyl as used herein means a substituent, moiety or group where an aryl moiety is bonded to an alkyl moiety, i.e., -alkyl-aryl, where alkyl and aryl groups are as described above, e.g., —CH 2 —C 6 H 5 or —CH 2 CH(CH 3 )—C 6 H 5 .
- arylalkyl is used as a Markush group (i.e., a substituent) the alkyl moiety of the arylalkyl is attached to a Markush formula with which it is associated through a sp 3 carbon of the alkyl moiety.
- Alkylaryl as used herein means a substituent, moiety or group where an alkyl moiety is bonded to an aryl moiety, i.e., -aryl-alkyl, where aryl and alkyl groups are as described above, e.g., —C 6 H 4 —CH 3 or —C 6 H 4 —CH 2 CH(CH 3 ).
- alkylaryl is used as a Markush group (i.e., a substituent) the aryl moiety of the alkylaryl is attached to a Markush formula with which it is associated through a sp 2 carbon of the aryl moiety.
- Substituted alkyl “Substituted cycloalkyl”, “substituted alkenyl”, “substituted alkynyl”, substituted alkylaryl”, “substituted arylalkyl”, “substituted heterocycle”, “substituted aryl” and the like as used herein mean an alkyl, alkenyl, alkynyl, alkylaryl, arylalkyl heterocycle, aryl or other group or moiety as defined or disclosed herein that has a substituent(s) that replaces a hydrogen atom(s) or a substituent(s) that interrupts a carbon atom chain.
- Alkenyl and alkynyl groups that comprise a substituent(s) are optionally substituted at a carbon that is one or more methylene moieties removed from the double bond.
- Optionally substituted alkyl mean an alkyl, alkenyl, alkynyl, alkylaryl, arylalkyl heterocycle, aryl, heteroaryl, alkylheteroaryl, heteroarylalkyl, or other substituent, moiety or group as defined or disclosed herein that has a substituent(s) that optionally replaces a hydrogen atom(s) or a substituent(s) that interrupts a carbon atom chain.
- substituents are as described herein.
- a phenyl moiety the arrangement of any two substituents present on the aromatic ring can be ortho (o), meta (m), or para (p).
- An optionally substituted fluoroalkyl is an alkyl or cycloalkyl moiety, typically a linear alkyl, wherein one or more hydrogen atoms is replaced by fluorine and at least one other atom other than carbon and fluorine.
- An optionally substituted or substituted substituent, moiety or group includes those having one or more additional group(s) that replace its hydrogen atom(s) individually and independently selected from alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, cyano, halo, nitro, haloalkyl, fluoroalkyl, fluoroalkoxy, and amino, including mono- and di-substituted amino groups, and the protected derivatives thereof.
- an optional substituent(s) may be halide, —CN, —NO 2 , or LsRs, wherein each Ls is independently selected from a bond, —O—, —C( ⁇ O)—, —C( ⁇ O)O—, —S—, —S( ⁇ O)—, —S( ⁇ O) 2 —, —NH—, —NHC( ⁇ O)—, —C( ⁇ O)NH—, S( ⁇ O) 2 NH—, —NHS( ⁇ O) 2 , —OC( ⁇ O)NH—, —NHC( ⁇ O)O—, or —(C 1 -C 6 alkylene)-; and each Rs is selected from —H, alkyl, fluoroalkyl, heteroalkyl, cycloalkyl, aryl, heteroaryl, or heterocycloalkyl.
- the protecting groups that may form the protective derivatives of the above substituents may be found in sources such as Greene and Wuts, above.
- Optional substituents include those selected from the group consisting of halogen, —CN, —NH 2 , —OH, —N(CH 3 ) 2 , alkyl, fluoroalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, and arylsulfone, those selected from the group consisting of halogen, —CN, —NH 2 , —OH, NH(CH 3 ), —N(CH 3 ) 2 , —CO 2 H, —CO 2 alkyl, —C( ⁇ O)NH 2 , —C( ⁇ O)NHalkyl, —C(
- an optionally substituted, substituent, moiety or group is substituted with one or two of the preceding groups, or more typically with one of the preceding groups.
- An optional substituent on an aliphatic carbon atom (acyclic or cyclic, saturated or unsaturated carbon atoms, excluding aromatic carbon atoms) further includes oxo ( ⁇ O).
- Heterocycle or “heterocyclic” as used herein means a cycloalkyl or aromatic ring system wherein one or more, typically 1, 2 or 3, but not all of the carbon atoms comprising the ring system are replaced by a heteroatom which is an atom other than carbon, including, N, O, S, Se, B, Si, P, typically N, O or S wherein two or more heteroatoms may be adjacent to each other or separated by one or more carbon atoms, typically 1-17 carbon atoms, 1-7 atoms or 1-3 atoms.
- Heterocycles includes heteroaromatic rings (also known as heteroaryls) and heterocycloalkyl rings (also known as heteroalicyclic groups) containing one to four heteroatoms in the ring(s), where each heteroatom in the ring(s) is selected from O, S and N, wherein each heterocyclic group has from 4 to 10 atoms in its ring system, and with the proviso that the any ring does not contain two adjacent O or S atoms.
- Non-aromatic heterocyclic, substituents, moieties or groups have at least 3 atoms in their ring system, and aromatic heterocyclic groups have at least 5 atoms in their ring system and include benzo-fused ring systems.
- Heterocyclics with 3, 4, 5, 6 and 10 atoms include aziridinyl azetidinyl, thiazolyl, pyridyl and quinolinyl, respectively.
- Nonaromatic heterocyclic substituents, moieties or groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, oxazolidinonyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, thioxanyl, piperazinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, pyrrolin-2-yl, pyrrolin-3-yl, indolinyl, 2H-pyranyl, 4H-pyranyl
- Aromatic heterocyclic includes, by way of example and not limitation, pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzo-thiophenyl, benzothiazolyl, benzoxazolyl, qui
- heterocycle When heterocycle is used as a Markush group (i.e., a substituent) the heterocycle is attached to a Markush formula with which it is associated through a carbon or a heteroatom of the heterocycle, where such an attachment does not result in an unstable or disallowed formal oxidation state of that carbon or heteroatom.
- a heterocycle that is C-linked is bonded to a molecule through a carbon atom include moieties such as —(CH 2 ) n -heterocycle where n is 1, 2 or 3 or —C ⁇ heterocycle where C ⁇ represents a carbon atom in a heterocycle ring.
- a heterocycle that is N-linked is a nitrogen containing heterocycle that is bonded a heterocycle ring nitrogen sometimes described as —N ⁇ heterocycle where N ⁇ represents a nitrogen atom in a heterocycle ring.
- nitrogen-containing heterocycles may be C-linked or N-linked and include pyrrole substituents, which may be pyrrol-1-yl (N-linked) or pyrrol-3-yl (C-linked), imidazole substituents, which may be imidazol-1-yl or imidazol-3-yl (both N-linked) or imidazol-2-yl, imidazol-4-yl or imidazol-5-yl (all C-linked).
- Heteroaryl as used herein means an aryl ring system wherein one or more, typically 1, 2 or 3, but not all of the carbon atoms comprising the aryl ring system are replaced by a heteroatom which is an atom other than carbon, including, N, O, S, Se, B, Si, P, typically, oxygen (—O—), nitrogen (—NX—) or sulfur (—S—) where X is —H, a protecting group or C 1-6 optionally substituted alkyl, wherein the heteroatom participates in the conjugated system either through pi-bonding with an adjacent atom in the ring system or through a lone pair of electrons on the heteroatom and may be optionally substituted on one or more carbons or heteroatoms, or a combination of both, in a manner which retains the cyclically conjugated system.
- Heterocycles and heteroaryls include, by way of example and not limitation, heterocycles and heteroaryls described in Paquette, Leo A.; “Principles of Modern Heterocyclic Chemistry” (W. A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; “The Chemistry of Heterocyclic Compounds, A series of Monographs” (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and J. Am. Chem. Soc. 1960, 82:5545-5473 particularly 5566-5573).
- heteroaryls include by way of example and not limitation pyridyl, thiazolyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, purinyl, imidazolyl, benzofuranyl, indolyl, isoindoyl, quinolinyl, isoquinolinyl, benzimidazolyl, pyridazinyl, pyrazinyl, benzothiopyran, benzotriazine, isoxazolyl, pyrazolopyrimidinyl, quinoxalinyl, thiadiazolyl, triazolyl and the like.
- Heterocycles that are not heteroaryls include, by way of example and not limitation, tetrahydrothiophenyl, tetrahydrofuranyl, indolenyl, piperidinyl, pyrrolidinyl, 2-pyrrolidonyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, octahydroisoquinolinyl, 2H-pyrrolyl, 3H-indolyl, 4H-quinolizinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, piperazinyl, quinuclidinyl, morpholinyl, oxazolidinyl and the like.
- heteroaryls include, by way of example and not limitation, the following moieties:
- Monocyclic heteroaryls include, by way of example and not limitation, pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, pyridazinyl, triazinyl, oxadiazolyl, thiadiazolyl, and furazanyl.
- Heteroaryls include those substituents, moieties or groups containing 0-3 N atoms, 1-3 N atoms or 0-3 N atoms, 0-1 O atoms and 0-1 S atoms.
- a heteroaryl may be monocyclic or bicyclic.
- the ring system of a heteroaryls ring typically contains 1-9 carbons (i.e., C 1 -C 9 heteroaryl).
- Monocyclic heteroaryls include C 1 -C 5 heteroaryls.
- Monocyclic heteroaryls include those having 5-membered or 6-membered ring systems.
- Bicyclic heteroaryls include C 5 -C 9 heteroaryls.
- a heteroaryl group can be a monoradical or a diradical (i.e., a heteroarylene group).
- Heterocycloalkyl or “heteroalicyclic” as used herein means a cycloalkyl group, moiety or substituent wherein at least on carbon of the cycloalkyl chain is replaces with a heteroatom selected from the group consisting of nitrogen, oxygen and sulfur.
- the heterocycloalkyl may be fused with an aryl or heteroaryl.
- Heterocycloalkyls also referred to as non-aromatic heterocycles, include by way of example and not limitation:
- Heterocycloalkyl includes, by way of example and not limitation, oxazolidinonyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, and indolinyl.
- Heteroalicyclics further includes all ring forms of carbohydrates, including but not limited to monosaccharides, disaccharides and oligosaccharides.
- a heterocycloalkyl is a C 2 -C 10 heterocycloalkyl and includes C 4 -C 10 heterocycloalkyl.
- a heterocycloalkyl may contain 0-2 N atoms, 0-2 O atoms or 0-1 S atoms.
- Heteroarylalkyl as used herein means a substituent, moiety or group where a heteroaryl moiety is bonded to an alkyl moiety, i.e., -alkyl-heteroaryl, where alkyl and heteroaryl groups are as described above.
- heteroarylalkyl is used as a Markush group (i.e., a substituent) the alkyl moiety of the heteroarylalkyl is attached to a Markush formula with which it is associated through a sp 3 carbon of the alkyl moiety.
- Alkylheteroaryl as used herein means a substituent, moiety or group where a heteroaryl moiety is bonded to an alkyl moiety, i.e., -heteroaryl-alkyl, where heteroaryl and alkyl groups are as described above.
- heteroarylalkyl is used as a Markush group (i.e., a substituent) the heteroaryl moiety of the heteroarylalkyl is attached to a Markush formula with which it is associated through a sp 2 carbon or heteroatom of the alkyl moiety.
- Halogen or “halo” as used herein means fluorine, chlorine, bromine or iodine.
- Haloalkyl as used herein means an alkyl substituent moiety or group in which one or more of its hydrogen atoms are replaced by one or more independently selected halide atoms.
- Haloalkyl includes C 1 -C 4 haloalkyl.
- Example but non-limiting C 1 -C 4 haloalkyls are —CH 2 Cl, CH 2 Br, —CH 2 I, —CHBrCl, —CHCl—CH 2 Cl and —CHCl—CH 2 I.
- Haloalkylene as used herein means an alkylene substituent, moiety or group in which one or more hydrogen atoms are replaced by one or more halide atoms.
- Haloalkylene includes C 1 -C 6 haloalkylenes or C 1 -C 4 haloalkylenes.
- Fluoroalkyl as used herein means an alkyl in which one or more hydrogen atoms are replaced by a fluorine atom. Fluoroalkyl includes C 1 -C 6 and C 1 -C 4 fluoroalkyls. Example but non-limiting fluoroalkyls include —CH 3 F, —CH 2 F 2 and —CF 3 and perfluroalkyls.
- Fluoroalkylene as used herein means an alkylene in which one or more hydrogen atoms are replaced by a fluorine atom. Fluoroalkylene includes C 1 -C 6 fluoroalkylenes or C 1 -C 4 fluoroalkylenes.
- heteroalkyl refers to an alkyl group in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorus or combinations thereof.
- a heteroalkyl is a C1-C6 heteroalkyl.
- Protecting group means a moiety that prevents or reduces the ability of the atom or functional group to which it is linked from participating in unwanted reactions.
- Non-limiting examples are for —OR PR , wherein R PR is a protecting group for the oxygen atom found in a hydroxyl, while for —C(O)—OR PR , R PR may be a carboxylic acid protecting group; for —SR PR , R PR may be a protecting group for sulfur in thiols and for —NHR PR or —N(R PR ) 2 —, at least one of R PR is a nitrogen atom protecting group for primary or secondary amines. Hydroxyl, amine, ketones and other reactive groups may require protection against reactions taking place elsewhere in the molecule.
- the protecting groups for oxygen, sulfur or nitrogen atoms are usually used to prevent unwanted reactions with electrophilic compounds, such as acylating agents.
- Typical protecting groups for atoms or functional groups are given in Greene (1999), “Protective groups in organic synthesis, 3 rd ed.”, Wiley Interscience.
- esters as used herein means a substituent, moiety or group that contains a —C(O)—O— structure (i.e., ester functional group) wherein the carbon atom of the structure is not directly connected to another heteroatom and is directly connected to —H or another carbon atom.
- esters comprise or consist of an organic moiety containing 1-50 carbon atoms, 1-20 carbon atoms or 1-8 carbon atoms and 0 to 10 independently selected heteroatoms (e.g., O, S, N, P, Si), typically 0-2 where the organic moiety is bonded through the —C(O)—O— structure and include ester moieties such as organic moiety-C(O)—O—.
- the organic moiety usually comprises one or more of any of the organic groups described herein, e.g., C 1-20 alkyl moieties, C 2-20 alkenyl moieties, C 2-20 alkynyl moieties, aryl moieties, C 3-8 heterocycles or substituted derivatives of any of these, e.g., comprising 1, 2, 3, 4 or more substituents, where each substituent is independently chosen.
- Exemplary, non-limiting substitutions for hydrogen or carbon atoms in these organic groups are as described above for substituted alkyl and other substituted moieties and are independently chosen.
- esters include by way of example and not limitation, one or more independently selected acetate, propionate, isopropionate, isobutyrate, butyrate, valerate, isovalerate, caproate, isocaproate, hexanoate, heptanoate, octanoate, phenylacetate esters or benzoate esters.
- ester is used as a Markush group (i.e., a substituent) the single bonded oxygen of the ester functional group is attached to a Markush formula with which it is associated.
- “Acetal”, “thioacetal”, “ketal”, “thioketal” and the like as used herein means a moiety, group or substituent comprising or consisting of a carbon to which is bonded two of the same or different heteroatoms wherein the heteroatoms are independently selected S and O.
- the carbon has two bonded oxygen atoms, a hydrogen atom and an organic moiety.
- the carbon has two bonded oxygen atoms and two independently selected organic moieties where the organic moiety is as described herein alkyl or optionally substituted alkyl group.
- For thioacetals and thioketals one or both of the oxygen atoms in acetal or ketal, respectively, is replaced by sulfur.
- the oxygen or sulfur atoms in ketals and thioketals are sometimes linked by an optionally substituted alkyl moiety.
- the alkyl moiety is an optionally substituted C 1-8 alkyl or branched alkyl structure such as —C(CH 3 ) 2 —, —CH(CH 3 )—, —CH 2 —, —CH 2 —CH 2 —, —C[(C 2 -C 4 alkyl) 2 ] 1, 2, 3 - or —[CH(C 2 -C 4 alkyl)] 1, 2, 3 -.
- moieties can serve as protecting groups for an aldehyde or ketone include, by way of example and not limitation, acetals for aldehydes and ketals for ketones and contain —O—CH 2 —CH 2 —CH 2 —O— or —O—CH 2 —CH 2 —O— moieties that form a spiro ring with the carbonyl carbon, and can be removed by chemical synthesis methods or by metabolism in cells or biological fluids.
- “Ether” as used herein means an organic moiety, group or substituent that comprises or consists of 1, 2, 3, 4 or more —O— moieties, usually 1 or 2, wherein no two —O— moieties are immediately adjacent (i.e., directly attached) to each other.
- ethers comprise an organic moiety containing 1-50 carbon atoms, 1-20 carbon atoms or 1-8 carbon atoms and 0 to 10 independently selected heteroatoms (e.g., O, S, N, P, Si), typically 0-2.
- An ether moiety, group or substituent includes organic moiety-O— wherein the organic moiety is as described herein for alkyl or optionally substituted alkyl group.
- ether When ether is used as a Markush group (i.e., a substituent) the oxygen of the ether functional group is attached to a Markush formula with which it is associated.
- ether When ether is a used as substituent in a Markush group it is sometimes designated as an “alkoxy” group.
- Alkoxy includes C1-C4 ether substituents such as, by way of example and not limitation, methoxy, ethoxy, propoxy, iso-propoxy and butoxy.
- Ether further includes those substituents, moieties or groups that contain one (excluding ketal) or more —OCH 2 CH 2 O—, moieties in sequence (i.e., polyethylene or PEG moieties).
- Carbonate as used here means a substituent, moiety or group that contains a —O—C( ⁇ O)—O— structure (i.e., carbonate functional group).
- carbonate groups as used here comprise or consist of an organic moiety containing 1-50 carbon atoms, 1-20 carbon atoms or 1-8 carbon atoms and 0 to 10 independently selected heteroatoms (e.g., O, S, N, P, Si), typically 0-2, bonded through the —O—C( ⁇ O)—O— structure, e.g., organic moiety-O—C( ⁇ O)—O—.
- a Markush group i.e., a substituent
- one of the singly bonded oxygen atoms of the carbonate functional group is attached to a Markush formula with which it is associated.
- “Carbamate” or “urethane” as used here means a substituent, moiety or group that contains a —O—C( ⁇ O)N(R PR )—, —O—C( ⁇ O)N(R PR ) 2 , —O—C( ⁇ O)NH(optionally substituted alkyl) or —O—C( ⁇ O)N (optionally substituted alkyl) 2 - structure (i.e., carbamate functional group) where R PR and optionally substituted alkyl are independently selected and R PR are independently —H, a protecting group or an organic moiety as described for ester, alkyl or optionally substituted alkyl.
- carbamate groups as used here comprise or consist of an organic moiety containing about 1-50 carbon atoms, 1-20 carbon atoms or 1-8 carbon atoms and 0 to 10 independently selected heteroatoms (e.g., O, S, N, P, Si), typically 0-2, bonded through the —O—C( ⁇ O)—NR PR — structure, e.g., organic moiety-O—C( ⁇ O)—NR PR — or —O—C( ⁇ O)—NR PR -organic moiety.
- heteroatoms e.g., O, S, N, P, Si
- carbamate When carbamate is used as a Markush group (i.e., a substituent) the singly bonded oxygen (O-linked) or nitrogen (N-linked) of the carbamate functional group is attached to a Markush formula with which it is associated.
- the linkage of the carbamate substituent is either explicitly stated (N- or O-linked) or implicit in the context to which this substituent is referred.
- any substituent group or moiety described by a given range of carbon atoms the designated range means that any individual number of carbon atoms is described.
- reference to, e.g., “C1-C4 optionally substituted alkyl”, “C2-6 alkenyl optionally substituted alkenyl”, “C3-C8 optionally substituted heterocycle” specifically means that a 1, 2, 3 or 4 carbon optionally substituted alkyl moiety as defined herein is present, or a 2, 3, 4, 5 or 6 carbon alkenyl, or a 3, 4, 5, 6, 7 or 8 carbon moiety comprising a heterocycle or optionally substituted alkenyl moiety as defined herein is present.
- C1-C4 optionally substituted alkyl includes, e.g., 3 carbon alkyl, 4 carbon substituted alkyl and 4 carbon alkyl, including all positional isomers and the like are disclosed and can be expressly referred to or named.
- esters, carbonates and carbamates defined by a given range of carbon atoms the designated range includes the carbonyl carbon of the respective functional group.
- a C1 ester refers to a formate ester and a C2 ester refers to an acetate ester.
- organic substituents, moieties and groups described herein, and for other any other moieties described herein, usually will exclude unstable moieties except where such unstable moieties are transient species that one can use to make a compound with sufficient chemical stability for the one or more of the uses described herein.
- Substituents, moieties or groups by operation of the definitions herein that results in those having a pentavalent carbon are specifically excluded.
- LPA-dependent means a disease or condition whose etiology, progression or persistence is effected by in whole or in part by signaling through one or more lysophosphatidic acid receptor subtypes, including by way of example and not limitation lysophosphatidic acid receptor subtypes 1-6 (LPARs).
- LPARs lysophosphatidic acid receptor subtypes 1-6
- LPA-dependent or LPA-mediated diseases and conditions include but not limited to fibrosis of organs (e.g., liver, kidney, lung, heart and the like), liver diseases (e.g., acute hepatatis, chronic hepatitis, liver fibrosis, liver cirrhosis, portal hypertension, regenerative failure, nonalcoholic steatohepatitis (NASH), liver hypofunction, hepatic blood flow disorder, and the like), cell proliferative disease (e.g., cancers, including but not limited to solid tumor, solid tumor metastasis, vascular fibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia, chronic lymphocytic leukemia (CLL), invasive metastasis of cancer cell, and the like), inflammatory disease (e.g., psoriasis, nephropathy, pneumonia and the like), gastrointestinal tract disease (e.g., irritable bowel syndrome (I
- LPA1R selective agents means agents or compounds that interact with the lysophosphatidic acid subtype 1 receptor in preference to the lysophosphatidic acid receptor 2-6. Typically, that preference is manifested by 10-fold stronger binding affinity of the agent to LPA1R in comparison to other known LPARs as measured by experimentally determined K D values.
- “Pharmaceutically acceptable formulation” as used herein means a composition comprising an active pharmaceutical ingredient, such as a compound having the formula of I-VI in addition to one or more pharmaceutically acceptable excipients or refers to a composition prepared from an active pharmaceutical ingredient and one or more pharmaceutically acceptable excipients, wherein the composition is suitable for administration to a subject, such as a human or an animal, in need thereof.
- a pharmaceutically acceptable formulation to be suitable for administration to a human the formulation must have biological activity for treating or preventing a disease or condition disclosed herein or an expectation must exist that the formulation would have a desired activity towards an “intent to treat” disease or condition.
- the “intent to treat” disease or condition is a lysophosphatidic acid receptor-mediated condition or disease.
- the disease or condition to be treated or prevented is a lysophosphatidic acid lysophosphatidic acid type 1 receptor-mediated disease or condition.
- a pharmaceutically acceptable formulation that is suitable for administration to an animal does not necessarily require a biological activity for treating or preventing a disease or condition, and may be administered to the animal in order to evaluate a potential pharmacological or biological activity of a Formula I-XII compound.
- Those formulations must therefore be suitable for treating or preventing a disease or condition disclosed herein in an animal in need thereof or is suitable for evaluating a pharmacological or biological activity of a Formula I-XII compound.
- Compositions that are suitable only for use in vitro assays or which contain a vehicle, component or excipient in an amount not permitted in a drug product are specifically excluded from the definition of a pharmaceutically acceptable formulation.
- the pharmaceutically acceptable formulation may be comprised of, or be prepared from, one, two or more Formula I-XII compounds, typically one or two, and one or more pharmaceutically acceptable excipients. More typically, the formulations will consist essentially of or consist of a single Formula I-XII compound and one or more pharmaceutically acceptable excipients. Other formulations may be comprised of, consist essentially of, or consist of one, two or more Formula I-XII compounds and one two or more compounds in current use for treating lysophosphatidic acid lysophosphatidic acid type 1 receptor-mediated disease or condition disclosed herein and one or more pharmaceutically acceptable excipients.
- those formulations will consist essentially of or consist of a single Formula I-XII compound, a single compound in current use for treating a lysophosphatidic acid lysophosphatidic acid type 1 receptor-mediated disease or condition and one or more pharmaceutically acceptable excipients.
- Solid formulation refers to a pharmaceutically acceptable formulation comprising at least one Formula I-XII compound and one or more pharmaceutically acceptable excipients in solid form(s) wherein the formulation is in a unit dosage form suitable for administration of a solid.
- the dosage units include tablets, capsules, caplets, gelcaps, suspensions and other dosage units typically associated with parenteral or enteral (oral) administration of a solid.
- Liquid formulation refers to a pharmaceutically acceptable formulation wherein at least one Formula I-XII compound has been admixed or contacted with one or more pharmaceutically acceptable excipients, wherein at least one of the excipients is in liquid form in proportions required for a liquid formulation, i.e., such that a majority of the mass amount of the Formula I-XII compound(s) is dissolved into the non-solid excipient.
- Dosage units containing a liquid formulation include syrups, gels, ointments and other dosage units typically associated with parenteral or enteral administration of a pharmaceutical formulation to a subject in need thereof in liquid form.
- the compounds presented herein possess one or more stereocenters and each center independently exists in either the R or S configuration.
- the compounds presented herein include all diastereomeric, enantiomeric, and epimeric forms as well as the appropriate mixtures thereof.
- Stereoisomers are obtained, if desired, by methods such as, stereoselective synthesis and/or the separation of stereoisomers by chiral chromatographic columns.
- the methods and formulations described herein include the use of pharmaceutically acceptable salts of compounds having the structure of Formulas (I-VI), as well as active metabolites of these compounds having the same type of activity. In some situations, compounds may exist as tautomers.
- the compounds described herein will exist as salts, including pharmaceutically acceptable salts.
- the salt forms include inorganic addition salts such as F ⁇ Cl ⁇ , Br ⁇ , I ⁇ and sulfate salts and organic addition salts such as mesylate, besylate, tosylate, citrate, succinate, fumarate and malonate.
- the compounds described herein exist as quaternary ammonium salts.
- R C is —CN, —F, —Cl, —Br, —I, —OC 1 -C 4 alkyl, C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, or C 1 -C 4 fluoroalkyl and R D is —N(R F )—C( ⁇ O)OCH(R G )—CY,
- R F and each R G independently are —H or C 1 -C 4 alkyl.
- R A is —CO 2 H, —CONHCN, tetrazolyl, or —C( ⁇ O)NHSO 2 R B , wherein R B is substituted or unsubstituted C 1 -C 4 alkyl.
- R A is —CO 2 H, —CONHCN, tetrazolyl, or —C( ⁇ O)NHSO 2 R B , wherein R B is —CH 3 .
- L 1 is substituted or unsubstituted C 1 -C 6 alkylene, C 1 -C 6 fluoroalkylene, or substituted or unsubstituted C 1 -C 6 heteroalkylene.
- L 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- Formula I compounds have R C defined as —CN, —F, —Cl, or C 1 -C 4 fluoroalkyl.
- Formula I compounds have R C defined as —F, or —Cl.
- Formula I compounds have R D defined as —N(R F )C( ⁇ O)—OCH(R G )—CY, wherein R F is —H or C 1 -C 4 alkyl and X, CY and R G are as previously defined.
- Formula I compounds have R D defined as —N(R F )C( ⁇ O)OCH(R G )—CY, wherein R F is —H and CY and R G are as previously defined.
- Formula I compounds have R F defined as H, C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl.
- Formula I compounds have R F defined as —H.
- R G is independently —H or C 1 -C 4 alkyl.
- Formula I compounds have R G defined as —CH 3 .
- CY is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein if CY is substituted then CY is substituted with 1, 2, or 3 independently selected R H .
- R A is —CO 2 H
- R C is —F or —Cl
- R D is —NR F C( ⁇ O)OCH(R G )—CY
- R F , R G , and CY are as previously defined.
- R A is tetrazolyl
- R C is —F or —Cl
- R D is —NR F C( ⁇ O)OCH(R G )—CY
- R F , R G , and CY are as previously defined.
- R A is —C( ⁇ O)NHSO 2 R B
- R C is —F or —Cl
- R D is —NR F C( ⁇ O)OCH(R G )—CY
- R B , R F , R G , and CY are as previously defined.
- R A is —CONHCN
- R C is —F or —Cl
- R D is —NR F C( ⁇ O)OCH(R G )—CY
- R F , R G , and CY are as previously defined.
- Embodiment 2 The compound of Embodiment 1 wherein R A is —CO 2 H or CONHCN.
- Embodiment 3 The compound of Embodiment 1 wherein R A is tetrazolyl.
- Embodiment 4 The compound of Embodiment 1 wherein R A is —C( ⁇ O)NHSO 2 R B where R B is —CH 3 .
- Embodiment 5 The compound of Embodiment 1-4 wherein R C is —CN, —F, or —Cl.
- Embodiment 6 The compound of Embodiment 1-5 wherein R C is —F or —Cl.
- Embodiment 7 The compound of Embodiment 1-6 wherein L 1 , when present, is a geminally substituted alkyl, cycloalkyl or heterocycloalkyl group,
- Embodiment 8 The compound of Embodiments 7 wherein L 1 is
- Embodiment 9 The compound of any one of Embodiments 1-8 wherein R F is —H.
- Embodiment 10 The compound of any one of Embodiments 1-9 wherein R G is —CH 3 .
- Embodiment 11 The compound of any one of Embodiments 1-10 wherein CY is substituted or unsubstituted phenyl.
- Embodiment 12 The compound of any one of Embodiments 1-11 wherein R H is —H, halogen, —CN, —NO 2 , —OH, C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, C 1 -C 4 fluoroalkoxy, and C 1 -C 4 alkoxy.
- Embodiment 13 The compound of any one of Embodiments 1-12 wherein R H are independently selected from —H, halogen or substituted or unsubstituted C 1 -C 4 alkyl or substituted C 1 -C 4 alkoxy.
- Embodiment 14 The compound of any one of Embodiments 1-13 wherein R H is independently —H, —Cl, —F, —CH 3 , —CF 3 , —OCH 3 or —OCF 3 .
- Embodiment 15 A compound of Formula II having the structure:
- L 1 is optionally substituted C 1 -C 6 alkylene; C 1 -C 6 fluoroalkylene; or optionally substituted C 1 -C 6 heteroalkylene or L 1 is
- Ring A has the structure:
- R A is —CO 2 H, —CONHCN, —C( ⁇ O)NHSO 2 R B , or tetrazolyl
- R B is CH 3
- R C is —F or —Cl
- R D is —NR F C( ⁇ O)OCH(R G )—CY and R F , R G and CY are as previously defined.
- Embodiment 16 A compound of Formula III having the structure:
- Ring A has the structure of one of:
- R H is —H, halogen, —CN, —NO 2 , —OH, C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, C 1 -C 4 fluoroalkoxy, and C 1 -C 4 alkoxy;
- Preferred Formula III compounds have R A is —CO 2 H, —CONHCN, —C( ⁇ O)NHSO 2 R B , or tetrazolyl, R B is CH 3 , R C is —F or —Cl, R D is —NR F C( ⁇ O)OCH(R G )—CY and R F is —H, R G is —CH 3 and CY is as previously defined.
- Embodiment 17 A composition comprising, essentially consisting of or consisting of one or more compounds of Formula I-III and one or more excipients.
- composition comprises, consists essentially of, or consists of one compound of Formula I-III and one or more excipients.
- composition is a pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of one compound of Formula I-III and one or more pharmaceutically acceptable excipients.
- Embodiment 18 A compound of Formula I-III or a pharmaceutically acceptable salt or prodrug thereof wherein the binding affinity of the compound to lysophosphatidic acid receptor-1 (LPA1R) is between about 10 ⁇ M and 1 pM or less
- Embodiment 19 The compound of Embodiment 1-18 wherein the compound is a selective lysophosphatidic acid receptor-1 (LPA1R) compound.
- LPA1R selective lysophosphatidic acid receptor-1
- Embodiment 20 A compound of Formula I-III or a pharmaceutically acceptable salt, or prodrug thereof wherein the compound is a selective lysophosphatidic acid receptor-1 (LPA1R) compound.
- LPA1R selective lysophosphatidic acid receptor-1
- Embodiment 21 The compound of Embodiment 1-20 wherein the compound is a selective lysophosphatidic acid receptor-1 (LPA1R) compound wherein the binding affinity (i.e., K D ) of the LPA1R compound is between about 1 ⁇ M and 1 pM or less.
- the K D is 100 nM or less, more preferably 10 nM or less.
- Embodiment 22 A compound of Table 1.
- Embodiment 23 The compound of Embodiment 22 wherein the compound is (R)-1-(4-(5-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-fluoro-1H-pyrazol-1-yl)pyridin-2-yl)phenyl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(3-fluoro-4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carbox
- Embodiment 24 The compound of Embodiment 22 wherein the compound is (R)-1-(4-(5-(4-chloro-5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-1H-pyrazol-1-yl)pyridin-2-yl)phenyl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-3-fluoro-[1,1′-biphenyl]-4-yl)cyclopropane-1-carbox
- Embodiment 25 The compound of Embodiment 22 wherein the compound is (R)-1- ⁇ 4′-[5-(1-Phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-yl]-biphenyl-4-yl ⁇ -cyclopropanecarboxylic acid, or (R)-1- ⁇ 2-Fluoro-4′-[5-(1-phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-yl]-biphenyl-4-yl ⁇ -cyclopropanecarboxylic acid;
- Embodiment 26 The compound of Embodiment 22 wherein the compound is (R)-1-(4′-(4-cyano-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-cyano-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-2-(4′-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-cyano-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)-2-methylpropanoic
- Embodiment 27 The compound of Embodiment 22 wherein the compound is (R)-1-(2-chlorophenyl)ethyl (4-fluoro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (4-fluoro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-chloro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclo
- Embodiment 28 The compound of Embodiment 22 wherein the compound is (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-chloro-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-chloro-1H-pyrazol-5-y
- Embodiment 29 The compound of Embodiment 22 wherein the compound is (R)-1-phenylethyl (4-chloro-1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-chloro-1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-2′-fluoro-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)c
- Embodiment 30 A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of Table 1 and one or more pharmaceutically acceptable excipients.
- Embodiment 31 A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of Embodiment 23 and one or more pharmaceutically acceptable excipients.
- Embodiment 32 A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of Embodiment 24 and one or more pharmaceutically acceptable excipients.
- Embodiment 33 A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of Embodiment 25 and one or more pharmaceutically acceptable excipients.
- Embodiment 34 A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of Embodiment 26 and one or more pharmaceutically acceptable excipients.
- Embodiment 35 A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of Embodiment 27 and one or more pharmaceutically acceptable excipients.
- Embodiment 36 A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of Embodiment 28 and one or more pharmaceutically acceptable excipients.
- Embodiment 37 A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of Embodiment 29 and one or more pharmaceutically acceptable excipients.
- Embodiment 38 A method comprising administering an effective amount of a Formula I-III compound to a subject having a LPA-dependent or LPA-mediated disease or condition.
- Embodiment 39 The method of Embodiment 38 wherein the LPA-dependent or LPA-mediated disease or condition is a disease with fibrosis of the organs.
- Embodiment 40 The method of Embodiment 39 wherein the fibrosis is of the liver, kidney, lung, heart, eye and the like.
- Embodiment 41 The method of Embodiment 38 wherein the LPA-dependent or LPA-mediated disease or condition is chronic pain
- Embodiment 42 The method of Embodiment 38 wherein the LPA-dependent or LPA-mediated disease or condition is pruritus.
- Embodiment 43 The method of Embodiment 38 wherein the LPA-mediated disease is a proliferative disease including cancer (solid tumor, solid tumor metastasis, vascular fibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia, chronic lymphocytic leukemia (CLL) and the like) and invasive metastasis of cancer cell, including ovarian, breast and triple negative breast cancer and the like,
- cancer solid tumor, solid tumor metastasis, vascular fibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia, chronic lymphocytic leukemia (CLL) and the like
- CLL chronic lymphocytic leukemia
- Embodiment 44 The method of Embodiment 38 wherein the LPA-mediated disease is an inflammatory disease including psoriasis, nephropathy, pneumonia and the like,
- Embodiment 45 The method of Embodiment 38 wherein the LPA-mediated disease is a gastrointestinal disease such as inflammatory bowel disease,
- Embodiment 46 The method of Embodiment 38 wherein the LPA-mediated disease is an ocular disease including age-related macular degeneration (AMD), diabetic retinopathy, proliferative vitreoretinopathy (PVR), cicatricial pemphigoid, glaucoma filtration surgery scarring, uveitis and the like,
- AMD age-related macular degeneration
- PVR proliferative vitreoretinopathy
- cicatricial pemphigoid glaucoma filtration surgery scarring
- uveitis a filtration surgery scarring
- Embodiment 47 The method of Embodiment 38 wherein the LPA-mediated disease is a liver disease including acute hepatitis, chronic hepatitis, liver fibrosis, liver cirrhosis, cholestatic pruritus, portal hypertension, regenerative failure, nonalcoholic steatohepatitis (NASH), liver hypofunction, hepatic blood flow disorder, and the like,
- a liver disease including acute hepatitis, chronic hepatitis, liver fibrosis, liver cirrhosis, cholestatic pruritus, portal hypertension, regenerative failure, nonalcoholic steatohepatitis (NASH), liver hypofunction, hepatic blood flow disorder, and the like
- Embodiment 48 The method of Embodiment 38 wherein the LPA-mediated disease is a renal disease including chronic kidney disease, end stage renal disease, uremic pruritus, nephropathy including diabetic nephropathy and the like,
- Embodiment 49 The method of Embodiment 38 wherein the LPA-mediated disease is a skin disease including scleroderma, skin scarring, atopic dermatitis, psoriasis and the like,
- Embodiment 50 The method of any one of Embodiments 38-49 wherein the subject is a human.
- Embodiment 51 The method of any one of Embodiments 38-50 wherein the compound is selected from Table 1.
- Embodiment 52 The method of any one of Embodiments 78-90 wherein the compound is (R)-1-(4-(5-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-fluoro-1H-pyrazol-1-yl)pyridin-2-yl)phenyl)cyclopropane-1-carboxylic acid, (R)-1-(4-(5-(4-chloro-5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-1H-pyrazol-1-yl)pyridin-2-yl)phenyl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropan
- Embodiment 53 The method of any one of Embodiments 38-50 wherein the compound is selected from Embodiment 23.
- Embodiment 54 The method of any one of Embodiments 38-50 wherein the compound is selected from Embodiment 24.
- Embodiment 55 The method of any one of Embodiments 38-50 wherein the compound is selected from Embodiment 25.
- Embodiment 56 The method of any one of Embodiments 38-50 wherein the compound is selected from Embodiment 26.
- Embodiment 57 The method of any one of Embodiments 38-50 wherein the compound is selected from Embodiment 27.
- Embodiment 58 The method of any one of Embodiments 38-50 wherein the compound is selected from Embodiment 28.
- Embodiment 59 The method of any one of Embodiments 38-50 wherein the compound is selected from Embodiment 29.
- Embodiment 60 A composition comprising, consisting essentially of or consisting of one or more compounds of Formula (I-III) and one or more agents currently used to treat a LPA-dependent or LPA-mediated disease or a disease or condition described herein.
- Embodiment 61 A pharmaceutically acceptable formulation comprising, consisting essentially of or consisting of one or more compounds of Formula (I-III), one or more agents currently used to treat a LPA-dependent or LPA-mediated disease and one or more pharmaceutically acceptable excipients.
- Embodiment 62 A method comprising administering in combination with or co-administrating a compound of Formula (I-III) to a subject with a LPA-dependent or LPA-mediated disease or condition and a currently used agent to treat a LPA-dependent or LPA-mediated disease
- the one or more additional therapeutically active agents other than compounds of Formula (I-III) are selected from: corticosteroids, immunosuppressants, analgesics, anti-cancer agents, anti-inflammatories, chemokine receptor antagonists, bronchodilators, leukotriene receptor antagonists, leukotriene formation inhibitors, platelet activating factor receptor antagonists, monoacylglycerol kinase inhibitors, phospholipase A 1 inhibitors, phospholipase A 2 inhibitors, and lysophospholipase D (lysoPLD) inhibitors, autotaxin inhibitors, decongestants, mast cell stabilizers, antihistamines, mucolytics, anticholinergics, antitussives, expectorants, and ⁇ -2 agonists.
- corticosteroids corticosteroids
- immunosuppressants analgesics
- anti-cancer agents anti-inflammatories
- chemokine receptor antagonists
- the currently used agent(s) are selected from those described in the Merck Index known to affect lysophosphatidic acid receptor signaling.
- the Formula (I-III) compound is selected from Table 1.
- therapies which combine a compound of Formula (I-III), with currently used agents that act on differing signalling pathways to the LPA synthesis or signalling pathway so as to provide complementary clinical outcomes, are encompassed herein for treating LPA-dependent or LPA-mediated diseases or conditions.
- additional therapeutic agents include, but are not limited to, any of the following: gossypol, genasense, polyphenol E, Chlorofusin, all trans-retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 5-aza-2′-deoxycytidine, all trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib, geldanamycin, 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 11-7082, PKC412, or PD 184352, TaxolTM (paclitaxel), and analogs of TaxolTM, such as TaxotereTM, U0126, PD98059, PD184352, PD0325901, ARRY
- Embodiment 63 The method of Embodiments 60-62 wherein the subject is a human.
- Embodiment 64 The method of Embodiments 60-62 wherein the Formula I-III compound(s) are selected from Table 1.
- Embodiment 65 The method of Embodiments 60-62 wherein the Formula I-III compound(s) are selected from the group consisting of (R)-1-(4-(5-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-fluoro-1H-pyrazol-1-yl)pyridin-2-yl)phenyl)cyclopropane-1-carboxylic acid, (R)-1-(4-(5-(4-chloro-5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-1H-pyrazol-1-yl)pyridin-2-yl)phenyl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl
- Embodiment 66 The method of Embodiments 60-63 wherein the Formula I-III compound(s) are selected from Embodiment 23.
- Embodiment 67 The method of Embodiments 60-63 wherein the Formula I-III compound(s) are selected from Embodiment 24.
- Embodiment 68 The method of Embodiments 60-63 wherein the Formula I-III compound(s) are selected from Embodiment 25.
- Embodiment 69 The method of Embodiment 60-63 wherein the Formula I-III compound(s) are selected from Embodiment 26.
- Embodiment 70 The method of Embodiment 60-63 wherein the Formula I-III compound(s) are selected from Embodiment 27.
- Embodiment 71 The method of Embodiment 60-63 wherein the Formula I-III compound(s) are selected from Embodiment 28.
- Embodiment 72 The method of Embodiment 60-63 wherein the Formula I-III compound(s) are selected from Embodiment 29.
- Embodiment 73 The composition of Embodiment 60 where the currently used agent is a mast cell stabilizing agent
- Embodiment 74 The composition of Embodiment 60 where the currently used agent is a platelet activating factor receptor antagonist,
- Embodiment 75 The composition of Embodiment 73 where the mast cell stabilizing agent is cromoglicate, nedocromil, azelastine, bepotastine, epinastine, ketotifen, olopatadine and rupatadine.
- the mast cell stabilizing agent is cromoglicate, nedocromil, azelastine, bepotastine, epinastine, ketotifen, olopatadine and rupatadine.
- Embodiment 76 The composition of Embodiment 74 where the platelet activating factor receptor antagonist is rupatadine, SM-12502, CV-3988 and WEB 2170.
- Embodiment 1A A compound wherein the compound has the structure of Formula I
- R C is —CN, —F, —Cl, —Br, —I, —OC 1 -C 4 alkyl, C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, or C 1 -C 4 fluoroalkyl and R D is —N(R F )—C( ⁇ O)OCH(R G )—CY,
- R F and each R G independently are —H or C 1 -C 4 alkyl.
- R A is —CO 2 H, —CONHCN, tetrazolyl, or —C( ⁇ O)NHSO 2 R B , wherein R B is substituted or unsubstituted C 1 -C 4 alkyl.
- R A is —CO 2 H, —CONHCN, tetrazolyl, or —C( ⁇ O)NHSO 2 R B , wherein R B is —CH 3 .
- L 1 is substituted or unsubstituted C 1 -C 6 alkylene, C 1 -C 6 fluoroalkylene, or substituted or unsubstituted C 1 -C 6 heteroalkylene.
- L 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- Formula I compounds have R C defined as —CN, —F, —Cl, or C 1 -C 4 fluoroalkyl.
- Formula I compounds have R C defined as —F, or —Cl.
- Formula I compounds have R D defined as —N(R F )C( ⁇ O)—OCH(R G )—CY, wherein R F is —H or C 1 -C 4 alkyl and X, CY and R G are as previously defined.
- Formula I compounds have R D defined as —N(R F )C( ⁇ O)OCH(R G )—CY, wherein R F is —H and CY and R G are as previously defined.
- Formula I compounds have R F defined as H, C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl.
- Formula I compounds have R F defined as —H.
- R G is independently —H or C 1 -C 4 alkyl.
- Formula I compounds have R G defined as —CH 3 .
- CY is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein if CY is substituted then CY is substituted with 1, 2, or 3 independently selected R H .
- R A is —CO 2 H
- R C is —F or —Cl
- R D is —NR F C( ⁇ O)OCH(R G )—CY
- R F , R G , and CY are as previously defined.
- R A is tetrazolyl
- R C is —F or —Cl
- R D is —NR F C( ⁇ O)OCH(R G )—CY
- R F , R G , and CY are as previously defined.
- R A is —C( ⁇ O)NHSO 2 R B
- R C is —F or —Cl
- R D is —NR F C( ⁇ O)OCH(R G )—CY
- R B , R F , R G , and CY are as previously defined.
- R A is —CONHCN
- R C is —F or —Cl
- R D is —NR F C( ⁇ O)OCH(R G )—CY
- R F , R G , and CY are as previously defined.
- Embodiment 2A The compound of Embodiment 1A, wherein:
- R H is —H, a halogen, or —CH 3 ;
- a 1 is CH or N and R H is —H;
- R H is —H or a halogen.
- Embodiment 3A The compound of Embodiment 2A, wherein:
- R H is —H
- a 1 is N and R H is —H;
- R H is —Cl
- R H can be located at any available carbon atom in the ring
- Embodiment 4A The compound of Embodiment 2A, wherein:
- R H is —H
- a 1 is N and R H is —H;
- R H is —Cl
- R H can be located at any available carbon atom in the ring
- Embodiment 5A The compound of Embodiment 2A, wherein
- a 1 is CH and R H is —H.
- Embodiment 6A The compound of Embodiment 5A, wherein:
- Embodiment 7A The compound of Embodiment 6A, wherein:
- R H is —H.
- Embodiment 8A The compound of Embodiment 7A, wherein
- R H is —H.
- R H can be located at any available carbon atom in the ring
- Embodiment 9A The compound of Embodiment 7A, wherein:
- R H is —H.
- R H can be located at any available carbon atom in the ring
- Embodiment 10A The compound of Embodiment 7A, wherein:
- R H is —H.
- R H can be located at any available carbon atom in the ring
- Embodiment 11A The compound of Embodiment 7A, wherein:
- R H is —Cl
- R H can be located at any available carbon atom in the ring
- Embodiment 12A The compound of Embodiment 6A, wherein:
- R H is —F.
- Embodiment 13A The compound of Embodiment 12A, wherein:
- R H is —H.
- R H can be located at any available carbon atom in the ring
- Exemplary molecules with this structure are Compound 7, (R)-1-(3-fluoro-4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, and Compound 8, (R)-1-(2-fluoro-4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid.
- Embodiment 14A The compound of Embodiment 12A, wherein:
- R H is —H.
- R H can be located at any available carbon atom in the ring
- Exemplary molecules with this structure are Compound 9, (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-3-fluoro-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, and Compound 10, R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-2-fluoro-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid.
- Embodiment 15A The compound of Embodiment 6A, wherein:
- R H is —Cl
- Embodiment 16A The compound of Embodiment 15A, wherein:
- R H is —H.
- R H can be located at any available carbon atom in the ring
- An exemplary molecule with this structure is Compound 11, (R)-1-(2-chloro-4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid.
- Embodiment 17A The compound of Embodiment 15A, wherein:
- R H is —H.
- R H can be located at any available carbon atom in the ring
- Embodiment 18A The compound of Embodiment 6A, wherein:
- R H is —CH 3 .
- Embodiment 19A The compound of Embodiment 18A, wherein:
- R H is —H.
- R H can be located at any available carbon atom in the ring
- Embodiment 20A The compound of Embodiment 18A, wherein:
- R H is —H.
- R H can be located at any available carbon atom in the ring
- Embodiment 21A The compound of Embodiment 5A, wherein:
- R H is —H
- R H is —Cl
- R H can be located at any available carbon atom in the ring
- Embodiment 22A The compound of Embodiment 5A, wherein:
- Embodiment 23A The compound of Embodiment 22A, wherein:
- R H is —F.
- Embodiment 24A The compound of Embodiment 23A, wherein:
- R H is —Cl
- R H can be located at any available carbon atom in the ring
- An exemplary molecule with this structure is Compound 16, (R)-1-(2-chlorophenyl)ethyl (4-fluoro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate.
- Embodiment 25A The compound of Embodiment 23A, wherein:
- R H is —H.
- R H can be located at any available carbon atom in the ring
- Embodiment 26A The compound of Embodiment 23A, wherein:
- R H is —Cl
- R H can be located at any available carbon atom in the ring
- An exemplary molecule with this structure is Compound 18, (R)-1-(2-chlorophenyl)ethyl (4-chloro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate.
- Embodiment 27A The compound of Embodiment 22A, wherein:
- R H is —H.
- Embodiment 28A The compound of Embodiment 27A, wherein:
- R H is —H.
- R H can be located at any available carbon atom in the ring
- Embodiment 29A The compound of Embodiment 27A, wherein:
- R H is —Cl
- R H can be located at any available carbon atom in the ring
- An exemplary molecule with this structure is Compound 20, (R)-1-(2-chlorophenyl)ethyl (4-fluoro-1-(4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate.
- Embodiment 30A The compound of Embodiment 5A, wherein:
- R H is —H.
- Embodiment 31A The compound of Embodiment 30A, wherein:
- R H is —Cl
- R H can be located at any available carbon atom in the ring
- Embodiment 32A The compound of Embodiment 30A, wherein:
- R H is —H.
- R H can be located at any available carbon atom in the ring
- Embodiment 33A The compound of Embodiment 30A, wherein:
- R H is —Cl
- R H can be located at any available carbon atom in the ring
- Embodiment 34A The compound of Embodiment 5A, wherein:
- R H is —H.
- Embodiment 35A The compound of Embodiment 34A, wherein:
- R H is —H.
- R H can be located at any available carbon atom in the ring
- Embodiment 36A The compound of Embodiment 33A, wherein:
- R H is —Cl
- R H can be located at any available carbon atom in the ring
- Embodiment 37A The compound of Embodiment 5A, wherein:
- R H is —F.
- Embodiment 38A The compound of Embodiment 37A, wherein:
- R H is —Cl
- R H can be located at any available carbon atom in the ring
- Embodiment 39A The compound of Embodiment 2A, wherein:
- R H is —H
- a 1 is CH and R H is —H;
- Embodiment 40A The compound of Embodiment 39A, wherein:
- R H is —Cl
- R H can be located at any available carbon atom in the ring
- Embodiment 41A The compound of Embodiment 39A, wherein:
- R H is —H.
- R H can be located at any available carbon atom in the ring
- Embodiment 42A The compound of Embodiment 1A, wherein R G is in an R or S configuration.
- Embodiment 43A The compound of Embodiment 2A wherein the compound is selected from Table 1.
- Embodiment 44A The compound of Embodiment 43A wherein the compound is (R)-1-(4-(5-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-fluoro-1H-pyrazol-1-yl)pyridin-2-yl)phenyl)cyclopropane-1-carboxylic acid, (R)-1-(4-(5-(4-chloro-5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-1H-pyrazol-1-yl)pyridin-2-yl)phenyl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-car
- Embodiment 45A A compound of any one of Embodiments 1A-44A for preparation of mendicant for treating a LPA-dependent disease or condition.
- the compounds of Table 1 are exemplary of the invention but not limiting, wherein additional compounds are prepared according to the appropriately modified procedures of the examples for preparation of compounds 1-28.
- HPLC traces for examples synthesized were recorded using a HPLC consisting of Agilent HPLC pumps, degasser and UV detector, equipped with an Agilent 1100 series auto-sampler.
- a MS detector (APCI) PE Sciex API 150 EX was incorporated for purposes of recording mass spectral data.
- HPLC/mass traces were obtained using one of three chromatographic methods:
- Method 4 Column Zorbax C18, size 4.6 mm ⁇ 50 mm, 5p particle size; Solvent A: acetonitrile; Solvent B: 0.1% HCOOH in water; Flow Rate—1.5 mL/min; Gradient 10-95% A in 2.5 minutes.
- the resulting mixture was heated to 88° C. overnight, then cooled to room temperature and concentrated in vacuo.
- the crude residue was purified by silica-gel column chromatography, eluting with a hexanes/ethyl acetate gradient. Two regioisomers were separated—the desired isomer A [ethyl 2-(6-chloro-3-pyridyl)-2H-pyrazole-3-carboxylate] eluted off the column first and the undesired regioisomer B [ethyl 1-(6-chloro-3-pyridyl)-1H-pyrazole-3-carboxylate] was isolated as the more polar compound.
- the desired product was obtained as a yellow oil, which solidified upon standing.
- Step 3 3-[(R)-1-(o-Chlorophenyl)ethoxycarbonylamino]-2-(6-chloro-3-pyridyl)-2H-pyrazole
- Step 4 3-[(R)-1-(o-Chlorophenyl)ethoxycarbonylamino]-2-(6-chloro-3-pyridyl)-4-fluoro-2H-pyrazole
- Step 5 (R)-1-(4-(5-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-fluoro-1H-pyrazol-1-yl)pyridin-2-yl)phenyl)cyclopropane-1-carboxylic acid
- the resulting mixture was heated to 85° C. and stirred for 16 hours at that temperature.
- the reaction mixture was cooled to room temperature and the product was extracted with ethyl acetate.
- the organic layer was washed with water and brine, dried over anhydrous MgSO 4 and filtered.
- concentration in vacuo the crude product was directly dissolved in THF (1 mL) and treated with a 1 M LiOH aqueous solution (1 mL).
- the resulting mixture was stirred at room temperature for 16 hours.
- the reaction mixture was treated with 1 M HCl aqueous in order to bring pH to 1.
- the product was extracted with ethyl acetate.
- the organic layer was washed with water and brine, dried over anhydrous MgSO 4 and filtered.
- Step 1 3-[(R)-1-(o-Chlorophenyl)ethoxycarbonylamino]-4-chloro-2-(6-chloro-3-pyridyl)-2H-pyrazole
- Step 2 (R)-1-(4-(5-(4-chloro-5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-1H-pyrazol-1-yl)pyridin-2-yl)phenyl)cyclopropane-1-carboxylic acid
- the resulting mixture was heated to 85° C. and stirred for 8 hours at that temperature.
- the reaction mixture was cooled to room temperature and the product was extracted with ethyl acetate.
- the organic layer was washed with water and brine, dried over anhydrous MgSO 4 and filtered.
- concentration in vacuo the crude product was directly dissolved in THF (1 mL) and treated with a 1 M LiOH aqueous solution (1 mL).
- the resulting mixture was stirred at room temperature for 16 hours.
- the reaction mixture was treated with 1 M HCl aqueous in order to bring pH to 1.
- the product was extracted with ethyl acetate.
- the organic layer was washed with water and brine, dried over anhydrous MgSO 4 and filtered.
- Step 6 3-[(R)-1-Phenylethoxycarbonylamino]-2-(p-bromophenyl)-2H-pyrazole
- Step 7 3-[(R)-1-Phenylethoxycarbonylamino]-2-(p-bromophenyl)-4-fluoro-2H-pyrazole
- Step 8 (R)-1-(4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid
- the reaction mixture was cooled to room temperature and the product was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous MgSO 4 and filtered. After concentration in vacuo, the crude product was directly dissolved in THF (1 mL) and treated with a 1 M LiOH aqueous solution (1 mL). The resulting mixture was stirred at room temperature for 16 hours. The reaction mixture was treated with 1 M HCl aqueous in order to bring pH to 1. The product was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous MgSO 4 and filtered.
- Step 1 3-[(R)-1-Phenylethoxycarbonylamino]-2-(p-bromophenyl)-4-chloro-2H-pyrazole
- Step 2 Methyl 1-(4′- ⁇ 5-[(R)-1-phenylethoxycarbonylamino]-4-chloro-1H-pyrazol-1-yl ⁇ -4-biphenylyl)cyclopropanecarboxylate
- Step 3 (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid
- Step 1 3-[(R)-1-Phenylethoxycarbonylamino]-2-(p-bromophenyl)-2H-pyrazole-4-carbonitrile
- a stirring suspension containing 5-amino-1-(4-bromophenyl)-1H-pyrazole-4-carbonitrile (262 mg, 1.0 mmol) and triphosgene (436 mg, 1.5 mmol) in THF (4.8 mL) was treated with a solution of triethylamine (730 ⁇ L, 5.26 mmol) in toluene (40 mL) dropwise.
- the resulting mixture was heated to 90° C. for 30 minutes and then treated with (R)-1-phenylethanol (160 ⁇ L, 1.3 mmol).
- the reaction was heated to 105° C. for 3 hours, after which time monitoring by TLC (5% acetone in toluene) indicated one main product formed.
- Step 2 Methyl 1-[p-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropanecarboxylate
- Step 3 Methyl 1-(4′- ⁇ 5-[(R)-1-phenylethoxycarbonylamino]-4-cyano-1H-pyrazol-1-yl ⁇ -4-biphenylyl)cyclopropanecarboxylate
- Step 4 (R)-1-(4′-(4-cyano-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid
- Step 1 3-[(R)-1-(o-Chlorophenyl)ethoxycarbonylamino]-2-(p-bromophenyl)-2H-pyrazole-4-carbonitrile
- a stirring suspension containing 5-amino-1-(4-bromophenyl)-1H-pyrazole-4-carbonitrile (262 mg, 1.0 mmol) and triphosgene (436 mg, 1.5 mmol) in THF (4.8 mL) was treated with a solution of triethylamine (730 ⁇ L, 5.26 mmol) in toluene (40 mL) dropwise.
- the resulting mixture was heated to 90° C. for 30 minutes and then treated with (R)-1-(2-chlorophenyl)ethanol (172 ⁇ L, 1.3 mmol).
- the reaction was heated to 105° C. for 3 hours, after which time monitoring by TLC (5% acetone in toluene) indicated one main product formed.
- Step 2 Methyl 1-(4′- ⁇ 5-[(R)-1-(o-chlorophenyl)ethoxycarbonylamino]-4-cyano-1H-pyrazol-1-yl ⁇ -4-biphenylyl)cyclopropanecarboxylate
- Step 3 (R)-1-(4′-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-cyano-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid
- Step 7 (R)-[2-(4-Bromo-phenyl)-4-fluoro-2H-pyrazol-3-yl]-carbamic acid 1-(2-chloro-phenyl)-ethyl ester
- Step 8 (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-carbamoylcyclopropyl)-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate
- Step 1 3-[(R)-1-(o-Chlorophenyl)ethoxycarbonylamino]-2-(p-bromophenyl)-2H-pyrazole
- the acid chloride was obtained as a beige solid.
- This material was dissolved in ethyl acetate (940 mL) and treated with a solution of NaN 3 (48.88 g, 752 mmol) dissolved in H 2 O (940 mL). After stirring for 1 hour at rt, LCMS shows complete conversion to the acyl azide. The organic layer was separated, dried over anhydrous MgSO 4 , filtered and evaporated at room temperature under vacuum. The acyl azide was obtained as a beige solid. This material was dissolved in toluene (1880 mL) with mechanical stirring. The reaction was heated to 100° C. for 1 hour and N 2 evolution was observed.
- Step 2 3-[(R)-1-(o-Chlorophenyl)ethoxycarbonylamino]-2-(p-bromophenyl)-4-fluoro-2H-pyrazole
- Step 4 1-(3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-N-(methylsulfonyl)cyclopropane-1-carboxamide
- Step 5 3-[(R)-1-(o-Chlorophenyl)ethoxycarbonylamino]-4-fluoro-2- ⁇ 2′-fluoro-4′-[1-(methylsulfonylamino)carbonylcyclopropyl]-4-biphenylyl ⁇ -2H-pyrazole
- Step 1 3-[(R)-1-(o-Chlorophenyl)ethoxycarbonylamino]-2-(p-bromophenyl)-4-chloro-2H-pyrazole
- Step 2 (R)-1-(2-chlorophenyl)ethyl (4-chloro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate
- Step 2 N-(methylsulfonyl)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropane-1-carboxamide
- Step 3 (R)-1-phenylethyl (4-chloro-1-(4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate
- Step 1 3-[(R)-1-(o-Chlorophenyl)ethoxycarbonylamino]-2-[4′-(1-cyanocyclopropyl)-4-biphenylyl]-4-fluoro-2H-pyrazole
- Step 2 (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate
- Step 1 3-[(R)-1-Phenylethoxycarbonylamino]-4-chloro-2-[4′-(1-cyanocyclopropyl)-4-biphenylyl]-2H-pyrazole
- Step 2 (R)-1-phenylethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-chloro-1H-pyrazol-5-yl)carbamate
- Step 1 3-[(R)-1-(o-Chlorophenyl)ethoxycarbonylamino]-4-chloro-2-[4′-(1-cyanocyclopropyl)-4-biphenylyl]-2H-pyrazole
- Step 2 (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-chloro-1H-pyrazol-5-yl)carbamate
- Step 2 N-cyano-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropane-1-carboxamide
- Step 3 (R)-1-(2-chlorophenyl)ethyl (4-chloro-1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate
- Step 1 (R)-1-(4′-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-fluoro-1H-pyrazol-1-yl)-2-fluoro-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid
- Step 2 (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-2′-fluoro-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate
- Step 1 Methyl 2-methyl-2-[p-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propionate
- Step 2 Methyl 2-(4′- ⁇ 5-[(R)-1-phenylethoxycarbonylamino]-4-cyano-1H-pyrazol-1-yl ⁇ -4-biphenylyl)-2-methylpropionate
- Step 3 (R)-2-(4′-(4-cyano-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)-2-methylpropanoic acid
- pyrazole substitutions are prepared following construction of the appropriate aryl pyrazole (8, Scheme 1). Direct flurorination, chlorination or trifluoromethylation provides arylbromide (9), intermediates suitable for further modification to compounds of the present invention according to procedures described for examples 1-28.
- Core pyrazole (8) may be prepared according to the approach depicted in Scheme 2:
- Binding affinity of compounds of Formula I-III were determined based on their ability to displace tritiated lysophosphatidic acid ([ 3 H]-LPA) from CHO cells expressing LPA1R in a protocol similar to that described in reference 17.
- CHO cells expressing human LPA1R [Cerep] were treated with [ 3 H]-LPA (2 nM).
- Test compounds were added in increasing concentration to each well and incubated at room temperature for 90 minutes. At this time the plates were washed and the wells counted for radioactivity. Results were compared to a control in which cells were treated with [ 3 H]-LPA in the presence of 10 ⁇ M unlabeled LPA.
- the specific ligand binding to the receptors was defined as the difference between the total binding and the nonspecific binding determined in the presence of an excess of unlabeled ligand.
- the results were expressed as a percent of control specific binding ((measured specific binding/control specific binding) ⁇ 100) and as a percent inhibition of control specific binding (100-((measured specific binding/control specific binding) ⁇ 100)) obtained in the presence of the test compounds.
- IC 50 value concentration causing a half-maximal inhibition of control specific binding
- Hill coefficient Hill coefficient
- LPA-stimulated Ca 2+ flux was used to assess compound potency using FLIPR technology in a 96 well plate format.
- the assay buffer used was a modified Hanks Balanced Salt Solution (HBSS) where HBSS was supplemented to contain 20 mM HEPES and 2.5 mM Probenecid at pH7.4 (Millipore, GPCR Profiler®).
- LPA1R expressing cells were plated and prepared 24 hours prior to assay of test articles.
- Ca 2+ ion flux was assessed from fluorescence of a Fluo-based No Wash Ca 2+ dye.
- Antagonist data are generated from plates with LPA concentrations sufficient to generate 80% efficacy [EC 80 ]. Percentage inhibition was calculated from a reduction of efficacy according to concentration of compounds of Formula I-VI. For dose responses the inhibition data was used to calculate compound IC 50 .
- the agonist assay was conducted on a FLIPR TETRA instrument where the test compound(s), vehicle controls, and reference agonist were added to the assay plate after a fluorescence baseline was established.
- the agonist assay was a total of 180 seconds and was used to assess each compound's ability to activate each GPCR assayed.
- the assay plate was removed from the FLIPR TETRA and incubated at 25° C. for seven (7) minutes. After the incubation period, the assay plate was placed back in the FLIPR TETRA and the antagonist assay was initiated.
- Antagonist Assay Using EC 80 potency values determined during the agonist assay, all pre-incubated sample compound wells were challenged with EC 80 concentration of reference agonist after establishment of a fluorescence baseline. The antagonist assay was conducted using the same assay plate that was used for the agonist assay. The antagonist assay was conducted on a FLIPR TETRA instrument where 9 vehicle controls and EC 80 concentration of reference agonist were added to appropriate wells. The antagonist assay was a total of 180 seconds and was used to assess each compound's ability to inhibit each GPCR assayed.
- Antagonist activity data for representative compounds prepared according to the synthetic methods disclosed herein are presented in Table 2.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions.
Description
- This invention was made with government support under Grant DK092005 awarded by the National Institutes of Health. The US government has certain rights in the invention.
- This application claims the benefit of U.S. patent application Ser. No. 16/010,755, filed Jun. 18, 2018, the entire contents of which is hereby incorporated by reference herein.
- The present invention relates to compounds having pharmacological activity, to processes for preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and prophylaxis of disease in a subject in need thereof, in particular for human and veterinarian treatments of pain, pruritus, cancer, inflammation and fibrotic diseases.
- Lysophospholipids affect fundamental cellular functions that include proliferation, differentiation, survival, migration, adhesion, invasion, and morphogensis. Abnormal functions influence many biological processes leading to disease that include, but are not limited to fibrotic disease, inflammation, cancer and peripheral nerve injury. Lysophosphatidic acid (LPA) is a lysophospholipid that has been shown to act through specific G protein-coupled receptors (GPCRs) in an autocrine and paracrine fashion. Antagonists of the LPA receptors find use in the treatment of diseases, disorders or conditions in which LPA plays a role.
- Agents that interact with the lysophosphatidic acid receptors [LPARs] to reduce signal transduction through those receptors (i.e., by competitive or noncompetitive inhibition or acting as inverse agonists) reduce manifestations of the diseases described herein. Diseases and conditions whose etiology, progression or persistence is effected by in whole or in part by signaling through the lysophosphatidic acid receptor subtype 1 (LPA1R) are considered LPA-dependent. New agents having therapeutic utility for treating those LPA-dependent and other conditions and diseases described herein are needed.
- Disclosed herein are compounds that inhibit the physiological activity of lysophosphatidic acid (LPA), and therefore, are useful as agents for the treatment or prevention of diseases in which inhibition of the physiological activity of LPA is useful.
- In one aspect, those compounds are useful for the treatment of fibrosis of organs (e.g., liver, kidney, lung, heart and the like), liver diseases (e.g., acute hepatatis, chronic hepatitis, liver fibrosis, liver cirrhosis, portal hypertension, regenerative failure, nonalcoholic steatohepatitis (NASH), liver hypofunction, hepatic blood flow disorder, and the like), cell proliferative disease such as cancers (including but not limited to solid tumor, solid tumor metastasis, vascular fibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia, chronic lymphocytic leukemia (CLL), invasive metastasis of cancer cell, and the like), inflammatory diseases (including but not limited to psoriasis, nephropathy, pneumonia and the like), gastrointestinal tract disease (including but not limited to (irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), abnormal pancreatic secretion, and the like), renal disease, urinary tract-associated disease (including but not limited to benign prostatic hyperplasia or symptoms associated with neuropathic bladder disease, spinal cord tumor, hernia of intervertebral disk, spinal canal stenosis, symptoms derived from diabetes, lower urinary tract disease (including but not limited to obstruction of lower urinary tract, and the like), inflammatory disease of lower urinary tract, (including but not limited to dysuria, frequent urination, and the like), pancreas disease, abnormal angiogenesis-associated disease (including but not limited to arterial obstruction and the like), scleroderma, brain-associated disease (including but not limited to cerebral infarction, cerebral hemorrhage, and the like), nervous system diseases (including but not limited to neuropathic pain, peripheral neuropathy, pruritus and the like), ocular disease (including but not limited to age-related macular degeneration (AMD), diabetic retinopathy, proliferative vitreo-retinopathy (PVR), cicatricial pemphigoid, glaucoma filtration surgery scarring, and the like).
- The compounds of the invention include compounds of Formula I that have the structure:
- or a pharmaceutically acceptable salt or prodrug thereof,
-
- wherein RA is —CO2H, —CO2RB, —CN, tetrazolyl, —C(═O)NH2, —C(═O)NHRB, —C(═O)NHSO2RB or —C(═O)NHCH2CH2SO3H or has the structure;
-
- RB is optionally substituted C1-C4 alkyl or has the structure of one of
-
- L1 is substituted or unsubstituted C1-C6 alkylene, substituted or unsubstituted C1-C6 fluoroalkylene, substituted or unsubstituted C3-C8 cycloalkylene, substituted or unsubstituted C1-C6 heteroalkylene;
- wherein A1 is —N═ or —CH;
- wherein Ring A has the structure of one of
-
- wherein RC is —CN, —F, —Cl, —Br, —I, —OC1-C4 alkyl, C3-C6 cycloalkyl, or C1-C4 fluoroalkyl;
- and RD is —N(RF)—C(═O)XCH(RG)—CY, wherein X is O and CY is phenyl substituted with one RH:
-
- RE, RF and RG independently are —H or C1-C4 alkyl or C3-C6 cycloalkyl or RE and RF independently are —H or C1-C4 alkyl or C1-C6 cycloalkyl and one RG is —C1-C4 alkyl and is taken together with the RH pheny moiety of the Ring A RD substituent and the carbon atom to which RG and said phenyl moiety is attached to define a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle;
- RH is independently —H, halogen, —CN, —NO2, —OH, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 fluoroalkoxy, or C1-C4 alkoxy,
- Other compounds of the invention have the structures indicated by the numbered embodiment and claims herein.
- As used herein and unless otherwise stated or implied by context, terms that are used herein have the meanings defined below. Unless otherwise contraindicated or implied, e.g., by including mutually exclusive elements or options, in these definitions and throughout this specification, the terms “a” and “an” mean one or more and the term “or” means and/or where permitted by context. Thus, as used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise.
- At various locations in the present disclosure, e.g., in any disclosed Embodiments or in the claims, reference is made to compounds, compositions, or methods that “comprise” one or more specified components, elements or steps. Invention Embodiments also specifically include those compounds, compositions, compositions or methods that are or that consist of or that consist essentially of those specified components, elements or steps. The terms “comprising”, “consist of” and “consist essentially of” have their normally accepted meanings under U.S. patent law unless otherwise specifically stated. The term “comprised of” is used interchangeably with the term “comprising” and are stated as equivalent terms. For example, disclosed compositions, devices, articles of manufacture or methods that “comprise” a component or step are open and they include or read on those compositions or methods plus an additional component(s) or step(s). Similarly, disclosed compositions, devices, articles of manufacture or methods that “consist of” a component or step are closed and they would not include or read on those compositions or methods having appreciable amounts of an additional component(s) or an additional step(s). Furthermore, use of the term “including” as well as other forms, such as “include”, “includes,” and “included,” is not limiting. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. Unless otherwise indicated, conventional methods of mass spectroscopy, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA techniques and pharmacology are employed.
- “Bond” or “single bond” as used herein means a chemical bond between two atoms, or two moieties when the atoms joined by the bond are considered to be part of larger substructure. As explicitly stated or implied by context, when a group described herein is a bond, the referenced group is absent thereby allowing a bond to be formed between the remaining identified groups.
- “Membered ring” as used herein means any cyclic structure. The term “membered” is meant to denote the number of skeletal atoms that constitute the ring. Thus, by way of example and not limitation, those membered rings include cyclohexyl, pyridinyl, pyranyl and thiopyranyl, which are 6-membered rings and cyclopentyl, pyrrolyl, furanyl, and thienyl, which are 5-membered rings.
- “Moiety” as used herein means a specific segment, fragment or functional group of a molecule or compound. Chemical moieties are sometimes indicated as chemical entities that are embedded in or appended (i.e., a substituent or variable group) to a molecule or compound.
- “Alkyl” as used herein is a collection of carbon atoms that are covalently linked together in normal, secondary, tertiary or cyclic arrangements, i.e., in a linear, branched, cyclic arrangement or some combination thereof. An alkyl substituent to a structure is that chain of carbon atoms that is covalently attached to the structure through a sp3 carbon of the substituent. The alkyl substituents, as used herein, contains one or more saturated moieties or groups and may additionally contain unsaturated alkyl moieties or groups, i.e., the substituent may comprise one, two, three or more independently selected double bonds or triple bonds of a combination thereof, typically one double or one triple bond if such unsaturated alkyl moieties or groups are present.
- Unsaturated alkyl moieties or groups include moieties or groups as described below for alkenyl, alkynyl, cycloalkyl, and aryl moieties. Saturated alkyl moieties contain saturated carbon atoms (sp3) and no aromatic, sp2 or sp carbon atoms. The number of carbon atoms in an alkyl moiety or group can vary and typically is 1 to about 50, e.g., about 1-30 or about 1-20, unless otherwise specified, e.g., C1-8 alkyl or C1-C8 alkyl means an alkyl moiety containing 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms and C1-6 alkyl or C1-C6 means an alkyl moiety containing 1, 2, 3, 4, 5 or 6 carbon atoms.
- When an alkyl substituent, moiety or group is specified, species may include methyl, ethyl, 1-propyl (n-propyl), 2-propyl (iso-propyl, —CH(CH3)2), 1-butyl (n-butyl), 2-methyl-1-propyl (iso-butyl, —CH2CH(CH3)2), 2-butyl (sec-butyl, —CH(CH3)CH2CH3), 2-methyl-2-propyl (t-butyl, —C(CH3)3), amyl, isoamyl, sec-amyl and other linear, cyclic and branch chain alkyl moieties. Unless otherwise specified, alkyl groups can contain species and groups described below for cycloalkyl, alkenyl, alkynyl groups, aryl groups, arylalkyl groups, alkylaryl groups and the like.
- Cycloalkyl as used here is a monocyclic, bicyclic or tricyclic ring system composed of only carbon atoms. The term “cycloalkyl” encompasses a monocyclic or polycyclic aliphatic, non-aromatic radical, wherein each of the atoms forming the ring (i.e. skeletal atoms) is a carbon atom. The number of carbon atoms in an cycloalkyl substituent, moiety or group can vary and typically is 3 to about 50, e.g., about 1-30 or about 1-20, unless otherwise specified, e.g., C3-8 alkyl or C3-C8 alkyl means an cycloalkyl substituent, moiety or group containing 3, 4, 5, 6, 7 or 8 carbon atoms and C3-6 alkyl or C3-C6 means an cycloalkyl substituent, moiety or group containing 3, 4, 5 or 6 carbon atoms. Cycloalkyl substituents, moieties or groups will typically have 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms and may contain exo or endo-cyclic double bonds or endo-cyclic triple bonds or a combination of both wherein the endo-cyclic double or triple bonds, or the combination of both, do not form a cyclic conjugated system of 4n+2 electrons; wherein the bicyclic ring system may share one (i.e., spiro ring system) or two carbon atoms and the tricyclic ring system may share a total of 2, 3 or 4 carbon atoms, typically 2 or 3.
- Unless otherwise specified, cycloalkyl substituents, moieties or groups can contain moieties and groups described for alkenyl, alkynyl, aryl, arylalkyl, alkylaryl and the like and can contain one or more other cycloalkyl moieties. Thus, cycloalkyls may be saturated, or partially unsaturated. Cycloalkyls may be fused with an aromatic ring, and the points of attachment to the aromatic ring are at a carbon or carbons of the cycloalkyl substituent, moiety or group that is not an aromatic ring carbon atom. Cycloalkyl groups include groups having from 3 to 10 ring atoms. Cycloalkyl substituents, moieties or groups include cyclopropyl, cyclopentyl, cyclohexyl, adamantly or other cyclic all carbon containing moieties. Cycloalkyls further include cyclobutyl, cyclopentenyl, cyclohexenyl, cycloheptyl and cyclooctyl. Cycloalkyl groups may be substituted or unsubstituted. Depending on the substituent structure, a cycloalkyl substituent can be a monoradical or a diradical (i.e., an cycloalkylene, such as, but not limited to, cyclopropan-1,1-diyl, cyclobutan-1,1-diyl, cyclopentan-1,1-diyl, cyclohexan-1,1-diyl, cyclohexan-1,4-diyl, cycloheptan-1,1-diyl, and the like). When cycloalkyl is used as a Markush group (i.e., a substituent) the cycloalkyl is attached to a Markush formula with which it is associated through a carbon involved in a cyclic carbon ring system carbon of the cycloalkyl group that is not an aromatic carbon.
- “Alkylamine” as used herein means an —N(alkyl)xHy group, moiety or substituent where x and y are independently selected from the group x=1, y=1 and x=2, y=O. Alkylamine includes those —N(alkyl)xHy groups wherein x=2 and y=0 and the alkyl groups taken together with the nitrogen atom to which they are attached form a cyclic ring system.
- “Heteroalkylene” as used herein means an alkylene (i.e. alkanediyl) group, moiety or substituent in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorus or combinations thereof. Heteroalkylene includes C1-C6 heteroalkylene or C1-C4 heteroalkylene. Exemplary heteroalkylenes include, but are not limited to, —OCH2—, —OCH(CH3)—, —OC(CH3)2—, —OCH2CH2—, —CH2O—, —CH(CH3)O—, C(CH3)2O—, —CH2CH2O—, —CH2OCH2—, —CH2OCH2CH2—, —CH2CH2OCH2—, —SCH2—, —SCH(CH3)—, —SC(CH3)2—, —SCH2CH2—, —CH2S—, —CH(CH3)S—, —C(CH3)2S—, —CH2CH2S—, —CH2SCH2—, —CH2SCH2CH2—, —CH2CH2SCH2—, —S(═O)2CH2—, —S(═O)2CH(CH3)—, —S(═O)2C(CH3)2—, —S(═O)2CH2CH2—, —CH2S(═O)2—, —CH(CH3)S(═O)2—, —C(CH3)2S(═O)2—, —CH2CH2S(═O)2—, —CH2S(═O)2CH2—, —CH2S(═O)2CH2CH2—, CH2CH2S(═O)2CH2—, —NHCH2—, —NHCH(CH3)—, —NHC(CH3)2—, —NHCH2CH2—, —CH2NH—, —CH(CH3)NH—, —C(CH3)2NH—, —CH2CH2NH—, —CH2NHCH2—, —CH2NHCH2CH2—, —CH2CH2NHCH2—, and the like.
- “Carboxylic acid bioisostere” as used herein means a functional group, moiety or substituent that exhibits similar physical, biological and/or chemical properties as a carboxylic acid moiety. By way of example and not limitation, carboxylic acid bioisosteres include,
- “Alkenyl” as used herein means a substituent, moiety or group that comprises one or more double bond moieties (e.g., —CH═CH—) or 1, 2, 3, 4, 5 or 6 or more, typically 1, 2 or 3 such moieties and can include an aryl moiety or group such as benzene, and additionally comprises linked normal, secondary, tertiary or cyclic carbon atoms, i.e., linear, branched, cyclic or any combination thereof unless the alkenyl moiety is a vinyl moiety (e.g., —CH═CH2). An alkenyl moiety, group or substituent with multiple double bonds may have the double bonds arranged contiguously (i.e. a 1,3 butadienyl moiety) or non-contiguously with one or more intervening saturated carbon atoms or a combination thereof, provided that a cyclic, contiguous arrangement of double bonds do not form a cyclically conjugated system of 4n+2 electrons (i.e., aromatic). The number of carbon atoms in an alkenyl group or moiety can vary and typically is 2 to about 50, e.g., about 2-30 or about 2-20, unless otherwise specified, e.g., C2-8 alkenyl or C2-8 alkenyl means an alkenyl moiety containing 2, 3, 4, 5, 6, 7 or 8 carbon atoms and C2-6 alkenyl or C2-6 alkenyl means an alkenyl moiety containing 2, 3, 4, 5 or 6 carbon atoms. Alkenyl moieties or groups will typically have 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms.
- When an alkenyl moiety, group or substituent is specified, species include, by way of example and not limitation, any of the alkyl or cycloalkyl, groups moieties or substituents described herein that has one or more double bonds, methylene (═CH2), methylmethylene (═CH—CH3), ethylmethylene (═CH—CH2—CH3), ═CH—CH2—CH2—CH3, vinyl (—CH═CH2), allyl, 1-methylvinyl, butenyl, iso-butenyl, 3-methyl-2-butenyl, 1-pentenyl, cyclopentenyl, 1-methyl-cyclopentenyl, 1-hexenyl, 3-hexenyl, cyclohexenyl and other linear, cyclic and branched chained all carbon containing moieties containing at least one double bond. When alkenyl is used as a Markush group (i.e., a substituent) the alkenyl is attached to a Markush formula with which it is associated through an unsaturated carbon of a double bond of the alkenyl moiety or group unless specified otherwise.
- “Alkynyl” as used herein means a substituent, moiety or group that comprises one or more triple bond moieties (i.e., —C≡C—), e.g., 1, 2, 3, 4, 5, 6 or more, typically 1 or 2 triple bonds, optionally comprising 1, 2, 3, 4, 5, 6 or more double bonds, with the remaining bonds (if present) being single bonds and comprising linked normal, secondary, tertiary or cyclic carbon atoms, i.e., linear, branched, cyclic or any combination thereof, unless the alkynyl moiety is ethynyl. The number of carbon atoms in an alkenyl moiety or group can vary and typically is 2 to about 50, e.g., about 2-30 or about 2-20, unless otherwise specified, e.g., C2-8 alkynyl or C2-8 alkynyl means an alkynyl moiety containing 2, 3, 4, 5, 6, 7 or 8 carbon atoms. Alkynyl groups will typically have 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms.
- When an alkynyl moiety or group is specified, species include, by way of example and not limitation, any of the alkyl moieties, groups or substituents described herein that has one or more double bonds, ethynyl, propynyl, butynyl, iso-butynyl, 3-methyl-2-butynyl, 1-pentynyl, cyclopentynyl, 1-methyl-cyclopentynyl, 1-hexynyl, 3-hexynyl, cyclohexynyl and other linear, cyclic and branched chained all carbon containing moieties containing at least one triple bond. When an alkynyl is used as a Markush group (i.e., a substituent) the alkynyl is attached to a Markush formula with which it is associated through one of the unsaturated carbons of the alkynyl functional group.
- “Aromatic” as used herein refers to a planar ring having a delocalized pi-electron system containing 4n+2 pi electrons, where n is a positive integer. Aromatic rings can be formed from five, six, seven, eight, nine, ten, or more than ten atoms. Aromatics are optionally substituted. The term “aromatic” includes both carboxcylic aryl (“aryl”, e.g., phenyl) and heterocyclic aryl (or “heteroaryl” or “heteroaromatic”) groups (e.g., pyridine). The term includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of carbon atoms) groups.
- “Aryl” as used here means an aromatic ring system or a fused ring system with no ring heteroatoms comprising 1, 2, 3 or 4 to 6 rings, typically 1 to 3 rings, wherein the rings are composed of only carbon atoms; and refers to a cyclically conjugated system of 4n+2 electrons (Huckel rule), typically 6, 10 or 14 electrons some of which may additionally participate in exocyclic conjugation (cross-conjugated (e.g., quinone). Aryl substituents, moieties or groups are typically formed by five, six, seven, eight, nine, or more than nine, carbon atoms. Aryl substituents, moieties or groups are optionally substituted. Exemplary aryls include C6-C10 aryls such as phenyl and naphthalenyl and phenanthryl. Depending on the structure, an aryl group can be a monoradical or a diradical (i.e., an arylene group). Exemplary arylenes include, but are not limited to, phenyl-1,2-ene, phenyl-1,3-ene, and phenyl-1,4-ene. When aryl is used as a Markush group (i.e., a substituent) the aryl is attached to a Markush formula with which it is associated through an aromatic carbon of the aryl group.
- “Arylalkyl” as used herein means a substituent, moiety or group where an aryl moiety is bonded to an alkyl moiety, i.e., -alkyl-aryl, where alkyl and aryl groups are as described above, e.g., —CH2—C6H5 or —CH2CH(CH3)—C6H5. When arylalkyl is used as a Markush group (i.e., a substituent) the alkyl moiety of the arylalkyl is attached to a Markush formula with which it is associated through a sp3 carbon of the alkyl moiety.
- “Alkylaryl” as used herein means a substituent, moiety or group where an alkyl moiety is bonded to an aryl moiety, i.e., -aryl-alkyl, where aryl and alkyl groups are as described above, e.g., —C6H4—CH3 or —C6H4—CH2CH(CH3). When alkylaryl is used as a Markush group (i.e., a substituent) the aryl moiety of the alkylaryl is attached to a Markush formula with which it is associated through a sp2 carbon of the aryl moiety.
- “Substituted alkyl”, “substituted cycloalkyl”, “substituted alkenyl”, “substituted alkynyl”, substituted alkylaryl”, “substituted arylalkyl”, “substituted heterocycle”, “substituted aryl” and the like as used herein mean an alkyl, alkenyl, alkynyl, alkylaryl, arylalkyl heterocycle, aryl or other group or moiety as defined or disclosed herein that has a substituent(s) that replaces a hydrogen atom(s) or a substituent(s) that interrupts a carbon atom chain. Alkenyl and alkynyl groups that comprise a substituent(s) are optionally substituted at a carbon that is one or more methylene moieties removed from the double bond.
- “Optionally substituted alkyl”, “optionally substituted alkenyl”, “optionally substituted alkynyl”, “optionally substituted alkylaryl”, “optionally substituted arylalkyl”, “optionally substituted heterocycle”, “optionally substituted aryl”, “optionally substituted heteroaryl”, “optionally substituted alkylheteroaryl”, “optionally substituted heteroarylalkyl” and the like as used herein mean an alkyl, alkenyl, alkynyl, alkylaryl, arylalkyl heterocycle, aryl, heteroaryl, alkylheteroaryl, heteroarylalkyl, or other substituent, moiety or group as defined or disclosed herein that has a substituent(s) that optionally replaces a hydrogen atom(s) or a substituent(s) that interrupts a carbon atom chain. Such substituents are as described herein. For a phenyl moiety, the arrangement of any two substituents present on the aromatic ring can be ortho (o), meta (m), or para (p). An optionally substituted fluoroalkyl is an alkyl or cycloalkyl moiety, typically a linear alkyl, wherein one or more hydrogen atoms is replaced by fluorine and at least one other atom other than carbon and fluorine.
- An optionally substituted or substituted substituent, moiety or group includes those having one or more additional group(s) that replace its hydrogen atom(s) individually and independently selected from alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, cyano, halo, nitro, haloalkyl, fluoroalkyl, fluoroalkoxy, and amino, including mono- and di-substituted amino groups, and the protected derivatives thereof. By way of example and not limitation an optional substituent(s) may be halide, —CN, —NO2, or LsRs, wherein each Ls is independently selected from a bond, —O—, —C(═O)—, —C(═O)O—, —S—, —S(═O)—, —S(═O)2—, —NH—, —NHC(═O)—, —C(═O)NH—, S(═O)2NH—, —NHS(═O)2, —OC(═O)NH—, —NHC(═O)O—, or —(C1-C6 alkylene)-; and each Rs is selected from —H, alkyl, fluoroalkyl, heteroalkyl, cycloalkyl, aryl, heteroaryl, or heterocycloalkyl. The protecting groups that may form the protective derivatives of the above substituents may be found in sources such as Greene and Wuts, above. Optional substituents include those selected from the group consisting of halogen, —CN, —NH2, —OH, —N(CH3)2, alkyl, fluoroalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, and arylsulfone, those selected from the group consisting of halogen, —CN, —NH2, —OH, NH(CH3), —N(CH3)2, —CO2H, —CO2alkyl, —C(═O)NH2, —C(═O)NHalkyl, —C(═O)N(alkyl)2, —S(═O)2NH2, —S(═O)2NH(alkyl), —S(═O)2N(alkyl)2, alkyl, cycloalkyl, fluoroalkyl, heteroalkyl, alkoxy, fluoroalkoxy, —S-alkyl and —S(═O)2alkyl or those selected from the group consisting of halogen, —CN, —NH2, —OH, —NH(CH3), —N(CH3)2, —CH3, —CH2CH3, —CF3, —OCH3, and —OCF3. Typically, an optionally substituted, substituent, moiety or group is substituted with one or two of the preceding groups, or more typically with one of the preceding groups. An optional substituent on an aliphatic carbon atom (acyclic or cyclic, saturated or unsaturated carbon atoms, excluding aromatic carbon atoms) further includes oxo (═O).
- “Heterocycle” or “heterocyclic” as used herein means a cycloalkyl or aromatic ring system wherein one or more, typically 1, 2 or 3, but not all of the carbon atoms comprising the ring system are replaced by a heteroatom which is an atom other than carbon, including, N, O, S, Se, B, Si, P, typically N, O or S wherein two or more heteroatoms may be adjacent to each other or separated by one or more carbon atoms, typically 1-17 carbon atoms, 1-7 atoms or 1-3 atoms. Heterocycles includes heteroaromatic rings (also known as heteroaryls) and heterocycloalkyl rings (also known as heteroalicyclic groups) containing one to four heteroatoms in the ring(s), where each heteroatom in the ring(s) is selected from O, S and N, wherein each heterocyclic group has from 4 to 10 atoms in its ring system, and with the proviso that the any ring does not contain two adjacent O or S atoms.
- Non-aromatic heterocyclic, substituents, moieties or groups (also known as heterocycloalkyls) have at least 3 atoms in their ring system, and aromatic heterocyclic groups have at least 5 atoms in their ring system and include benzo-fused ring systems. Heterocyclics with 3, 4, 5, 6 and 10 atoms include aziridinyl azetidinyl, thiazolyl, pyridyl and quinolinyl, respectively. Nonaromatic heterocyclic substituents, moieties or groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, oxazolidinonyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, thioxanyl, piperazinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, pyrrolin-2-yl, pyrrolin-3-yl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0)hexanyl, 3azabicyclo[4.1.0)heptanyl, 3H-indolyl and quinolizinyl. Aromatic heterocyclic includes, by way of example and not limitation, pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzo-thiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. Non-aromatic heterocycles may be substituted with one or two oxo (═O) moieties, and includes pyrrolidin-2-one.
- When heterocycle is used as a Markush group (i.e., a substituent) the heterocycle is attached to a Markush formula with which it is associated through a carbon or a heteroatom of the heterocycle, where such an attachment does not result in an unstable or disallowed formal oxidation state of that carbon or heteroatom. A heterocycle that is C-linked is bonded to a molecule through a carbon atom include moieties such as —(CH2)n-heterocycle where n is 1, 2 or 3 or —C<heterocycle where C<represents a carbon atom in a heterocycle ring. A heterocycle that is N-linked is a nitrogen containing heterocycle that is bonded a heterocycle ring nitrogen sometimes described as —N<heterocycle where N<represents a nitrogen atom in a heterocycle ring. Thus, nitrogen-containing heterocycles may be C-linked or N-linked and include pyrrole substituents, which may be pyrrol-1-yl (N-linked) or pyrrol-3-yl (C-linked), imidazole substituents, which may be imidazol-1-yl or imidazol-3-yl (both N-linked) or imidazol-2-yl, imidazol-4-yl or imidazol-5-yl (all C-linked).
- “Heteroaryl” as used herein means an aryl ring system wherein one or more, typically 1, 2 or 3, but not all of the carbon atoms comprising the aryl ring system are replaced by a heteroatom which is an atom other than carbon, including, N, O, S, Se, B, Si, P, typically, oxygen (—O—), nitrogen (—NX—) or sulfur (—S—) where X is —H, a protecting group or C1-6 optionally substituted alkyl, wherein the heteroatom participates in the conjugated system either through pi-bonding with an adjacent atom in the ring system or through a lone pair of electrons on the heteroatom and may be optionally substituted on one or more carbons or heteroatoms, or a combination of both, in a manner which retains the cyclically conjugated system.
- Heterocycles and heteroaryls, include, by way of example and not limitation, heterocycles and heteroaryls described in Paquette, Leo A.; “Principles of Modern Heterocyclic Chemistry” (W. A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; “The Chemistry of Heterocyclic Compounds, A series of Monographs” (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and J. Am. Chem. Soc. 1960, 82:5545-5473 particularly 5566-5573). Examples of heteroaryls include by way of example and not limitation pyridyl, thiazolyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, purinyl, imidazolyl, benzofuranyl, indolyl, isoindoyl, quinolinyl, isoquinolinyl, benzimidazolyl, pyridazinyl, pyrazinyl, benzothiopyran, benzotriazine, isoxazolyl, pyrazolopyrimidinyl, quinoxalinyl, thiadiazolyl, triazolyl and the like. Heterocycles that are not heteroaryls include, by way of example and not limitation, tetrahydrothiophenyl, tetrahydrofuranyl, indolenyl, piperidinyl, pyrrolidinyl, 2-pyrrolidonyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, octahydroisoquinolinyl, 2H-pyrrolyl, 3H-indolyl, 4H-quinolizinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, piperazinyl, quinuclidinyl, morpholinyl, oxazolidinyl and the like.
- Other heteroaryls include, by way of example and not limitation, the following moieties:
- Monocyclic heteroaryls include, by way of example and not limitation, pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, pyridazinyl, triazinyl, oxadiazolyl, thiadiazolyl, and furazanyl. Heteroaryls include those substituents, moieties or groups containing 0-3 N atoms, 1-3 N atoms or 0-3 N atoms, 0-1 O atoms and 0-1 S atoms. A heteroaryl may be monocyclic or bicyclic. The ring system of a heteroaryls ring typically contains 1-9 carbons (i.e., C1-C9 heteroaryl). Monocyclic heteroaryls include C1-C5 heteroaryls. Monocyclic heteroaryls include those having 5-membered or 6-membered ring systems. Bicyclic heteroaryls include C5-C9 heteroaryls. Depending on the structure, a heteroaryl group can be a monoradical or a diradical (i.e., a heteroarylene group).
- “Heterocycloalkyl” or “heteroalicyclic” as used herein means a cycloalkyl group, moiety or substituent wherein at least on carbon of the cycloalkyl chain is replaces with a heteroatom selected from the group consisting of nitrogen, oxygen and sulfur. The heterocycloalkyl may be fused with an aryl or heteroaryl. Heterocycloalkyls, also referred to as non-aromatic heterocycles, include by way of example and not limitation:
- Heterocycloalkyl includes, by way of example and not limitation, oxazolidinonyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, and indolinyl. Heteroalicyclics further includes all ring forms of carbohydrates, including but not limited to monosaccharides, disaccharides and oligosaccharides. Typically, a heterocycloalkyl is a C2-C10 heterocycloalkyl and includes C4-C10 heterocycloalkyl. A heterocycloalkyl may contain 0-2 N atoms, 0-2 O atoms or 0-1 S atoms.
- “Heteroarylalkyl” as used herein means a substituent, moiety or group where a heteroaryl moiety is bonded to an alkyl moiety, i.e., -alkyl-heteroaryl, where alkyl and heteroaryl groups are as described above. When heteroarylalkyl is used as a Markush group (i.e., a substituent) the alkyl moiety of the heteroarylalkyl is attached to a Markush formula with which it is associated through a sp3 carbon of the alkyl moiety.
- “Alkylheteroaryl” as used herein means a substituent, moiety or group where a heteroaryl moiety is bonded to an alkyl moiety, i.e., -heteroaryl-alkyl, where heteroaryl and alkyl groups are as described above. When heteroarylalkyl is used as a Markush group (i.e., a substituent) the heteroaryl moiety of the heteroarylalkyl is attached to a Markush formula with which it is associated through a sp2 carbon or heteroatom of the alkyl moiety.
- “Halogen” or “halo” as used herein means fluorine, chlorine, bromine or iodine.
- “Haloalkyl” as used herein means an alkyl substituent moiety or group in which one or more of its hydrogen atoms are replaced by one or more independently selected halide atoms. Haloalkyl includes C1-C4 haloalkyl. Example but non-limiting C1-C4 haloalkyls are —CH2Cl, CH2Br, —CH2I, —CHBrCl, —CHCl—CH2Cl and —CHCl—CH2I.
- “Haloalkylene” as used herein means an alkylene substituent, moiety or group in which one or more hydrogen atoms are replaced by one or more halide atoms. Haloalkylene includes C1-C6 haloalkylenes or C1-C4 haloalkylenes.
- “Fluoroalkyl” as used herein means an alkyl in which one or more hydrogen atoms are replaced by a fluorine atom. Fluoroalkyl includes C1-C6 and C1-C4 fluoroalkyls. Example but non-limiting fluoroalkyls include —CH3F, —CH2F2 and —CF3 and perfluroalkyls.
- “Fluoroalkylene” as used herein means an alkylene in which one or more hydrogen atoms are replaced by a fluorine atom. Fluoroalkylene includes C1-C6 fluoroalkylenes or C1-C4 fluoroalkylenes.
- The term “heteroalkyl” refers to an alkyl group in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorus or combinations thereof. In one aspect, a heteroalkyl is a C1-C6 heteroalkyl.
- “Protecting group” as used here means a moiety that prevents or reduces the ability of the atom or functional group to which it is linked from participating in unwanted reactions. Non-limiting examples are for —ORPR, wherein RPR is a protecting group for the oxygen atom found in a hydroxyl, while for —C(O)—ORPR, RPR may be a carboxylic acid protecting group; for —SRPR, RPR may be a protecting group for sulfur in thiols and for —NHRPR or —N(RPR)2—, at least one of RPR is a nitrogen atom protecting group for primary or secondary amines. Hydroxyl, amine, ketones and other reactive groups may require protection against reactions taking place elsewhere in the molecule. The protecting groups for oxygen, sulfur or nitrogen atoms are usually used to prevent unwanted reactions with electrophilic compounds, such as acylating agents. Typical protecting groups for atoms or functional groups are given in Greene (1999), “Protective groups in organic synthesis, 3rd ed.”, Wiley Interscience.
- “Ester” as used herein means a substituent, moiety or group that contains a —C(O)—O— structure (i.e., ester functional group) wherein the carbon atom of the structure is not directly connected to another heteroatom and is directly connected to —H or another carbon atom. Typically, esters comprise or consist of an organic moiety containing 1-50 carbon atoms, 1-20 carbon atoms or 1-8 carbon atoms and 0 to 10 independently selected heteroatoms (e.g., O, S, N, P, Si), typically 0-2 where the organic moiety is bonded through the —C(O)—O— structure and include ester moieties such as organic moiety-C(O)—O—. The organic moiety usually comprises one or more of any of the organic groups described herein, e.g., C1-20 alkyl moieties, C2-20 alkenyl moieties, C2-20 alkynyl moieties, aryl moieties, C3-8 heterocycles or substituted derivatives of any of these, e.g., comprising 1, 2, 3, 4 or more substituents, where each substituent is independently chosen. Exemplary, non-limiting substitutions for hydrogen or carbon atoms in these organic groups are as described above for substituted alkyl and other substituted moieties and are independently chosen. The substitutions listed above are typically substituents that one can use to replace one or more carbon atoms, e.g., —O— or —C(O)—, or one or more hydrogen atom, e.g., halogen, —NH2 or —OH. Exemplary esters include by way of example and not limitation, one or more independently selected acetate, propionate, isopropionate, isobutyrate, butyrate, valerate, isovalerate, caproate, isocaproate, hexanoate, heptanoate, octanoate, phenylacetate esters or benzoate esters. When ester is used as a Markush group (i.e., a substituent) the single bonded oxygen of the ester functional group is attached to a Markush formula with which it is associated.
- “Acetal”, “thioacetal”, “ketal”, “thioketal” and the like as used herein means a moiety, group or substituent comprising or consisting of a carbon to which is bonded two of the same or different heteroatoms wherein the heteroatoms are independently selected S and O. For acetal the carbon has two bonded oxygen atoms, a hydrogen atom and an organic moiety. For ketal, the carbon has two bonded oxygen atoms and two independently selected organic moieties where the organic moiety is as described herein alkyl or optionally substituted alkyl group. For thioacetals and thioketals one or both of the oxygen atoms in acetal or ketal, respectively, is replaced by sulfur. The oxygen or sulfur atoms in ketals and thioketals are sometimes linked by an optionally substituted alkyl moiety. Typically, the alkyl moiety is an optionally substituted C1-8 alkyl or branched alkyl structure such as —C(CH3)2—, —CH(CH3)—, —CH2—, —CH2—CH2—, —C[(C2-C4 alkyl)2]1, 2, 3- or —[CH(C2-C4 alkyl)]1, 2, 3-. Some of these moieties can serve as protecting groups for an aldehyde or ketone include, by way of example and not limitation, acetals for aldehydes and ketals for ketones and contain —O—CH2—CH2—CH2—O— or —O—CH2—CH2—O— moieties that form a spiro ring with the carbonyl carbon, and can be removed by chemical synthesis methods or by metabolism in cells or biological fluids.
- “Ether” as used herein means an organic moiety, group or substituent that comprises or consists of 1, 2, 3, 4 or more —O— moieties, usually 1 or 2, wherein no two —O— moieties are immediately adjacent (i.e., directly attached) to each other. Typically, ethers comprise an organic moiety containing 1-50 carbon atoms, 1-20 carbon atoms or 1-8 carbon atoms and 0 to 10 independently selected heteroatoms (e.g., O, S, N, P, Si), typically 0-2. An ether moiety, group or substituent includes organic moiety-O— wherein the organic moiety is as described herein for alkyl or optionally substituted alkyl group. When ether is used as a Markush group (i.e., a substituent) the oxygen of the ether functional group is attached to a Markush formula with which it is associated. When ether is a used as substituent in a Markush group it is sometimes designated as an “alkoxy” group. Alkoxy includes C1-C4 ether substituents such as, by way of example and not limitation, methoxy, ethoxy, propoxy, iso-propoxy and butoxy. Ether further includes those substituents, moieties or groups that contain one (excluding ketal) or more —OCH2CH2O—, moieties in sequence (i.e., polyethylene or PEG moieties).
- “Carbonate” as used here means a substituent, moiety or group that contains a —O—C(═O)—O— structure (i.e., carbonate functional group). Typically, carbonate groups as used here comprise or consist of an organic moiety containing 1-50 carbon atoms, 1-20 carbon atoms or 1-8 carbon atoms and 0 to 10 independently selected heteroatoms (e.g., O, S, N, P, Si), typically 0-2, bonded through the —O—C(═O)—O— structure, e.g., organic moiety-O—C(═O)—O—. When carbonate is used as a Markush group (i.e., a substituent) one of the singly bonded oxygen atoms of the carbonate functional group is attached to a Markush formula with which it is associated.
- “Carbamate” or “urethane” as used here means a substituent, moiety or group that contains a —O—C(═O)N(RPR)—, —O—C(═O)N(RPR)2, —O—C(═O)NH(optionally substituted alkyl) or —O—C(═O)N (optionally substituted alkyl)2- structure (i.e., carbamate functional group) where RPR and optionally substituted alkyl are independently selected and RPR are independently —H, a protecting group or an organic moiety as described for ester, alkyl or optionally substituted alkyl. Typically, carbamate groups as used here comprise or consist of an organic moiety containing about 1-50 carbon atoms, 1-20 carbon atoms or 1-8 carbon atoms and 0 to 10 independently selected heteroatoms (e.g., O, S, N, P, Si), typically 0-2, bonded through the —O—C(═O)—NRPR— structure, e.g., organic moiety-O—C(═O)—NRPR— or —O—C(═O)—NRPR-organic moiety. When carbamate is used as a Markush group (i.e., a substituent) the singly bonded oxygen (O-linked) or nitrogen (N-linked) of the carbamate functional group is attached to a Markush formula with which it is associated. The linkage of the carbamate substituent is either explicitly stated (N- or O-linked) or implicit in the context to which this substituent is referred.
- For any substituent group or moiety described by a given range of carbon atoms, the designated range means that any individual number of carbon atoms is described. Thus, reference to, e.g., “C1-C4 optionally substituted alkyl”, “C2-6 alkenyl optionally substituted alkenyl”, “C3-C8 optionally substituted heterocycle” specifically means that a 1, 2, 3 or 4 carbon optionally substituted alkyl moiety as defined herein is present, or a 2, 3, 4, 5 or 6 carbon alkenyl, or a 3, 4, 5, 6, 7 or 8 carbon moiety comprising a heterocycle or optionally substituted alkenyl moiety as defined herein is present. All such designations are expressly intended to disclose all of the individual carbon atom groups and thus “C1-C4 optionally substituted alkyl” includes, e.g., 3 carbon alkyl, 4 carbon substituted alkyl and 4 carbon alkyl, including all positional isomers and the like are disclosed and can be expressly referred to or named. For esters, carbonates and carbamates defined by a given range of carbon atoms, the designated range includes the carbonyl carbon of the respective functional group. Thus, a C1 ester refers to a formate ester and a C2 ester refers to an acetate ester. The organic substituents, moieties and groups described herein, and for other any other moieties described herein, usually will exclude unstable moieties except where such unstable moieties are transient species that one can use to make a compound with sufficient chemical stability for the one or more of the uses described herein. Substituents, moieties or groups by operation of the definitions herein that results in those having a pentavalent carbon are specifically excluded.
- “LPA-dependent”, “LPA-mediated” or like terms as used herein means a disease or condition whose etiology, progression or persistence is effected by in whole or in part by signaling through one or more lysophosphatidic acid receptor subtypes, including by way of example and not limitation lysophosphatidic acid receptor subtypes 1-6 (LPARs). LPA-dependent or LPA-mediated diseases and conditions include but not limited to fibrosis of organs (e.g., liver, kidney, lung, heart and the like), liver diseases (e.g., acute hepatatis, chronic hepatitis, liver fibrosis, liver cirrhosis, portal hypertension, regenerative failure, nonalcoholic steatohepatitis (NASH), liver hypofunction, hepatic blood flow disorder, and the like), cell proliferative disease (e.g., cancers, including but not limited to solid tumor, solid tumor metastasis, vascular fibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia, chronic lymphocytic leukemia (CLL), invasive metastasis of cancer cell, and the like), inflammatory disease (e.g., psoriasis, nephropathy, pneumonia and the like), gastrointestinal tract disease (e.g., irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), abnormal pancreatic secretion, and the like), renal disease, urinary tract-associated disease (e.g., benign prostatic hyperplasia or symptoms associated with neuropathic bladder disease), spinal cord tumor, hernia of intervertebral disk, spinal canal stenosis, symptoms derived from diabetes, lower urinary tract disease (e.g., obstruction of lower urinary tract, and the like), inflammatory disease of lower urinary tract (e.g., dysuria, frequent urination, and the like), pancreas disease, abnormal angiogenesis-associated disease (e.g., arterial obstruction and the like), scleroderma, brain-associated disease (e.g., cerebral infarction, cerebral hemorrhage, and the like), nervous system diseases (e.g., neuropathic pain, peripheral neuropathy, pruritus and the like), ocular disease (e.g., age-related macular degeneration (AMD), diabetic retinopathy, proliferative vitreo-retinopathy (PVR), cicatricial pemphigoid, glaucoma filtration surgery scarring, and the like).
- “LPA1R selective agents”, LPA1R selective compounds” and like terms as used herein means agents or compounds that interact with the lysophosphatidic acid subtype 1 receptor in preference to the lysophosphatidic acid receptor 2-6. Typically, that preference is manifested by 10-fold stronger binding affinity of the agent to LPA1R in comparison to other known LPARs as measured by experimentally determined KD values.
- “Pharmaceutically acceptable formulation” as used herein means a composition comprising an active pharmaceutical ingredient, such as a compound having the formula of I-VI in addition to one or more pharmaceutically acceptable excipients or refers to a composition prepared from an active pharmaceutical ingredient and one or more pharmaceutically acceptable excipients, wherein the composition is suitable for administration to a subject, such as a human or an animal, in need thereof. For a pharmaceutically acceptable formulation to be suitable for administration to a human the formulation must have biological activity for treating or preventing a disease or condition disclosed herein or an expectation must exist that the formulation would have a desired activity towards an “intent to treat” disease or condition. Typically, the “intent to treat” disease or condition is a lysophosphatidic acid receptor-mediated condition or disease. More typically the disease or condition to be treated or prevented is a lysophosphatidic acid lysophosphatidic acid type 1 receptor-mediated disease or condition. A pharmaceutically acceptable formulation that is suitable for administration to an animal does not necessarily require a biological activity for treating or preventing a disease or condition, and may be administered to the animal in order to evaluate a potential pharmacological or biological activity of a Formula I-XII compound. Those formulations must therefore be suitable for treating or preventing a disease or condition disclosed herein in an animal in need thereof or is suitable for evaluating a pharmacological or biological activity of a Formula I-XII compound. Compositions that are suitable only for use in vitro assays or which contain a vehicle, component or excipient in an amount not permitted in a drug product are specifically excluded from the definition of a pharmaceutically acceptable formulation.
- The pharmaceutically acceptable formulation may be comprised of, or be prepared from, one, two or more Formula I-XII compounds, typically one or two, and one or more pharmaceutically acceptable excipients. More typically, the formulations will consist essentially of or consist of a single Formula I-XII compound and one or more pharmaceutically acceptable excipients. Other formulations may be comprised of, consist essentially of, or consist of one, two or more Formula I-XII compounds and one two or more compounds in current use for treating lysophosphatidic acid lysophosphatidic acid type 1 receptor-mediated disease or condition disclosed herein and one or more pharmaceutically acceptable excipients. Typically, those formulations will consist essentially of or consist of a single Formula I-XII compound, a single compound in current use for treating a lysophosphatidic acid lysophosphatidic acid type 1 receptor-mediated disease or condition and one or more pharmaceutically acceptable excipients.
- “Solid formulation” as used herein refers to a pharmaceutically acceptable formulation comprising at least one Formula I-XII compound and one or more pharmaceutically acceptable excipients in solid form(s) wherein the formulation is in a unit dosage form suitable for administration of a solid. The dosage units include tablets, capsules, caplets, gelcaps, suspensions and other dosage units typically associated with parenteral or enteral (oral) administration of a solid.
- “Liquid formulation” as used herein refers to a pharmaceutically acceptable formulation wherein at least one Formula I-XII compound has been admixed or contacted with one or more pharmaceutically acceptable excipients, wherein at least one of the excipients is in liquid form in proportions required for a liquid formulation, i.e., such that a majority of the mass amount of the Formula I-XII compound(s) is dissolved into the non-solid excipient. Dosage units containing a liquid formulation include syrups, gels, ointments and other dosage units typically associated with parenteral or enteral administration of a pharmaceutical formulation to a subject in need thereof in liquid form.
- “Prevent, “preventing” and like terms as used herein takes on its normal and customary meaning in the medical arts and therefore does not require that each instance to which the term refers be avoided with certainty.
- The following embodiments exemplify the invention and are not meant to limit the invention in any manner. In certain embodiments, the compounds presented herein possess one or more stereocenters and each center independently exists in either the R or S configuration. The compounds presented herein include all diastereomeric, enantiomeric, and epimeric forms as well as the appropriate mixtures thereof. Stereoisomers are obtained, if desired, by methods such as, stereoselective synthesis and/or the separation of stereoisomers by chiral chromatographic columns. The methods and formulations described herein include the use of pharmaceutically acceptable salts of compounds having the structure of Formulas (I-VI), as well as active metabolites of these compounds having the same type of activity. In some situations, compounds may exist as tautomers. All tautomers are included within the scope of the compounds presented herein. In specific embodiments, the compounds described herein will exist as salts, including pharmaceutically acceptable salts. The salt forms include inorganic addition salts such as F− Cl−, Br−, I− and sulfate salts and organic addition salts such as mesylate, besylate, tosylate, citrate, succinate, fumarate and malonate. In other embodiments, the compounds described herein exist as quaternary ammonium salts.
- Embodiment 1. A compound of Formula I having the structure
- or a pharmaceutically acceptable salt or prodrug thereof,
-
- wherein RA is —CO2H, —CO2RB, —CN, tetrazolyl, —C(═O)NH2, —C(═O)NHRB, C(═O)NHSO2RB or —C(═O)NHCH2CH2SO3H or has the structure;
-
- RB is optionally substituted C1-C4 alkyl or has the structure of one of
- and;
-
- wherein RB is substituted or unsubstituted C1-C4 alkyl;
- L1 is substituted or unsubstituted C1-C6 alkylene, substituted or unsubstituted C1-C6 fluoroalkylene, substituted or unsubstituted C3-C8 cycloalkylene, substituted or unsubstituted C1-C6 heteroalkylene;
- wherein A1 is —N═ or —CH;
- wherein Ring A has the structure of one of
-
- wherein RC is —CN, —F, —Cl, —Br, —I, —OC1-C4 alkyl, C3-C6 cycloalkyl, or C1-C4 fluoroalkyl;
- and RD is —N(RF)—C(═O)XCH(RG)—CY, wherein X is O and CY is phenyl substituted with one RH:
-
- RE, RF and RG independently are —H or C1-C4 alkyl or C3-C6 cycloalkyl or RE and RF independently are —H or C1-C4 alkyl or C1-C6 cycloalkyl and one RG is —C1-C4 alkyl and is taken together with the RH pheny moiety of the Ring A RD substituent and the carbon atom to which RG and said phenyl moiety is attached to define a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle;
- RH is independently —H, halogen, —CN, —NO2, —OH, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 fluoroalkoxy, or C1-C4 alkoxy,
- In some embodiments RC is —CN, —F, —Cl, —Br, —I, —OC1-C4 alkyl, C1-C4 alkyl, C3-C6 cycloalkyl, or C1-C4 fluoroalkyl and RD is —N(RF)—C(═O)OCH(RG)—CY,
- wherein RF and each RG independently are —H or C1-C4 alkyl.
- In preferred embodiments RA is —CO2H, —CONHCN, tetrazolyl, or —C(═O)NHSO2RB, wherein RB is substituted or unsubstituted C1-C4 alkyl.
- In particularly preferred embodiments RA is —CO2H, —CONHCN, tetrazolyl, or —C(═O)NHSO2RB, wherein RB is —CH3.
- In some embodiments L1 is substituted or unsubstituted C1-C6 alkylene, C1-C6 fluoroalkylene, or substituted or unsubstituted C1-C6 heteroalkylene.
- In particularly preferred embodiments L1 is
- In some embodiments, Formula I compounds have RC defined as —CN, —F, —Cl, or C1-C4 fluoroalkyl.
- In more preferred embodiments, Formula I compounds have RC defined as —F, or —Cl.
- In some embodiments, Formula I compounds have RD defined as —N(RF)C(═O)—OCH(RG)—CY, wherein RF is —H or C1-C4 alkyl and X, CY and RG are as previously defined.
- In more preferred embodiments, Formula I compounds have RD defined as —N(RF)C(═O)OCH(RG)—CY, wherein RF is —H and CY and RG are as previously defined.
- In some embodiments, Formula I compounds have RF defined as H, C1-C4 alkyl or C3-C6 cycloalkyl.
- In more preferred embodiments, Formula I compounds have RF defined as —H.
- In some embodiments of Formula I compounds RG is independently —H or C1-C4 alkyl.
- In more preferred embodiments, Formula I compounds have RG defined as —CH3.
- In some embodiments of Formula I compounds CY is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein if CY is substituted then CY is substituted with 1, 2, or 3 independently selected RH.
- In preferred Formula I compounds have RA is —CO2H, RC is —F or —Cl, RD is —NRFC(═O)OCH(RG)—CY, and RF, RG, and CY are as previously defined.
- In other preferred Formula I compounds RA is tetrazolyl, RC is —F or —Cl, RD is —NRFC(═O)OCH(RG)—CY, and RF, RG, and CY are as previously defined.
- In other preferred Formula I compounds RA is —C(═O)NHSO2RB, RC is —F or —Cl, RD is —NRFC(═O)OCH(RG)—CY, and RB, RF, RG, and CY are as previously defined.
- In other preferred Formula I compounds RA is —CONHCN, RC is —F or —Cl, RD is —NRFC(═O)OCH(RG)—CY, and RF, RG, and CY are as previously defined.
- Embodiment 2. The compound of Embodiment 1 wherein RA is —CO2H or CONHCN.
- Embodiment 3. The compound of Embodiment 1 wherein RA is tetrazolyl.
- Embodiment 4. The compound of Embodiment 1 wherein RA is —C(═O)NHSO2RB where RB is —CH3.
- Embodiment 5. The compound of Embodiment 1-4 wherein RC is —CN, —F, or —Cl.
- Embodiment 6. The compound of Embodiment 1-5 wherein RC is —F or —Cl.
- Embodiment 7. The compound of Embodiment 1-6 wherein L1, when present, is a geminally substituted alkyl, cycloalkyl or heterocycloalkyl group,
- Embodiment 8. The compound of Embodiments 7 wherein L1 is
- Embodiment 9. The compound of any one of Embodiments 1-8 wherein RF is —H.
- Embodiment 10. The compound of any one of Embodiments 1-9 wherein RG is —CH3.
- Embodiment 11. The compound of any one of Embodiments 1-10 wherein CY is substituted or unsubstituted phenyl.
- Embodiment 12. The compound of any one of Embodiments 1-11 wherein RH is —H, halogen, —CN, —NO2, —OH, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 fluoroalkoxy, and C1-C4 alkoxy.
- Embodiment 13. The compound of any one of Embodiments 1-12 wherein RH are independently selected from —H, halogen or substituted or unsubstituted C1-C4 alkyl or substituted C1-C4 alkoxy.
- Embodiment 14. The compound of any one of Embodiments 1-13 wherein RH is independently —H, —Cl, —F, —CH3, —CF3, —OCH3 or —OCF3.
- Embodiment 15. A compound of Formula II having the structure:
-
- or a pharmaceutically acceptable salt or prodrug thereof,
- wherein RA is —CO2H, —CO2RB, tetrazolyl, —C(═O)NH2, —CONHCN or C(═O)NHSO2RB;
- RB is optionally substituted C1-C4 alkyl
- L1 is optionally substituted C1-C6 alkylene; C1-C6 fluoroalkylene; or optionally substituted C1-C6 heteroalkylene or L1 is
- or disubstituted dimethylmethane.
-
- A1 is ═N— or ═CH—;
- Ring A has the structure:
-
- RC is —ON, —F, —Cl, or C1-C4 fluoroalkyl;
- RD is —N(RF)—C(═O)XCH(RG)—CY, wherein X is O and CY is phenyl substituted with one RH:
-
- RE, RF and RG independently are —H or C1-C4 alkyl or C3-C6 cycloalkyl or RE and RF independently are —H or C1-C4 alkyl or C1-C6 cycloalkyl and one RG is —C1-C4 alkyl and is taken together with the RH pheny moiety of the Ring A RD substituent and the carbon atom to which RG and said phenyl moiety is attached to define a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle;
- RH is —H, halogen, —CN, —NO2, —OH, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 fluoroalkoxy, and C1-C4 alkoxy;
- In particularly preferred Formula II compounds RA is —CO2H, —CONHCN, —C(═O)NHSO2RB, or tetrazolyl, RB is CH3, RC is —F or —Cl, RD is —NRFC(═O)OCH(RG)—CY and RF, RG and CY are as previously defined.
- Embodiment 16. A compound of Formula III having the structure:
-
- or a pharmaceutically acceptable salt or prodrug thereof,
- wherein RA is —CO2H, —CONHCN, tetrazolyl, or —C(═O)NHSO2RB;
- RB is optionally substituted C1-C4 alkyl
- L1 is substituted C1-C6 alkylene; C1-C6 fluoroalkylene; or optionally substituted C1-C6 heteroalkylene, or L1, when present is
- or disubstituted dimethylmethane.
-
- A1 is ═N— or ═CH—;
- Ring A has the structure of one of:
-
- RC is —CN, —F, or —Cl;
- wherein CY is phenyl substituted with one RH;
- RF and RG independently are —H or C1-C4 alkyl or C3-C6 cycloalkyl or RF independently is —H or C1-C4 alkyl or C1-C6 cycloalkyl and one RG is —C1-C4 alkyl and is taken together with the RH pheny moiety of the Ring A RD substituent and the carbon atom to which RG and said phenyl moiety is attached to define a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle;
- RH is —H, halogen, —CN, —NO2, —OH, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 fluoroalkoxy, and C1-C4 alkoxy;
- Preferred Formula III compounds have RA is —CO2H, —CONHCN, —C(═O)NHSO2RB, or tetrazolyl, RB is CH3, RC is —F or —Cl, RD is —NRFC(═O)OCH(RG)—CY and RF is —H, RG is —CH3 and CY is as previously defined.
- Embodiment 17. A composition comprising, essentially consisting of or consisting of one or more compounds of Formula I-III and one or more excipients.
- In preferred embodiments the composition comprises, consists essentially of, or consists of one compound of Formula I-III and one or more excipients.
- In other preferred embodiments the composition is a pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of one compound of Formula I-III and one or more pharmaceutically acceptable excipients.
- Embodiment 18. A compound of Formula I-III or a pharmaceutically acceptable salt or prodrug thereof wherein the binding affinity of the compound to lysophosphatidic acid receptor-1 (LPA1R) is between about 10 μM and 1 pM or less
- Embodiment 19. The compound of Embodiment 1-18 wherein the compound is a selective lysophosphatidic acid receptor-1 (LPA1R) compound.
- Embodiment 20. A compound of Formula I-III or a pharmaceutically acceptable salt, or prodrug thereof wherein the compound is a selective lysophosphatidic acid receptor-1 (LPA1R) compound.
- Embodiment 21. The compound of Embodiment 1-20 wherein the compound is a selective lysophosphatidic acid receptor-1 (LPA1R) compound wherein the binding affinity (i.e., KD) of the LPA1R compound is between about 1 μM and 1 pM or less. In preferred Embodiments the KD is 100 nM or less, more preferably 10 nM or less.
- Embodiment 22. A compound of Table 1.
- Embodiment 23. The compound of Embodiment 22 wherein the compound is (R)-1-(4-(5-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-fluoro-1H-pyrazol-1-yl)pyridin-2-yl)phenyl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(3-fluoro-4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(2-fluoro-4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(2-chloro-4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-2-methyl-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, or (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-carbamoylcyclopropyl)-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate;
- Embodiment 24. The compound of Embodiment 22 wherein the compound is (R)-1-(4-(5-(4-chloro-5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-1H-pyrazol-1-yl)pyridin-2-yl)phenyl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-3-fluoro-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-2-fluoro-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(2-chloro-4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, or (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-2-methyl-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid;
- Embodiment 25. The compound of Embodiment 22 wherein the compound is (R)-1-{4′-[5-(1-Phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid, or (R)-1-{2-Fluoro-4′-[5-(1-phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid;
- Embodiment 26. The compound of Embodiment 22 wherein the compound is (R)-1-(4′-(4-cyano-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-cyano-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-2-(4′-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-cyano-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)-2-methylpropanoic acid, or (R)-2-(4′-(4-cyano-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)-2-methylpropanoic acid;
- Embodiment 27. The compound of Embodiment 22 wherein the compound is (R)-1-(2-chlorophenyl)ethyl (4-fluoro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (4-fluoro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-chloro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (4-chloro-1-(4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, or (R)-1-(2-chlorophenyl)ethyl (4-fluoro-1-(4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate;
- Embodiment 28. The compound of Embodiment 22 wherein the compound is (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-chloro-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-chloro-1H-pyrazol-5-yl)carbamate;
- Embodiment 29. The compound of Embodiment 22 wherein the compound is (R)-1-phenylethyl (4-chloro-1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-chloro-1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-2′-fluoro-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate;
- Embodiment 30. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of Table 1 and one or more pharmaceutically acceptable excipients.
- Embodiment 31. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of Embodiment 23 and one or more pharmaceutically acceptable excipients.
- Embodiment 32. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of Embodiment 24 and one or more pharmaceutically acceptable excipients.
- Embodiment 33. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of Embodiment 25 and one or more pharmaceutically acceptable excipients.
- Embodiment 34. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of Embodiment 26 and one or more pharmaceutically acceptable excipients.
- Embodiment 35. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of Embodiment 27 and one or more pharmaceutically acceptable excipients.
- Embodiment 36. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of Embodiment 28 and one or more pharmaceutically acceptable excipients.
- Embodiment 37. A pharmaceutically acceptable formulation comprising, consisting essentially of, or consisting of a compound of Embodiment 29 and one or more pharmaceutically acceptable excipients.
- Embodiment 38. A method comprising administering an effective amount of a Formula I-III compound to a subject having a LPA-dependent or LPA-mediated disease or condition.
- Embodiment 39. The method of Embodiment 38 wherein the LPA-dependent or LPA-mediated disease or condition is a disease with fibrosis of the organs.
- Embodiment 40. The method of Embodiment 39 wherein the fibrosis is of the liver, kidney, lung, heart, eye and the like.
- Embodiment 41. The method of Embodiment 38 wherein the LPA-dependent or LPA-mediated disease or condition is chronic pain
- Embodiment 42. The method of Embodiment 38 wherein the LPA-dependent or LPA-mediated disease or condition is pruritus.
- Embodiment 43. The method of Embodiment 38 wherein the LPA-mediated disease is a proliferative disease including cancer (solid tumor, solid tumor metastasis, vascular fibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia, chronic lymphocytic leukemia (CLL) and the like) and invasive metastasis of cancer cell, including ovarian, breast and triple negative breast cancer and the like,
- Embodiment 44. The method of Embodiment 38 wherein the LPA-mediated disease is an inflammatory disease including psoriasis, nephropathy, pneumonia and the like,
- Embodiment 45. The method of Embodiment 38 wherein the LPA-mediated disease is a gastrointestinal disease such as inflammatory bowel disease,
- Embodiment 46. The method of Embodiment 38 wherein the LPA-mediated disease is an ocular disease including age-related macular degeneration (AMD), diabetic retinopathy, proliferative vitreoretinopathy (PVR), cicatricial pemphigoid, glaucoma filtration surgery scarring, uveitis and the like,
- Embodiment 47. The method of Embodiment 38 wherein the LPA-mediated disease is a liver disease including acute hepatitis, chronic hepatitis, liver fibrosis, liver cirrhosis, cholestatic pruritus, portal hypertension, regenerative failure, nonalcoholic steatohepatitis (NASH), liver hypofunction, hepatic blood flow disorder, and the like,
- Embodiment 48. The method of Embodiment 38 wherein the LPA-mediated disease is a renal disease including chronic kidney disease, end stage renal disease, uremic pruritus, nephropathy including diabetic nephropathy and the like,
- Embodiment 49. The method of Embodiment 38 wherein the LPA-mediated disease is a skin disease including scleroderma, skin scarring, atopic dermatitis, psoriasis and the like,
- Embodiment 50. The method of any one of Embodiments 38-49 wherein the subject is a human.
- Embodiment 51. The method of any one of Embodiments 38-50 wherein the compound is selected from Table 1.
- Embodiment 52. The method of any one of Embodiments 78-90 wherein the compound is (R)-1-(4-(5-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-fluoro-1H-pyrazol-1-yl)pyridin-2-yl)phenyl)cyclopropane-1-carboxylic acid, (R)-1-(4-(5-(4-chloro-5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-1H-pyrazol-1-yl)pyridin-2-yl)phenyl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-cyano-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-cyano-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(3-fluoro-4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(2-fluoro-4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-3-fluoro-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-2-fluoro-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(2-chloro-4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(2-chloro-4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-2-methyl-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-2-methyl-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-carbamoylcyclopropyl)-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-fluoro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (4-fluoro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-chloro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (4-chloro-1-(4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-fluoro-1-(4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-chloro-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-chloro-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (4-chloro-1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-chloro-1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-2′-fluoro-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate, (R)-2-(4′-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-cyano-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)-2-methylpropanoic acid, (R)-2-(4′-(4-cyano-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)-2-methylpropanoic acid;
- Embodiment 53. The method of any one of Embodiments 38-50 wherein the compound is selected from Embodiment 23.
- Embodiment 54. The method of any one of Embodiments 38-50 wherein the compound is selected from Embodiment 24.
- Embodiment 55. The method of any one of Embodiments 38-50 wherein the compound is selected from Embodiment 25.
- Embodiment 56. The method of any one of Embodiments 38-50 wherein the compound is selected from Embodiment 26.
- Embodiment 57. The method of any one of Embodiments 38-50 wherein the compound is selected from Embodiment 27.
- Embodiment 58. The method of any one of Embodiments 38-50 wherein the compound is selected from Embodiment 28.
- Embodiment 59. The method of any one of Embodiments 38-50 wherein the compound is selected from Embodiment 29.
- Embodiment 60. A composition comprising, consisting essentially of or consisting of one or more compounds of Formula (I-III) and one or more agents currently used to treat a LPA-dependent or LPA-mediated disease or a disease or condition described herein.
- Embodiment 61. A pharmaceutically acceptable formulation comprising, consisting essentially of or consisting of one or more compounds of Formula (I-III), one or more agents currently used to treat a LPA-dependent or LPA-mediated disease and one or more pharmaceutically acceptable excipients.
- Embodiment 62. A method comprising administering in combination with or co-administrating a compound of Formula (I-III) to a subject with a LPA-dependent or LPA-mediated disease or condition and a currently used agent to treat a LPA-dependent or LPA-mediated disease
- The one or more additional therapeutically active agents other than compounds of Formula (I-III) are selected from: corticosteroids, immunosuppressants, analgesics, anti-cancer agents, anti-inflammatories, chemokine receptor antagonists, bronchodilators, leukotriene receptor antagonists, leukotriene formation inhibitors, platelet activating factor receptor antagonists, monoacylglycerol kinase inhibitors, phospholipase A1 inhibitors, phospholipase A2 inhibitors, and lysophospholipase D (lysoPLD) inhibitors, autotaxin inhibitors, decongestants, mast cell stabilizers, antihistamines, mucolytics, anticholinergics, antitussives, expectorants, and β-2 agonists.
- In preferred embodiments the currently used agent(s) are selected from those described in the Merck Index known to affect lysophosphatidic acid receptor signaling. In other preferred embodiments the Formula (I-III) compound is selected from Table 1.
- In other embodiments, therapies which combine a compound of Formula (I-III), with currently used agents that act on differing signalling pathways to the LPA synthesis or signalling pathway so as to provide complementary clinical outcomes, are encompassed herein for treating LPA-dependent or LPA-mediated diseases or conditions.
- Examples of additional therapeutic agents include, but are not limited to, any of the following: gossypol, genasense, polyphenol E, Chlorofusin, all trans-retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 5-aza-2′-deoxycytidine, all trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib, geldanamycin, 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 11-7082, PKC412, or PD 184352, Taxol™ (paclitaxel), and analogs of Taxol™, such as Taxotere™, U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600 125, BAY 43-9006, wortmannin, or LY294002, Adriamycin, Dactinomycin, Bleomycin, Vinblastine, Cisplatin, acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; amino glutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine; dexormaplatin; deazaguanine; deazaguanine mesylate; diaziquone; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflornithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flurocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; iimofosine; interleukin II (including recombinant interleukin II, or rlL2), interferon alfa-2a; interferon alfa-2b; interferon alfa-n1; interferon alfa-n3; interferon beta-I a; interferon gamma-I b; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazoie; nogalamycin; ormaplatin; oxisuran; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spiro germanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozotocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfm; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride, mechloroethamine, cyclophosphamide, chlorambucil, meiphalan, etc.), ethylenimine, hexamethlymelamine, thiotepa, busulfan), carmustine, lomusitne, semustine, streptozocin, ortriazenes, dacarbazine, methotrexate, fluorouracil, floxouridine, Cytarabine, mercaptopurine, thioguanine, pentostatin, hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate, estrogens, diethlystilbestrol, ethinyl estradiol, tamoxifen), testosterone propionate, fluoxymesterone, flutamide, leuprolide, cisplatin, carboblatin, mitoxantrone), procarbazine, mitotane, amino glutethimide, Erbulozole, Dolastatin 10, Mivobulin isethionate, Vincristine, NSC-639829, Discodermolide, ABT-751, Altorhyrtin A and Altorhyrtin C), Spongistatins 1-9, Cemadotin hydrochloride, Epothilone A, Epothilone B, Epothilone C, Epothilone D, Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone AN-oxide, 16-aza-epothilone B, 21aminoepothilone B, 21-hydroxyepothilone D, 26-fluoroepothilone, Auristatin PE, Soblidotin, Cryptophycin 52, Vitilevuamide, Tubulysin A, Canadensol, Centaureidin, Oncocidin Al Fijianolide B, Laulimalide, Narcosine, Nascapine, Hemiasterlin, Vanadocene acetylacetonate, Indanocine Eleutherobins (such as Desmethyleleutherobin, Desacetyleleutherobin, Isoeleutherobin A, and Z-Eleutherobin), Caribaeoside, Caribaeolin, Halichondrin B, Diazonamide A, Taccalonolide A, Diozostatin, (−)-Phenylahistin, Myoseverin B, Resverastatin phosphate sodium, Aprepitant, cannabis, marinol, dronabinol, erythropoetin-α, Filgrastim, rituximab, natalizumab, cyclophosphamide, penicillamine, cyclosporine, nitrosoureas, cisplatin, carboplatin, oxaliplatin, methotrexate, azathioprine, mercaptopurine, pyrimidine analogues, protein synthesis inhibitors, dactinomycin, anthracyclines, mitomycin C, bleomycin, mithramycin, Atgam® Thymoglobuline®, OKT3®, basiliximab, daclizumab, cyclosporin, tacrolimus, sirolimus, Interferons, opioids, infliximab, etanercept, adalimumab, golimumab, leflunomide, sulfasalazine, hydroxychloroquinine, minocycline, rapamicin, mycophenolic acid, mycophenolate mofetil, FTY720, Cyclosporin A (CsA) or tacrolimus (FK506), aspirin, salicylic acid, gentisic acid, choline magnesium salicylate, choline salicylate, choline magnesium salicylate, choline salicylate, magnesium salicylate, sodium salicylate, diflunisal, carprofen, fenoprofen, fenoprofen calcium, flurobiprofen, ibuprofen, ketoprofen, nabutone, ketolorac, ketorolac tromethamine, naproxen, oxaprozin, diclofenac, etodolac, indomethacin, sulindac, tolmetin, meclofenamate, meclofenamate sodium, mefenamic acid, piroxicam, meloxicam, valdecoxib, parecoxib, etoricoxib, lumiracoxib, betamethasone, prednisone, alclometasone, aldosterone, amcinonide, beclometasone, betamethasone, budesonide, ciclesonide, clobetasol, clobetasone, clocortolone, cloprednol, cortisone, cortivazol, deflazacort, deoxycorticosterone, desonide, desoximetasone, desoxycortone, dexamethasone, diflorasone, diflucortolone, difluprednate, fluclorolone, fludrocortisone, fludroxycortide, flumetasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin, fluocortolone, fluorometholone, fluperolone, fluprednidene, fluticasone, formocorta1, halcinonide, halometasone, hydrocortisone/cortisol, hydrocortisone aceponate, hydrocortisone buteprate, hydrocortisone butyrate, lotepredno1, medrysone, meprednisone, methylprednisolone, methylprednisolone aceponate, mometasone furoate, paramethasone, prednicarbate, prednisone/prednisolone, rimexolone, tixocortol, triamcinolone, ulobetasol, pioglitazone, clofibrate, fenofibrate gemfibrozil, folic acid, isbogrel, ozagrel, ridogrel, dazoxiben, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, nisvastatin, and rosuvastatin, edaravone, vitamin C, TROLOX™, citicoline and minicycline, (2R)-2-propyloctanoic acid, propranolol, nadolol, timolol, pindolol, labetalol, metoprolol, atenolol, esmolol and acebutolol, memantine, traxoprodil, tirofiban lamifiban, argatroban, enalapril, cyclandelate, losartan, valsartan, candesartan, irbesartan, telmisartan, olmesartan, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, remogliflozin etabonate, sotagliflozin, tofogliflozin, exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, semaglutide, mepyramine (pyrilamine), antazoline, diphenhydramine, carbinoxamine, doxylamine, clemastine, dimenhydrinate, pheniramine, chlorphenamine (chlorpheniramine), dexchlorpheniramine, brompheniramine, triprolidine, cetirizine, cyclizine, chlorcyclizine, hydroxyzine, meclizine, loratadine, desloratidine, promethazine, alimemazine (trimeprazine), cyproheptadine, azatadine, ketotifen, acrivastine, astemizole, cetirizine, mizolastine, terfenadine, azelastine, epinastine, levocabastine, olopatadine, levocetirizine, fexofenadine, rupatadine, bepotastine), mucolytics, anticholinergics, antitussives, analgesics, expectorants, albuterol, ephedrine, epinephrine, fomoterol, metaproterenol, terbutaline, budesonide, ciclesonide, dexamethasone, flunisolide, fluticasone propionate, triamcinolone acetonide, ipratropium bromide, pseudoephedrine, theophylline, montelukast, pranlukast, tomelukast, zafirlukast, ambrisentan, bosentan, enrasentan, sitaxsentan, tezosentan, iloprost, treprostinil, pirfenidone, epinephrine, isoproterenol, orciprenaline, xanthines, zileuton.
- Embodiment 63. The method of Embodiments 60-62 wherein the subject is a human.
- Embodiment 64. The method of Embodiments 60-62 wherein the Formula I-III compound(s) are selected from Table 1.
- Embodiment 65. The method of Embodiments 60-62 wherein the Formula I-III compound(s) are selected from the group consisting of (R)-1-(4-(5-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-fluoro-1H-pyrazol-1-yl)pyridin-2-yl)phenyl)cyclopropane-1-carboxylic acid, (R)-1-(4-(5-(4-chloro-5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-1H-pyrazol-1-yl)pyridin-2-yl)phenyl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-cyano-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-cyano-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(3-fluoro-4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(2-fluoro-4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-3-fluoro-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-2-fluoro-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(2-chloro-4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(2-chloro-4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-2-methyl-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-2-methyl-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-carbamoylcyclopropyl)-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-fluoro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (4-fluoro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-chloro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (4-chloro-1-(4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-fluoro-1-(4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-chloro-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-chloro-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (4-chloro-1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-chloro-1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-2′-fluoro-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate, (R)-2-(4′-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-cyano-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)-2-methylpropanoic acid, (R)-2-(4′-(4-cyano-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)-2-methylpropanoic acid;
- Embodiment 66. The method of Embodiments 60-63 wherein the Formula I-III compound(s) are selected from Embodiment 23.
- Embodiment 67. The method of Embodiments 60-63 wherein the Formula I-III compound(s) are selected from Embodiment 24.
- Embodiment 68. The method of Embodiments 60-63 wherein the Formula I-III compound(s) are selected from Embodiment 25.
- Embodiment 69. The method of Embodiment 60-63 wherein the Formula I-III compound(s) are selected from Embodiment 26.
- Embodiment 70. The method of Embodiment 60-63 wherein the Formula I-III compound(s) are selected from Embodiment 27.
- Embodiment 71. The method of Embodiment 60-63 wherein the Formula I-III compound(s) are selected from Embodiment 28.
- Embodiment 72. The method of Embodiment 60-63 wherein the Formula I-III compound(s) are selected from Embodiment 29.
- Embodiment 73. The composition of Embodiment 60 where the currently used agent is a mast cell stabilizing agent
- Embodiment 74. The composition of Embodiment 60 where the currently used agent is a platelet activating factor receptor antagonist,
- Embodiment 75. The composition of Embodiment 73 where the mast cell stabilizing agent is cromoglicate, nedocromil, azelastine, bepotastine, epinastine, ketotifen, olopatadine and rupatadine.
- Embodiment 76. The composition of Embodiment 74 where the platelet activating factor receptor antagonist is rupatadine, SM-12502, CV-3988 and WEB 2170.
- Embodiment 1A. A compound wherein the compound has the structure of Formula I
- or a pharmaceutically acceptable salt or prodrug thereof,
-
- wherein RA is —CO2H, —CONHCN, tetrazolyl, or C(═O)NHSO2RB;
- wherein RB is substituted or unsubstituted C1-C4 alkyl;
- L1 is substituted or unsubstituted C1-C6 alkylene, substituted or unsubstituted C1-C6 fluoroalkylene, substituted or unsubstituted C3-C8 cycloalkylene, substituted or unsubstituted C1-C6 heteroalkylene;
- wherein A1 is —N═ or —CH;
- wherein Ring A has the structure of one of
-
- wherein RC is —CN, —F, —Cl, —Br, —I, —OC1-C4 alkyl, C3-C6 cycloalkyl, or C1-C4 fluoroalkyl;
- and RD is —N(RF)—C(═O)XCH(RG)—CY, wherein X is O and CY is phenyl substituted with one RH:
-
- RE, RF and RG independently are —H or C1-C4 alkyl or C3-C6 cycloalkyl or RE and RF independently are —H or C1-C4 alkyl or C1-C6 cycloalkyl and one RG is —C1-C4 alkyl and is taken together with the RH pheny moiety of the Ring A RD substituent and the carbon atom to which RG and said phenyl moiety is attached to define a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle;
- RH is independently —H, halogen, —CN, —NO2, —OH, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 fluoroalkoxy, or C1-C4 alkoxy,
- In some embodiments RC is —CN, —F, —Cl, —Br, —I, —OC1-C4 alkyl, C1-C4 alkyl, C3-C6 cycloalkyl, or C1-C4 fluoroalkyl and RD is —N(RF)—C(═O)OCH(RG)—CY,
- wherein RF and each RG independently are —H or C1-C4 alkyl.
- In preferred embodiments RA is —CO2H, —CONHCN, tetrazolyl, or —C(═O)NHSO2RB, wherein RB is substituted or unsubstituted C1-C4 alkyl.
- In particularly preferred embodiments RA is —CO2H, —CONHCN, tetrazolyl, or —C(═O)NHSO2RB, wherein RB is —CH3.
- In some embodiments L1 is substituted or unsubstituted C1-C6 alkylene, C1-C6 fluoroalkylene, or substituted or unsubstituted C1-C6 heteroalkylene.
- In particularly preferred embodiments L1 is
- In some embodiments, Formula I compounds have RC defined as —CN, —F, —Cl, or C1-C4 fluoroalkyl.
- In more preferred embodiments, Formula I compounds have RC defined as —F, or —Cl.
- In some embodiments, Formula I compounds have RD defined as —N(RF)C(═O)—OCH(RG)—CY, wherein RF is —H or C1-C4 alkyl and X, CY and RG are as previously defined.
- In more preferred embodiments, Formula I compounds have RD defined as —N(RF)C(═O)OCH(RG)—CY, wherein RF is —H and CY and RG are as previously defined.
- In some embodiments, Formula I compounds have RF defined as H, C1-C4 alkyl or C3-C6 cycloalkyl.
- In more preferred embodiments, Formula I compounds have RF defined as —H.
- In some embodiments of Formula I compounds RG is independently —H or C1-C4 alkyl.
- In more preferred embodiments, Formula I compounds have RG defined as —CH3.
- In some embodiments of Formula I compounds CY is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein if CY is substituted then CY is substituted with 1, 2, or 3 independently selected RH.
- In preferred Formula I compounds have RA is —CO2H, RC is —F or —Cl, RD is —NRFC(═O)OCH(RG)—CY, and RF, RG, and CY are as previously defined.
- In other preferred Formula I compounds have RA is tetrazolyl, RC is —F or —Cl, RD is —NRFC(═O)OCH(RG)—CY, and RF, RG, and CY are as previously defined.
- In other preferred Formula I compounds have RA is —C(═O)NHSO2RB, RC is —F or —Cl, RD is —NRFC(═O)OCH(RG)—CY, and RB, RF, RG, and CY are as previously defined.
- In other preferred Formula I compounds RA is —CONHCN, RC is —F or —Cl, RD is —NRFC(═O)OCH(RG)—CY, and RF, RG, and CY are as previously defined.
- Embodiment 2A. The compound of Embodiment 1A, wherein:
-
- RA is —CO2H, tetrazolyl
- —C(═O)NH2, or —C(═O)NHSO2RB;
-
- L1 is —CH2—,
- or disubstituted dimethylmethane;
-
- in the ring
- RH is —H, a halogen, or —CH3;
-
- in the ring
- A1 is CH or N and RH is —H;
-
- Ring A has the structure of
-
- RC is —F, —Cl, —CN, or —CF3;
- RF is —H;
- RG is —CH3 in an R configuration; and
- in the CY ring
- RH is —H or a halogen.
- Embodiment 3A. The compound of Embodiment 2A, wherein:
-
- RA is CO2H;
- L1 is
-
- in the ring
-
-
- in the ring
- A1 is N and RH is —H;
-
- RC is —F; and
- in the CY ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 1, (R)-1-(4-(5-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-fluoro-1H-pyrazol-1-yl)pyridin-2-yl)phenyl)cyclopropane-1-carboxylic acid.
- Embodiment 4A. The compound of Embodiment 2A, wherein:
-
- RA is CO2H;
- L1 is
-
- in the ring
-
-
- in the ring
- A1 is N and RH is —H;
-
- RC is —Cl; and
- in the CY ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 2, (R)-1-(4-(5-(4-chloro-5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-1H-pyrazol-1-yl)pyridin-2-yl)phenyl)cyclopropane-1-carboxylic acid.
- Embodiment 5A. The compound of Embodiment 2A, wherein
-
- in the ring
- A1 is CH and RH is —H.
- Embodiment 6A. The compound of Embodiment 5A, wherein:
-
- RA is CO2H; and
- L1 is
- Embodiment 7A. The compound of Embodiment 6A, wherein:
-
- in the ring
- Embodiment 8A. The compound of Embodiment 7A, wherein
-
- RC is —F; and
- in the CY ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 3, (R)-1-(4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid.
- Embodiment 9A. The compound of Embodiment 7A, wherein:
-
- RC is —Cl; and
- in the ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 4, (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid.
- Embodiment 10A. The compound of Embodiment 7A, wherein:
-
- RC is —CN; and
- in the ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 5, (R)-1-(4′-(4-cyano-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid.
- Embodiment 11A. The compound of Embodiment 7A, wherein:
-
- RC is —CN; and
- in the ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 6, (R)-1-(4′-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-cyano-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid.
- Embodiment 12A. The compound of Embodiment 6A, wherein:
-
- in the ring
- Embodiment 13A. The compound of Embodiment 12A, wherein:
-
- RC is —F; and
- in the CY ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. Exemplary molecules with this structure are Compound 7, (R)-1-(3-fluoro-4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, and Compound 8, (R)-1-(2-fluoro-4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid.
- Embodiment 14A. The compound of Embodiment 12A, wherein:
-
- RC is —Cl; and
- in the CY ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. Exemplary molecules with this structure are Compound 9, (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-3-fluoro-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, and Compound 10, R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-2-fluoro-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid.
- Embodiment 15A. The compound of Embodiment 6A, wherein:
-
- in the ring
- Embodiment 16A. The compound of Embodiment 15A, wherein:
-
- RC is —F; and
- in the CY ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 11, (R)-1-(2-chloro-4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid.
- Embodiment 17A. The compound of Embodiment 15A, wherein:
-
- RC is —Cl; and
- in the CY ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 12, (R)-1-(2-chloro-4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid.
- Embodiment 18A. The compound of Embodiment 6A, wherein:
-
- in the ring
- RH is —CH3.
- Embodiment 19A. The compound of Embodiment 18A, wherein:
-
- RC is —F; and,
- in the CY ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 13, (R)-1-(4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-2-methyl-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid.
- Embodiment 20A. The compound of Embodiment 18A, wherein:
-
- RC is —Cl; and
- in the CY ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 14, (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-2-methyl-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid.
- Embodiment 21A. The compound of Embodiment 5A, wherein:
-
- RA is —C(═O)NH2;
- L1 is
-
- in the ring
-
-
- RC is —F; and
- in the CY ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 15, (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-carbamoylcyclopropyl)-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate.
- Embodiment 22A. The compound of Embodiment 5A, wherein:
-
- RA is —C(═O)NHSO2RB, where RB is —CH3; and
- L1 is
- Embodiment 23A. The compound of Embodiment 22A, wherein:
-
- in the ring
- Embodiment 24A. The compound of Embodiment 23A, wherein:
-
- RC is —F; and
- in the CY ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 16, (R)-1-(2-chlorophenyl)ethyl (4-fluoro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate.
- Embodiment 25A. The compound of Embodiment 23A, wherein:
-
- RC is —F; and
- in the CY ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 17, (R)-1-phenylethyl (4-fluoro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate.
- Embodiment 26A. The compound of Embodiment 23A, wherein:
-
- RC is —Cl; and
- in the CY ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 18, (R)-1-(2-chlorophenyl)ethyl (4-chloro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate.
- Embodiment 27A. The compound of Embodiment 22A, wherein:
-
- in the ring
- Embodiment 28A. The compound of Embodiment 27A, wherein:
-
- RC is —Cl; and
- in the CY ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 27, (R)-1-phenylethyl (4-chloro-1-(4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate.
- Embodiment 29A. The compound of Embodiment 27A, wherein:
-
- RC is —F; and
- in the CY ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 20, (R)-1-(2-chlorophenyl)ethyl (4-fluoro-1-(4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate.
- Embodiment 30A. The compound of Embodiment 5A, wherein:
-
- RA is tetrazolyl
-
- L1 is
- and
-
- in the ring
- Embodiment 31A. The compound of Embodiment 30A, wherein:
-
- RC is —F; and
- in the CY ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 21, (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate.
- Embodiment 32A. The compound of Embodiment 30A, wherein:
-
- RC is —Cl; and
- in the CY ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 22, (R)-1-phenylethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-chloro-1H-pyrazol-5-yl)carbamate.
- Embodiment 33A. The compound of Embodiment 30A, wherein:
-
- RC is —Cl; and
- in the CY ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 23, (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-chloro-1H-pyrazol-5-yl)carbamate.
- Embodiment 34A. The compound of Embodiment 5A, wherein:
-
- RA is CONHCN
- L1 is
- and
-
- in the ring
- Embodiment 35A. The compound of Embodiment 34A, wherein:
-
- RC is —Cl; and
- in the CY ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 24(R)-1-phenylethyl (4-chloro-1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate.
- Embodiment 36A. The compound of Embodiment 33A, wherein:
-
- RC is —Cl; and
- in the CY ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 25, (R)-1-(2-chlorophenyl)ethyl (4-chloro-1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate.
- Embodiment 37A. The compound of Embodiment 5A, wherein:
-
- RA is CONHCN
- L1 is
- and
-
- in the ring
- Embodiment 38A. The compound of Embodiment 37A, wherein:
-
- RC is —F; and
- in the CY ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 26, (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-2′-fluoro-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate.
- Embodiment 39A. The compound of Embodiment 2A, wherein:
-
- RA is CO2H;
- L1 is dimethylmethane
-
- in the ring
-
-
- in the ring
- A1 is CH and RH is —H;
-
- and RC is —CN.
- Embodiment 40A. The compound of Embodiment 39A, wherein:
-
- in the CY ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 27, (R)-2-(4′-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-cyano-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)-2-methylpropanoic acid.
- Embodiment 41A. The compound of Embodiment 39A, wherein:
-
- in the CY ring
- In this embodiment, it is understood that RH can be located at any available carbon atom in the ring
- the ring
- and the CY ring
- individually. An exemplary molecule with this structure is Compound 28, (R)-2-(4′-(4-cyano-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)-2-methylpropanoic acid.
- Embodiment 42A. The compound of Embodiment 1A, wherein RG is in an R or S configuration.
- Embodiment 43A. The compound of Embodiment 2A wherein the compound is selected from Table 1.
- Embodiment 44A. The compound of Embodiment 43A wherein the compound is (R)-1-(4-(5-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-fluoro-1H-pyrazol-1-yl)pyridin-2-yl)phenyl)cyclopropane-1-carboxylic acid, (R)-1-(4-(5-(4-chloro-5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-1H-pyrazol-1-yl)pyridin-2-yl)phenyl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-cyano-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-cyano-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(3-fluoro-4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(2-fluoro-4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-3-fluoro-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-2-fluoro-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(2-chloro-4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(2-chloro-4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-2-methyl-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-2-methyl-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid, (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-carbamoylcyclopropyl)-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-fluoro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (4-fluoro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-chloro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (4-chloro-1-(4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-fluoro-1-(4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-chloro-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-chloro-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (4-chloro-1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-chloro-1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-2′-fluoro-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate, (R)-2-(4′-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-cyano-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)-2-methylpropanoic acid, (R)-2-(4′-(4-cyano-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)-2-methylpropanoic acid.
- Embodiment 45A. A compound of any one of Embodiments 1A-44A for preparation of mendicant for treating a LPA-dependent disease or condition.
- The compounds of Table 1 are exemplary of the invention but not limiting, wherein additional compounds are prepared according to the appropriately modified procedures of the examples for preparation of compounds 1-28.
-
TABLE 1 Compound Name 1 (R)-1-(4-(5-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-fluoro-1H- pyrazol-1-yl)pyridin-2-yl)phenyl)cyclopropane-1-carboxylic acid 2 (R)-1-(4-(5-(4-chloro-5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-1H- pyrazol-1-yl)pyridin-2-yl)phenyl)cyclopropane-1-carboxylic acid 3 (R)-1-(4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)- [1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid 4 (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)- [1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid 5 (R)-1-(4′-(4-cyano-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)- [1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid 6 (R)-1-(4′-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-cyano-1H- pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid 7 (R)-1-(3-fluoro-4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H- pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid 8 (R)-1-(2-fluoro-4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H- pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid 9 (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-3- fluoro-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid 10 (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-2- fluoro-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid 11 (R)-1-(2-chloro-4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H- pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid 12 (R)-1-(2-chloro-4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H- pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid 13 (R)-1-(4′-(4-fluoro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-2- methyl-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid 14 (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-2- methyl-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid 15 (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-carbamoylcyclopropyl)-[1,1′-biphenyl]- 4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate 16 (R)-1-(2-chlorophenyl)ethyl (4-fluoro-1-(2′-fluoro-4′-(1- ((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5- yl)carbamate 17 (R)-1-phenylethyl (4-fluoro-1-(2′-fluoro-4′-(1- ((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5- yl)carbamate 18 (R)-1-(2-chlorophenyl)ethyl (4-chloro-1-(2′-fluoro-4′-(1- ((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5- yl)carbamate 19 (R)-1-phenylethyl (4-chloro-1-(4′-(1- ((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5- yl)carbamate 20 (R)-1-(2-chlorophenyl)ethyl (4-fluoro-1-(4′-(1- ((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5- yl)carbamate 21 (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′- biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate 22 (R)-1-phenylethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4- yl)-4-chloro-1H-pyrazol-5-yl)carbamate 23 (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′- biphenyl]-4-yl)-4-chloro-1H-pyrazol-5-yl)carbamate 24 (R)-1-phenylethyl (4-chloro-1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-[1,1′- biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate 25 (R)-1-(2-chlorophenyl)ethyl (4-chloro-1-(4′-(1- (cyanocarbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5- yl)carbamate 26 (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-2′- fluoro-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate 27 (R)-2-(4′-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-cyano-1H- pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)-2-methylpropanoic acid 28 (R)-2-(4′-(4-cyano-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)- [1,1′-biphenyl]-4-yl)-2-methylpropanoic acid - HPLC Methods
- HPLC traces for examples synthesized were recorded using a HPLC consisting of Agilent HPLC pumps, degasser and UV detector, equipped with an Agilent 1100 series auto-sampler. A MS detector (APCI) PE Sciex API 150 EX was incorporated for purposes of recording mass spectral data. HPLC/mass traces were obtained using one of three chromatographic methods:
- Method 1: Column Zorbax C18, size 4.6 mm×7.5 cm; Solvent A: 0.05% TFA in water, Solvent B: 0.05% TFA in acetonitrile; Flow rate—0.7 mL/min; Gradient: 5% B to 100% B in 9 min, hold at 100% B for 4 min and 100% B to 5% B in 0.5 min; UV detector—channel 1=220 nm, channel 2=254 nm.
- Method 2: Column Zorbax C18, size 4.6 mm×7.5 cm; Solvent A: 0.05% TFA in water, Solvent B: 0.05% TFA in acetonitrile; Flow rate—0.7 mL/min; Gradient: 5% B to 100% B in 5 min, hold at 100% B for 2 min and 100% B to 5% B in 0.5 min; UV detector—channel 1=220 nm, channel 2=254 nm.
- Method 3: SunFire™ (Waters) C18, size 2.1 mm×50 mm; Solvent A: 0.05% TFA in water, Solvent B: 0.05% TFA in acetonitrile; Flow rate—0.8 mL/min; Gradient: 10% B to 90% B in 2.4 min, hold at 90% B for 1.25 min and 90% B to 10% B in 0.25 min, hold at 10% B for 1.5 min.; UV detector—channel 1=220 nm, channel 2=254 nm.
- Method 4: Column Zorbax C18, size 4.6 mm×50 mm, 5p particle size; Solvent A: acetonitrile; Solvent B: 0.1% HCOOH in water; Flow Rate—1.5 mL/min; Gradient 10-95% A in 2.5 minutes.
- A mixture of ethyl pyruvate (3.89 mL, 35.0 mmol), dimethylformamide dimethylacetal (9.30 mL, 70.0 mmol) and para-toluene sulfonic acid (10 mg) was stirred at room temperature overnight and then heated to 80° C. for 2 hours. The mixture was cooled to room temperature and concentrated in vacuo to dryness. The crude ethyl 4-(dimethylamino)-2-oxo-3-butenoate was dissolved in ethanol (90 mL) and treated with (6-chloro-3-pyridyl)hydrazine hydrochloride (7.5 g, 35.0 mmol) and concentrated hydrochloric acid (250 μL). The resulting mixture was heated to 88° C. overnight, then cooled to room temperature and concentrated in vacuo. The crude residue was purified by silica-gel column chromatography, eluting with a hexanes/ethyl acetate gradient. Two regioisomers were separated—the desired isomer A [ethyl 2-(6-chloro-3-pyridyl)-2H-pyrazole-3-carboxylate] eluted off the column first and the undesired regioisomer B [ethyl 1-(6-chloro-3-pyridyl)-1H-pyrazole-3-carboxylate] was isolated as the more polar compound. The desired product was obtained as a yellow oil, which solidified upon standing.
- Isomer A, Yield=216 mg (2%). Method 3, Rt 2.68 min. MS (ESI) m/z 251.9 [M+H+]. 1H NMR (CDCl3) δ 8.50 (d, J=2.0 Hz, 1H); 7.78 (dd, J1=6.8 Hz, J2=2.0 Hz, 1H); 7.75 (d, J=1.6 Hz, 1H); 7.43 (d, J=6.8 Hz, 1H); 7.08 (d, J=1.6 Hz, 1H); 4.28 (q, J=5.6 Hz, 2H); 1.31, (t, J=5.6 Hz, 3H).
- Isomer B, Yield=150 mg (1.7%). Method 3, Rt 2.70 min. MS (ESI) m/z 251.9 [M+H+]. 1H NMR (CDCl3) δ 8.77 (d, J=2.4 Hz, 1H); 8.15 (dd, J1=7.2 Hz, J2=2.4 Hz, 1H); 7.96 (d, J=2.0 Hz, 1H); 7.46 (d, J=6.8 Hz, 1H); 7.04 (d, J=2.0 Hz, 1H); 4.45 (q, J=5.6 Hz, 2H); 1.43, (t, J=5.6 Hz, 3H).
- A solution of ethyl 2-(6-chloro-3-pyridyl)-2H-pyrazole-3-carboxylate [Example 1, Step 1] (205 mg, 0.814 mmol) in THF (4 mL) was treated with a 2 M aqueous LiOH solution (4 mL) and the resulting mixture was stirred vigorously at room temperature for 16 hours. LCMS showed completed conversion to product. The reaction mixture was transferred to a separatory funnel and treated with 0.1 N HCl aqueous solution to bring the pH to approximately 1. The product was extracted with ethyl acetate. The organic layer was dried over anhydrous MgSO4, filtered and evaporated to yield the product as a white solid. Yield=190 mg (quantitative). Method 3, Rt 1.71 min (broad). MS (ESI) m/z 224.5 [M+H+].
- 2-(6-Chloro-3-pyridyl)-2H-pyrazole-3-carboxylic acid [Example 1, Step 2] (190 mg, 0.82 mmol) was suspended in dichloromethane (4 mL) and treated with a catalytic amount of N,N-dimethylformamide (2 drops) at room temperature. The reaction mixture was cooled to 0° C. with an ice/water bath. Oxalyl chloride (143 μL, 1.64 mmol) was added dropwise and the resulting mixture was stirred at 0° C. for 15 minutes and at room temperature for 2 hours. An aliquot was dissolved in methanol and subjected to LCMS analysis, which indicated complete conversion to the corresponding acid chloride. The volatiles were removed under reduced pressure to yield the crude acid chloride as a white solid. This material was suspended in ethyl acetate (4 mL) and treated with a solution of NaN3 (107 mg, 1.64 mmol) in water (4 mL) under vigorous magnetic stirring at room temperature. After 1 hour, an aliquot was dissolved in methanol and subjected to LCMS analysis, which indicated complete conversion to the corresponding acyl azide. The organic layer was separated, dried over anhydrous MgSO4, filtered and evaporated under vacuum at room temperature to yield the crude acyl azide as a white solid. This material was suspended in toluene (4 mL) and heated to 95° C. with stirring for 30 minutes, when gas evolution was observed. (R)-1-(o-Chlorophenyl)-1-ethanol (157 mg, 1.0 mmol) was added and the resulting mixture was heated to 65° C. overnight. The reaction mixture was cooled to room temperature, concentrated in vacuo to dryness and the crude residue was directly purified by silica-gel chromatography, eluting with a hexanes/ethyl acetate gradient. The pure product was obtained as a colorless oil. Yield=308 mg (quantitative). Method 3, Rt 2.97 min. MS (ESI) m/z 377.2 [M+H+].
- Selectfluor® (236 mg, 0.67 mmol) was added to a stirring solution containing 3-[(R)-1-(o-chlorophenyl)ethoxycarbonylamino]-2-(6-chloro-3-pyridyl)-2H-pyrazole [Example 1, Step 3] (100 mg, 0.27 mmol) in acetonitrile (2.7 mL) and glacial acetic acid (270 μL) at room temperature. The resulting mixture was stirred overnight and then the volatiles were removed in vacuo. The residue was dissolved in ethyl acetate and washed with saturated NaHCO3 aqueous and brine. The organic layer was separated, dried over anhydrous MgSO4, filtered and evaporated. Purification by preparative thin layer chromatography (TLC) eluting with a 4:1 v/v mixture of hexanes/ethyl acetate furnished the pure product as a colorless film. Yield=42 mg (40%). Method 3, Rt 3.04 min. MS (ESI) m/z 395.3 [M+H+].
- A stirring mixture of 3-[(R)-1-(o-chlorophenyl)ethoxycarbonylamino]-2-(6-chloro-3-pyridyl)-4-fluoro-2H-pyrazole [Example 1, Step 4] (42 mg, 0.107 mmol), 2:1 v/v mixture of toluene and ethanol (1 mL), 2M Na2CO3 aqueous solution (360 μL) and 4-[(1-methoxycarbonyl)cyclopropyl]phenylboronic acid pinacol ester (48 mg, 0.161 mmol) was degassed under N2 for 10 minutes and treated with Pd[Ph3P]4 (6 mg, 0.005 mmol). The resulting mixture was heated to 85° C. and stirred for 16 hours at that temperature. The reaction mixture was cooled to room temperature and the product was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous MgSO4 and filtered. After concentration in vacuo, the crude product was directly dissolved in THF (1 mL) and treated with a 1 M LiOH aqueous solution (1 mL). The resulting mixture was stirred at room temperature for 16 hours. The reaction mixture was treated with 1 M HCl aqueous in order to bring pH to 1. The product was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous MgSO4 and filtered. After concentration in vacuo, the residue was purified by preparative thin layer chromatography on silica-gel, eluting with a 50:50 v/v hexanes/ethyl acetate mixture. Yield=19 mg (34%). Method 3, Rt 2.98 min. MS (ESI) m/z 521.5 [M+H+].
- A solution of 3-[(R)-1-(o-chlorophenyl)ethoxycarbonylamino]-2-(6-chloro-3-pyridyl)-2H-pyrazole [Example 1, Step 3] (158 mg, 0.42 mmol) in acetonitrile (2.1 mL) was treated with N-chlorosuccinimide (64 mg, 0.48 mmol) under stirring at room temperature. The resulting mixture was heated to 80° C. for 1 hour. The resulting mixture was cooled to room temperature and directly purified by preparative thin layer chromatography, eluting with a 4:1 v/v mixture of hexanes/ethyl acetate, respectively. The desired product was isolated with Rf=0.2 as a white solid. Yield=13 mg (8%). Method 3, Rt 3.09 min. MS (ESI) m/z 411.4 [M+H+].
- A stirring mixture of 3-[(R)-1-(o-Chlorophenyl)ethoxycarbonylamino]-4-chloro-2-(6-chloro-3-pyridyl)-2H-pyrazole [Example 2, Step 1] (13 mg, 0.032 mmol), 2:1 v/v mixture of toluene and ethanol (1 mL), 2M Na2CO3 aqueous solution (300 μL) and methyl 1-[p-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropanecarboxylate (15 mg, 0.048 mmol) was degassed under N2 for 10 minutes and treated with Pd[Ph3P]4 (4 mg, 0.0032 mmol). The resulting mixture was heated to 85° C. and stirred for 8 hours at that temperature. The reaction mixture was cooled to room temperature and the product was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous MgSO4 and filtered. After concentration in vacuo, the crude product was directly dissolved in THF (1 mL) and treated with a 1 M LiOH aqueous solution (1 mL). The resulting mixture was stirred at room temperature for 16 hours. The reaction mixture was treated with 1 M HCl aqueous in order to bring pH to 1. The product was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous MgSO4 and filtered. After concentration in vacuo, the residue was purified by preparative thin layer chromatography on silica-gel, eluting with a 50:50 v/v hexanes/ethyl acetate mixture. Yield=1.7 mg (10%). Method 3, Rt 3.07 min. MS (ESI) m/z 537.1 [M+H+].
- A mixture of ethyl acetoacetate (200.0 g, 1.54 mol) and dimethylformamide dimethyl acetal (219.7 g, 1.84 mol) was stirred at room temperature for 16 hours. Reaction was monitored by thin layer chromatography (30% ethyl acetate in hexanes). The reaction mixture was concentrated under reduced pressure to yield 290.0 g of crude product, which was taken to the next step without further purification. Method 4, Rt 1.584 min. MS (ESI) m/z 186.00-187.00 [M+H+].
- 1H NMR (DMSO-d6) δ 7.60 (s, 1H); 4.13 (q, 2H); 3.34-2.90 (br, 6H); 2.14 (s, 3H); 1.24 (t, 3H).
- To a solution of ethyl-2-acetyl-3-(dimethylamino)acrylate [Example 3, Step 1](290.0 g, 1.57 mol) in ethanol (4.35 L) was added 4-bromophenyl hydrazine hydrochloride (315.0 g, 1.41 mol) at room temperature. The resulting mixture was refluxed for 3 hours. Reaction progress was monitored by thin layer chromatography (40% ethyl acetate in hexanes). The reaction mixture was concentrated to dryness under reduced pressure to yield the crude product, which was recrystallized with 10% of diethyl ether in hexane to yield 174.0 g of the title compound as a pale yellow solid. The mother liquor was concentrated to dryness and recrystallized with 10% of diethyl ether in hexane to yield another 116.0 g of product. Total yield=290.0 g (60%). Method 4, Rt 2.954 min. MS (ESI) m/z 309.00-310.00 [M+H+].
- 1H NMR (DMSO-d6) δ 8.03 (s, 1H); 7.78 (d, 2H); 7.53 (d, 2H); 4.26 (m, 2H); 3.34 (s, 3H); 1.30 (m, 3H).
- To a solution of ethyl 1-(p-bromophenyl)-5-methyl-1H-pyrazole-4-carboxylate [Example 3, Step 2] (200.0 g, 0.65 mol) in ethanol (1.4 L) and was added an aqueous solution of KOH (72.45 g, 1.29 mol) dissolved in water (1 L) at room temperature. The resulting mixture was refluxed for 3 hours. Reaction was monitored by thin layer chromatography (10% methanol in chloroform). The reaction mixture was concentrated under reduced pressure to yield the corresponding potassium salt, which was dissolved in water and washed with diethyl ether. The aqueous layer was neutralized with aqueous 6N HCl solution and extracted with ethyl acetate. The organic layer was washed with water, brine then dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to yield 172.0 g of product as an off white solid (Yield=95%). Method 4, Rt 2.341 min. MS (ESI) m/z 280.8-280.9 [M+H+].
- 1H NMR (DMSO-d6) δ 12.48 (s, 1H); 7.99 (s, 1H); 7.77 (d, 2H); 7.53 (d, 2H); 3.36 (s, 3H).
- 1-(p-Bromophenyl)-5-methyl-1H-pyrazole-4-carboxylic acid [Example 3, Step 3](300.0 g, 1.07 mol) was placed in a 3 liter round bottom flask and was stirred at 260° C. (bath temp 280 to 300° C.) for 10 h. Reaction was monitored by thin layer chromatography (10% methanol in chloroform). The reaction mixture was diluted with diethyl ether and washed with 10% of sodium carbonate, water, and brine then dried over sodium sulfate and filtered. The organic layer was concentrated under reduced pressure to yield 200.0 g of product, as a pale brown liquid (Yield-79%). Method 4, Rt 2.739 min. MS (ESI) m/z 237.0-239.9 [M+H+].
- A solution of 1-(p-bromophenyl)-5-methyl-1H-pyrazole [Example 3, Step 4](200.0 g, 0.84 mol) in tert-butanol (2 L) was treated with an aqueous solution of KOH (141.7 g, 2.53 mol) dissolved in water (1 L) at RT followed by KMnO4 (266.6 g, 1.69 mol). The resulting mixture was refluxed for 3 hours then the same amount of KMnO4 was added twice within a 1-hour interval, continuing heating for 10 hours. Reaction was monitored by thin layer chromatography (10% methanol in chloroform). The reaction mixture was filtered through a pad of Celite and washed with hot water. The aqueous solution washed with diethyl ether, then neutralized with 6N HCl solution and extracted with ethyl acetate. The organic layer was washed with water, brine then dried over sodium sulfate, filtered and concentrated under reduced pressure to yield 120.0 g of product, as a pale yellow solid (Yield=53%). Method 4, Rt 2.210 min. MS (ESI) m/z 269.00 [M+H+].
- 1H NMR (DMSO-d6) δ 13.40 (s, 1H); 7.79 (s, 1H); 7.66 (d, 2H); 7.43 (d, 2H); 7.03 (s, 1H).
- A suspension of 2-(p-bromophenyl)-2H-pyrazole-3-carboxylic acid [Example 3, Step 5] (1.69 g, 6.36 mmol) in toluene (64 mL) was treated with triethylamine (1.07 mL, 7.63 mmol), (R)-1-phenyl-1-ethanol (1.16 g, 9.54 mmol) and diphenylphosphoryl azide (1.94 g, 7.04 mmol) sequentially. The resulting solution was heated to 90° C. for 6 hours with reaction monitoring by LCMS. The reaction was cooled to room temperature and the volatiles removed in vacuo. The crude residue was purified by silica gel chromatography, eluting with hexanes/ethyl acetate gradient. The product was obtained as a yellow oil, which solidified upon standing. Yield=839 mg (34%). Method 3, Rt 3.05 min. MS (ESI) m/z 388.0 [M+H+].
- A stirred solution of 3-[(R)-1-phenylethoxycarbonylamino]-2-(p-bromophenyl)-2H-pyrazole [Example 3, Step 6] (385 mg, 1.0 mmol) in acetonitrile (3.3 mL) and acetic acid (1.3 mL) was treated with Selectfluor® (354 mg, 1.0 mmol) and the resulting mixture was stirred at room temperature overnight. LCMS indicates 90% conversion to product. Another portion of Selectfluor® (70 mg) was added and the reaction was allowed to stir at room temperature for another 10 hours. LCMS shows reaction complete. The reaction mixture was concentrated in vacuo and the crude residue was partitioned between ethyl acetate and water. The organic layer was washed with water, saturated NaHCO3 aqueous and brine. Organics were dried over anhydrous MgSO4, filtered and evaporated. The thick amber film was purified by silica-gel chromatography, eluting with a hexanes/ethyl acetate gradient. Yield=278 mg (69%). Method 3, Rt 3.36 min. MS (ESI) m/z 404-.1-406.0 [M+H+].
- A stirring mixture of 3-[(R)-1-phenylethoxycarbonylamino]-2-(p-bromophenyl)-4-fluoro-2H-pyrazole [Example 3, Step 7] (55 mg, 0.136 mmol), 2:1 v/v mixture of toluene and ethanol (1.4 mL), 2M Na2CO3 aqueous solution (450 μL) and 4-[(1-methoxycarbonyl)cyclopropyl]phenylboronic acid pinacol ester (54 mg, 0.180 mmol) was degassed under N2 for 10 minutes and treated with Pd[Ph3P]4 (8 mg, 0.0068 mmol). The resulting mixture was heated to 85° C. and stirred for 16 hours at that temperature. The reaction mixture was cooled to room temperature and the product was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous MgSO4 and filtered. After concentration in vacuo, the crude product was directly dissolved in THF (1 mL) and treated with a 1 M LiOH aqueous solution (1 mL). The resulting mixture was stirred at room temperature for 16 hours. The reaction mixture was treated with 1 M HCl aqueous in order to bring pH to 1. The product was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous MgSO4 and filtered. After concentration in vacuo, the residue was purified by preparative thin layer chromatography on silica-gel, eluting with a 95:5 v/v dichloromethane/methanol mixture. Yield=28 mg (43%). Method 3, Rt 3.25 min. MS (ESI) m/z 486.2 [M+H+].
- N-Chlorosuccinimide (97 mg, 0.73 mmol) was added to a stirring solution containing 3-[(R)-1-phenylethoxycarbonylamino]-2-(p-bromophenyl)-2H-pyrazole [Example 3, Step 6] (281 mg, 0.73 mmol) in acetonitrile (3.7 mL) at room temperature. The resulting mixture was heated to 80° C. for 5 hours, after which time the reaction was deemed complete by LCMS. The reaction mixture was cooled to room temperature, concentrated in vacuo and purified directly via silica-gel column chromatography, eluting with a hexanes/ethyl acetate gradient. The product was obtained as a yellow oil, which solidified upon standing. Yield=277 mg (91%). Method 3, Rt 3.24 min. MS (ESI) m/z 422.1 [M+H+].
- A stirring mixture of 3-[(R)-1-phenylethoxycarbonylamino]-2-(p-bromophenyl)-4-chloro-2H-pyrazole [Example 4, Step 1] (43 mg, 0.103 mmol), 2:1 v/v mixture of toluene and ethanol (1 mL), 2M Na2CO3 aqueous solution (343 μL) and methyl 1-[p-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropanecarboxylate (40 mg, 0.134 mmol) was degassed under N2 for 10 minutes and treated with Pd[Ph3P]4 (6 mg, 0.052 mmol). The resulting mixture was heated to 85° C. and stirred overnight at that temperature. The reaction mixture was cooled to room temperature and the product was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous MgSO4 and filtered. After concentration in vacuo, the residue was purified by silica-gel chromatography, eluting with a hexanes/ethyl acetate gradient. Yield=45 mg (85%). Method 3, Rt 3.34 min. MS (ESI) m/z 516.1 [M+H+].
- Methyl 1-(4′-{5-[(R)-1-phenylethoxycarbonylamino]-4-chloro-1H-pyrazol-1-yl}-4-biphenylyl)cyclopropanecarboxylate [Example 4, Step 2] (45 mg, 0.087 mmol) was dissolved in THF (1 mL) and treated with a 1 M LiOH aqueous solution (1 mL). The resulting mixture was stirred at room temperature for 24 hours. The reaction mixture was treated with 1 M HCl aqueous in order to bring pH to 1. The product was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous MgSO4 and filtered. After concentration in vacuo, the residue was purified by preparative thin layer chromatography on silica-gel, eluting with a 95:5 v/v dichloromethane/methanol mixture. Yield=23 mg (53%). Method 3, Rt 3.11 min. MS (ESI) m/z 502.3 [M+H+].
- A stirring suspension containing 5-amino-1-(4-bromophenyl)-1H-pyrazole-4-carbonitrile (262 mg, 1.0 mmol) and triphosgene (436 mg, 1.5 mmol) in THF (4.8 mL) was treated with a solution of triethylamine (730 μL, 5.26 mmol) in toluene (40 mL) dropwise. The resulting mixture was heated to 90° C. for 30 minutes and then treated with (R)-1-phenylethanol (160 μL, 1.3 mmol). The reaction was heated to 105° C. for 3 hours, after which time monitoring by TLC (5% acetone in toluene) indicated one main product formed. The reaction was cooled to room temperature and concentrated in vacuo. The residue was directly purified by preparative thin layer chromatography, eluting with a 95:5 v/v mixture of toluene and acetone, respectively. The product was obtained as a solid. Yield=153 mg (37%). Method 3, Rt 3.53 min. MS (ESI) m/z 411.5-413.6 [M+H+].
- 1-(p-Bromophenyl)cyclopropanecarboxylic acid (1.22 g, 5.0 mmol) was dissolved in methanol (20 mL), cooled to −20° C. using ice water (2 parts) and salt (1 part). To this solution, thionyl chloride (1.45 mL, 20.0 mmol) was added dropwise. After completion of addition, the reaction was stirred for 15 minutes at −20° C. and then allowed to warm to room temperature over a period of 2 hours. LCMS indicated product formation. The reaction was concentrated in vacuo and the residue was partitioned between dichloromethane and an aqueous saturated Na2CO3 solution. The organic layer was dried over anhydrous MgSO4, filtered and evaporated to yield methyl 1-(p-bromophenyl)cyclopropanecarboxylate (1.08 g, 4.2 mmol, 84%). This material was dissolved in 1,4-dioxane (20 mL), treated with bis(pinacolato)diboron (3.19 g, 12.1 mmol), KOAc (1.24 g, 12.6 mmol) and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (328 mg, 0.54 mmol). The resulting mixture was heated to 100° C. overnight and then cooled to room temperature, filter through a pad of CELITE and rinsed with methanol. The filtrate was concentrated in vacuo. Part of the crude material was purified by preparative thin layer chromatography on silica gel, eluting with hexanes. The product is a white solid. Yield=270 mg. Method 3, Rt 3.08 min. MS (ESI) m/z 303.4 [M+H+].
- A stirring mixture of 3-[(R)-1-phenylethoxycarbonylamino]-2-(p-bromophenyl)-2H-pyrazole-4-carbonitrile [Example 5, Step 1] (58 mg, 0.14 mmol), 1,4-dioxane (2 mL), 2M Na2CO3 aqueous solution (315 μL) and methyl 1-[p-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropanecarboxylate [Example 5, Step 2] (51 mg, 0.17 mmol) was degassed under N2 for 10 minutes and treated with Pd[Ph3P]4 (23 mg, 0.02 mmol). The resulting mixture was heated to 95° C. overnight. The reaction mixture was cooled to room temperature, filtered through a pad of CELITE and rinsed with methanol. The filtrates were concentrated in vacuo and the crude residue was purified directly by preparative thin layer chromatography, eluting with 70:30 v/v mixture of hexanes and ethyl acetate, respectively. Yield=18 mg (26%). Method 3, Rt 3.13 min. MS (ESI) m/z 507.6 [M+H+].
- Methyl 1-(4′-{5-[(R)-1-phenylethoxycarbonylamino]-4-cyano-1H-pyrazol-1-yl}-4-biphenylyl)cyclopropanecarboxylate [Example 5, Step 3] (18 mg, 0.03 mmol) was dissolved in THF (1 mL) and treated with a 1 M LiOH aqueous solution (1 mL) and the resulting mixture was stirred at room temperature overnight. Reaction progress was monitored by thin layer chromatography (30% ethyl acetate in hexanes). The reaction was treated with 1 M aqueous HCl solution (3 mL) and the product was extracted with ethyl acetate. The organic layer was dried over anhydrous MgSO4, filtered and evaporated. The crude residue was purified by preparative thin layer chromatography, eluting with a 70:30 v/v mixture of toluene and acetone, respectively. The product was obtained as a white solid. Yield=10 mg (71%). Method 3, Rt 2.77 min. MS (ESI) m/z 493.6 [M+H+].
- A stirring suspension containing 5-amino-1-(4-bromophenyl)-1H-pyrazole-4-carbonitrile (262 mg, 1.0 mmol) and triphosgene (436 mg, 1.5 mmol) in THF (4.8 mL) was treated with a solution of triethylamine (730 μL, 5.26 mmol) in toluene (40 mL) dropwise. The resulting mixture was heated to 90° C. for 30 minutes and then treated with (R)-1-(2-chlorophenyl)ethanol (172 μL, 1.3 mmol). The reaction was heated to 105° C. for 3 hours, after which time monitoring by TLC (5% acetone in toluene) indicated one main product formed. The reaction was cooled to room temperature and concentrated in vacuo. The residue was directly purified by preparative thin layer chromatography, eluting with a 95:5 v/v mixture of toluene and acetone, respectively. The product was obtained as a solid. Yield=153 mg (37%). Method 3, Rt 2.94 min. MS (ESI) m/z 445.5-447.5 [M+H+].
- A stirring mixture of 3-[(R)-1-(o-chlorophenyl)ethoxycarbonylamino]-2-(p-bromophenyl)-2H-pyrazole-4-carbonitrile [Example 6, Step 1] (51 mg, 0.14 mmol), 1,4-dioxane (2 mL), 2M Na2CO3 aqueous solution (315 μL) and methyl 1-[p-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropanecarboxylate [Example 5, Step 2] (51 mg, 0.17 mmol) was degassed under N2 for 10 minutes and treated with Pd[Ph3P]4 (23 mg, 0.02 mmol). The resulting mixture was heated to 95° C. overnight. The reaction mixture was cooled to room temperature, filtered through a pad of CELITE and rinsed with methanol. The filtrates were concentrated in vacuo and the crude residue was purified directly by preparative thin layer chromatography, eluting with 70:30 v/v mixture of hexanes and ethyl acetate, respectively. Yield=25 mg (33%). Method 3, Rt 3.20 min. MS (ESI) m/z 541.3 [M+H+].
- Methyl 1-(4′-{5-[(R)-1-(o-chlorophenyl)ethoxycarbonylamino]-4-cyano-1H-pyrazol-1-yl}-4-biphenylyl)cyclopropanecarboxylate [Example 6, Step 2] (25 mg, 0.03 mmol) was dissolved in THF (1 mL) and treated with a 1 M LiOH aqueous solution (1 mL) and the resulting mixture was stirred at room temperature overnight. Reaction progress was monitored by thin layer chromatography (30% ethyl acetate in hexanes). The reaction was treated with 1 M aqueous HCl solution (3 mL) and the product was extracted with ethyl acetate. The organic layer was dried over anhydrous MgSO4, filtered and evaporated. The crude residue was purified by preparative thin layer chromatography, eluting with a 70:30 v/v mixture of toluene and acetone, respectively. The product was obtained as a white solid. Yield=12 mg (76%). Method 3, Rt 2.88 min. MS (ESI) m/z 527.5 [M+H+].
- A stirring mixture of 3-[(R)-1-phenylethoxycarbonylamino]-2-(p-bromophenyl)-4-fluoro-2H-pyrazole [Example 3, Step 7] (55 mg, 0.136 mmol), 2:1 v/v mixture of toluene and ethanol (1.4 mL), 2M Na2CO3 aqueous solution (450 μL) and 4-(1-carboxycyclopropyl)-3-fluorophenylboronic acid pinacol ester (55 mg, 0.180 mmol) was degassed under N2 for 10 minutes and treated with Pd[Ph3P]4 (8 mg, 0.0068 mmol). The resulting mixture was heated to 85° C. and stirred for 16 hours at that temperature. The reaction mixture was cooled to room temperature and treated with 1 M HCl aqueous in order to bring pH to 1. The product was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous MgSO4 and filtered. After concentration in vacuo, the crude product was purified by preparative thin layer chromatography on silica-gel, eluting with a 95:5 v/v dichloromethane/methanol mixture. Yield=7 mg (10%). Method 3, Rt 3.26 min. MS (ESI) m/z 504.2 [M+H+].
- A stirring mixture of 3-[(R)-1-phenylethoxycarbonylamino]-2-(p-bromophenyl)-4-fluoro-2H-pyrazole [Example 3, Step 7] (55 mg, 0.136 mmol), 2:1 v/v mixture of toluene and ethanol (1.4 mL), 2M Na2CO3 aqueous solution (450 μL) and 4-(1-carboxycyclopropyl)-2-fluorophenylboronic acid pinacol ester (55 mg, 0.180 mmol) was degassed under N2 for 10 minutes and treated with Pd[Ph3P]4 (8 mg, 0.0068 mmol). The resulting mixture was heated to 85° C. and stirred for 16 hours at that temperature. The reaction mixture was cooled to room temperature and treated with 1 M HCl aqueous in order to bring pH to 1. The product was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous MgSO4 and filtered. After concentration in vacuo, the crude product was purified by preparative thin layer chromatography on silica-gel, eluting with a 95:5 v/v dichloromethane/methanol mixture. Yield=19 mg (28%). Method 3, Rt 3.27 min. MS (ESI) m/z 504.2 [M+H+].
- A stirring mixture of 3-[(R)-1-phenylethoxycarbonylamino]-2-(p-bromophenyl)-4-chloro-2H-pyrazole [Example 4, Step 1] (43 mg, 0.103 mmol), 2:1 v/v mixture of toluene and ethanol (1 mL), 2M Na2CO3 aqueous solution (343 μL) and 1-[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropanecarboxylic acid (41 mg, 0.134 mmol) was degassed under N2 for 10 minutes and treated with Pd[Ph3P]4 (6 mg, 0.052 mmol). The resulting mixture was heated to 85° C. and stirred overnight at that temperature. The reaction mixture was cooled to room temperature, treated carefully with 1 M HCl aqueous to bring the solution pH ˜1. Ethyl acetate (1 mL) was added and the resulting mixture stirred vigorously for 5 minutes. The organic layer was separated and purified directly by preparative thin layer chromatography, eluting with 95:5 v/v mixture of dichloromethane and methanol, respectively. Yield=17 mg (32%). Method 3, Rt 3.33 min. MS (ESI) m/z 520.2 [M+H+].
- A stirring mixture of 3-[(R)-1-phenylethoxycarbonylamino]-2-(p-bromophenyl)-4-chloro-2H-pyrazole [Example 4, Step 1] (43 mg, 0.103 mmol), 2:1 v/v mixture of toluene and ethanol (1 mL), 2M Na2CO3 aqueous solution (343 μL) and 1-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropanecarboxylic acid (41 mg, 0.134 mmol) was degassed under N2 for 10 minutes and treated with Pd[Ph3P]4 (6 mg, 0.052 mmol). The resulting mixture was heated to 85° C. and stirred overnight at that temperature. The reaction mixture was cooled to room temperature, treated carefully with 1 M HCl aqueous to bring the solution pH ˜1. Ethyl acetate (1 mL) was added and the resulting mixture stirred vigorously for 5 minutes. The organic layer was separated and purified directly by preparative thin layer chromatography, eluting with 95:5 v/v mixture of dichloromethane and methanol, respectively. Yield=9 mg (17%). Method 3, Rt 3.14 min. MS (ESI) m/z 520.3 [M+H+].
- A stirring mixture of 3-[(R)-1-phenylethoxycarbonylamino]-2-(p-bromophenyl)-4-fluoro-2H-pyrazole [Example 3, Step 7] (55 mg, 0.136 mmol), 2:1 v/v mixture of toluene and ethanol (1.4 mL), 2M Na2CO3 aqueous solution (450 μL) and 1-[3-chloro-4-(dihydroxyboranyl)phenyl]cyclopropane-1-carboxylic acid (43 mg, 0.180 mmol) was degassed under N2 for 10 minutes and treated with Pd[Ph3P]4 (8 mg, 0.0068 mmol). The resulting mixture was heated to 85° C. and stirred for 16 hours at that temperature. The reaction mixture was cooled to room temperature and treated with 1 M HCl aqueous in order to bring pH to 1. The product was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous MgSO4 and filtered. After concentration in vacuo, the crude product was purified by preparative thin layer chromatography on silica-gel, eluting with a 95:5 v/v dichloromethane/methanol mixture. Yield=13 mg (19%). Method 3, Rt 3.31 min. MS (ESI) m/z 520.3 [M+H+].
- A stirring mixture of 3-[(R)-1-phenylethoxycarbonylamino]-2-(p-bromophenyl)-4-chloro-2H-pyrazole [Example 4, Step 1] (43 mg, 0.103 mmol), 2:1 v/v mixture of toluene and ethanol (1 mL), 2M Na2CO3 aqueous solution (343 μL) and 1-[3-chloro-4-(dihydroxyboranyl)phenyl]cyclopropane-1-carboxylic acid (32 mg, 0.134 mmol) was degassed under N2 for 10 minutes and treated with Pd[Ph3P]4 (6 mg, 0.052 mmol). The resulting mixture was heated to 85° C. and stirred overnight at that temperature. The reaction mixture was cooled to room temperature, treated carefully with 1 M HCl aqueous to bring the solution pH ˜1. Ethyl acetate (1 mL) was added and the resulting mixture stirred vigorously for 5 minutes. The organic layer was separated and purified directly by preparative thin layer chromatography, eluting with 95:5 v/v mixture of dichloromethane and methanol, respectively. Yield=21 mg (38%). Method 3, Rt 3.20 min. MS (ESI) m/z 536.1 [M+H+].
- A stirring mixture of 3-[(R)-1-phenylethoxycarbonylamino]-2-(p-bromophenyl)-4-fluoro-2H-pyrazole [Example 3, Step 7] (55 mg, 0.136 mmol), 2:1 v/v mixture of toluene and ethanol (1.4 mL), 2M Na2CO3 aqueous solution (450 μL) and 1-[4-(dihydroxyboranyl)-3-methylphenyl]cyclopropane-1-carboxylic acid (30 mg, 0.180 mmol) was degassed under N2 for 10 minutes and treated with Pd[Ph3P]4 (8 mg, 0.0068 mmol). The resulting mixture was heated to 85° C. and stirred for 16 hours at that temperature. The reaction mixture was cooled to room temperature and treated with 1 M HCl aqueous in order to bring pH to 1. The product was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous MgSO4 and filtered. After concentration in vacuo, the crude product was purified by preparative thin layer chromatography on silica-gel, eluting with a 95:5 v/v dichloromethane/methanol mixture. Yield=12 mg (18%). Method 3, Rt 3.13 min. MS (ESI) m/z 500.4 [M+H+].
- A stirring mixture of 3-[(R)-1-phenylethoxycarbonylamino]-2-(p-bromophenyl)-4-chloro-2H-pyrazole [Example 4, Step 1] (43 mg, 0.103 mmol), 2:1 v/v mixture of toluene and ethanol (1 mL), 2M Na2CO3 aqueous solution (343 μL) and 1-[4-(dihydroxyboranyl)-3-methylphenyl]cyclopropane-1-carboxylic acid (29 mg, 0.134 mmol) was degassed under N2 for 10 minutes and treated with Pd[Ph3P]4 (6 mg, 0.052 mmol). The resulting mixture was heated to 85° C. and stirred overnight at that temperature. The reaction mixture was cooled to room temperature, treated carefully with 1 M HCl aqueous to bring the solution pH ˜1. Ethyl acetate (1 mL) was added and the resulting mixture stirred vigorously for 5 minutes. The organic layer was separated and purified directly by preparative thin layer chromatography, eluting with 95:5 v/v mixture of dichloromethane and methanol, respectively. Yield=23 mg (43%). Method 3, Rt 3.18 min. MS (ESI) m/z 516.3 [M+H+].
- A stirring solution of 1-(p-bromophenyl)cyclopropanecarbonitrile (500 mg, 2.25 mmol) in ethanol (5 mL) was treated with a 1 M KOH aqueous solution (0.3 mL) and 30% H2O2 (3 mL). The resulting mixture was heated to 85° C. for 2 hours. The reaction was cooled to room temperature, quenched with water and the product was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous MgSO4, filtered and evaporated. The crude product was obtained as a white solid, which was used directly in the next step without any further purification. Yield=0.44 g (81%).
- 1-(p-Bromophenyl)cyclopropanecarboxamide [Example 15, Step 1] (430 mg, 1.8 mmol) was dissolved in 1,4-dioxane (5 mL) and treated with KOAc (210 mg, 2.1 mmol) and bis(pinacolato)diboron (545 mg, 2.1 mmol). The resulting mixture was degassed under N2 for 5 minutes, treated with [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane adduct (73 mg, 0.08 mmol) and heated to 95° C. for 4 hours. The reaction was cooled, filtered through a pad of CELITE and rinsed with ethyl acetate. The filtrates were washed with water and brine. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and evaporated. The crude was obtained as a dark oil (0.99 g). This material was used in the next step without further purification.
- Ethyl pyruvate (5 g, 43.1 mmol) was dissolved in CH2Cl2 (86 mL) and treated with dimethylformamide dimethylacetal (5.73 mL, 43.1 mmol). The reaction was stirred at room temperature for 2 hours and concentrated in vacuo. The crude was used as is in the next step. Yield=7.4 g.
- 4-Bromophenyl hydrazine hydrochloride (2.0 g, 8.95 mmol) was dissolved in MeOH (18 mL) and treated with crude ethyl (E)-4-(dimethylamino)-2-oxo-but-3-enoate [Example 15, Step 3] (1.54 g, 9.0 mmol). The resulting mixture was stirred at room temperature for 6 hours. The volatiles were removed in vacuo and the residue was purified by chromatography on silica-gel, eluting with a 95:5 mixture of hexanes/ethyl acetate v/v, increasing the polarity to 9:1 over time. Two isomeric products were isolated: ethyl 2-(4-bromophenyl)pyrazole-3-carboxylate as an orange solid (0.82 g, 2.78 mmol, 31%) and ethyl 1-(4-bromophenyl)pyrazole-3-carboxylate as a red solid (0.44 g, 1.49 mmol, 17%).
- Ethyl 2-(4-bromophenyl)pyrazole-3-carboxylate: HPLC (254 nm): Method 2 Rt 5.22 min. MS (ESI) m/z 297 [M+H+]; 294.8 [M+H+]; 252 [(M−EtO)+H+]; 250 [(M−EtO)+H+].
- 1H NMR (500 MHz, CDCl3) δ 7.69 (d, J=1.9 Hz, 1H); 7.58 (d, J=8.7 Hz, 2H); 7.32 (d, J=8.7 Hz, 2H); 7.03 (d, J=1.9 Hz, 1H); 4.26 (q, J=7.1 Hz, 2H); 1.28 (t, J=7.1 Hz, 3H).
- Ethyl 1-(4-bromophenyl)pyrazole-3-carboxylate: 1H NMR (500 MHz, CDCl3) δ 7.91 (d, J=2.4 Hz, 1H); 7.65 (d, J=7.2 Hz, 2H); 7.60 (d, J=7.2 Hz, 2H); 7.00 (d, J=2.4 Hz, 1H); 4.44 (q, J=7.0 Hz, 2H); 1.43 (t, J=7.0 Hz, 3H).
- Ethyl 2-(4-bromophenyl)pyrazole-3-carboxylate [Example 15, Step 4] (1.08 g, 3.68 mmol) was dissolved in acetonitrile (12 mL) and the resulting mixture was treated with glacial acetic acid (4.6 mL). To this solution, 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (Selectfluor®, 3.91 g, 11.04 mmol) was added in one portion and the resulting mixture was heated to 105° C. for 18 hours. The mixture was cooled to room temperature and the volatiles were removed in vacuo. The crude residue was loaded directly onto a silica-gel column and purified by elution with 95:5 mixture of hexanes/ethyl acetate v/v, increasing the polarity to 9:1 over time. The product was isolated as a white solid (410 mg, 1.31 mmol, 36%) and starting material was recovered (272 mg, 0.93 mmol, 25%). For 2-(4-Bromo-phenyl)-4-fluoro-2H-pyrazole-3-carboxylic acid ethyl ester: HPLC (254 nm): Method 3 Rt 2.97 min. MS (ESI) m/z 313.1 [M+H+].
- 1H NMR (500 MHz, CDCl3) δ 7.60 (s, 1H); 7.58 (d, J=9 Hz, 2H); 7.29 (d, J=9 Hz, 2H); 4.30 (q, J=7.1 Hz, 2H); 1.28 (t, J=7.1 Hz, 3H).
- A stirred solution of 2-(4-bromo-phenyl)-4-fluoro-2H-pyrazole-3-carboxylic acid ethyl ester [Example 15, Step 5] (410 mg, 1.31 mmol) in THF (13 mL) was treated with LiOH 1 N aqueous solution (13 mL) and the resulting mixture was stirred at room temperature overnight. The reaction was deemed complete by thin layer chromatography and HPLC/MS. The reaction mixture was partitioned between ethyl acetate and 1 N aqueous HCl solution (100 mL v/v) and transferred to a separatory funnel. The organic layer was separated and the aqueous layer was back-extracted with ethyl acetate (30 mL). The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated in vacuo to afford the pure product as a white solid (347 mg, 1.22 mmol, 93%). HPLC (254 nm): Method 3 Rt 2.82 min. MS (ESI) m/z 285.1 [M+H+].
- 2-(4-Bromo-phenyl)-4-fluoro-2H-pyrazole-3-carboxylic acid [Example 15, Step 6](347 mg, 1.22 mmol) was suspended in toluene (12 mL) and treated with triethylamine (205 μL, 1.46 mmol). The resulting solution was treated with diphenylphosphoryl azide (316 μL, 1.46 mmol) and heated to 65° C. (R)-1-(2-Chloro-phenyl)-ethanol (230 mg, 1.46 mmol) was added to the reaction mixture and the temperature was increased to 105° C. for 30 minutes, during which time vigorous gas evolution was observed. The reaction was brought to 65° C. and stirred at that temperature for 4 hours. The reaction was deemed complete by HPLC/MS. After cooling, the volatiles were removed in vacuo and the crude residue was purified by silica gel chromatography, eluting with a hexanes/ethyl acetate gradient. Product isolated as a white solid (452 mg, 1.03 mmol, 85%). HPLC (254 nm): Method 3 Rt 3.16 min. MS (ESI) m/z 440.1 [M+H+].
- (R)-[2-(4-bromo-phenyl)-4-fluoro-2H-pyrazol-3-yl]-carbamic acid 1-(2-chloro-phenyl)-ethyl ester [Example 15, Step 7] (200 mg, 0.45 mmol) and 1-[p-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropanecarboxamide [Example 15, Step 2] (196 mg, 0.68 mmol) were dissolved in acetonitrile (3 mL) and treated with a 2M Na2CO3 aqueous solution (1.5 mL). The resulting mixture was degassed under N2 for 10 minutes, treated with Pd[Ph3P]4 (8 mg, 0.006 mmol) and heated to 80° C. for 6 hours, after which time reaction was deemed completed by LCMS. After cooling to room temperature, the reaction mixture was filtered through a pad of CELITE and rinsed with ethyl acetate. The filtrates were washed with water and brine. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and evaporated. The product was purified by silica gel chromatography, eluting with a hexanes/ethyl acetate gradient. The pure product was obtained as a tan solid. Yield=28 mg (12%). Method 3, Rt 3.07 min. MS (ESI) m/z 518.4 [M+H+].
- A suspension of 2-(p-bromophenyl)-2H-pyrazole-3-carboxylic acid [Example 3, Step 5] (100 g, 376 mmol) in dichloromethane (1880 mL) and N,N-dimethylformamide (1 mL) was stirred mechanically and cooled to 0° C. under an atmosphere of N2. Oxalyl chloride (65.6 mL, 752 mmol) was added dropwise via addition funnel in approximately 30 minutes. The resulting suspension was warmed to room temperature and then heated to reflux. After 2 hours of reflux, LCMS showed complete conversion to the acid chloride. The reaction mixture was cooled to rt, and the volatiles were removed in vacuo to dryness. The acid chloride was obtained as a beige solid. This material was dissolved in ethyl acetate (940 mL) and treated with a solution of NaN3 (48.88 g, 752 mmol) dissolved in H2O (940 mL). After stirring for 1 hour at rt, LCMS shows complete conversion to the acyl azide. The organic layer was separated, dried over anhydrous MgSO4, filtered and evaporated at room temperature under vacuum. The acyl azide was obtained as a beige solid. This material was dissolved in toluene (1880 mL) with mechanical stirring. The reaction was heated to 100° C. for 1 hour and N2 evolution was observed. Conversion to the isocyanate intermediate was monitored by LCMS after MeOH quenching. (1R)-1-(o-Chlorophenyl)-1-ethanol (64.77 g, 413.6 mmol) was added dropwise and the resulting mixture was stirred overnight at 65° C. The reaction was cooled. concentrated in vacuo to dryness. The crude is a thick amber oil. This oil was dissolved in iPr2O (500 mL) and stirred for 1 hour at rt. The thick beige precipitate was filtered, rinsed with iPr2O and air-dried. Obtained 97 g (61%) of pure product. The mother liquor was concentrated to dryness and the resulting oily residue was re-dissolved in iPr2O (200 mL) and stirred at rt overnight. The solids were filtered, rinsed with iPr2O and air dried. Obtained 10 g (6%). Overall yield=107 g (67%). Method 3, Rt 3.18 min. MS (ESI) m/z 422.1 [M+H+].
- A stirred solution of 3-[(R)-1-(o-chlorophenyl)ethoxycarbonylamino]-2-(p-bromophenyl)-2H-pyrazole [Example 16, Step 1] (50 g, 119 mmol) in acetonitrile (1190 mL) and acetic acid (119 mL) was treated with Selectfluor® (105.4 g, 297.5 mmol) and the resulting mixture was heated to 50° C. After 1.5 hours, LCMS indicates clean conversion to product. The reaction mixture was cooled and concentrated in vacuo. The crude residue was partitioned between ethyl acetate and water. The organic layer was washed with water and brine. Organics dried over anhydrous MgSO4, filtered and evaporated. The thick amber oil was dissolved in iPr2O (300 mL) and stirred at room temperature. The precipitate was filtered under vacuum and air-dried to give 40 g (77%) of pure product. Method 3, Rt 3.38 min. MS (ESI) m/z 439.8 [M+H+].
- 1-(4-Bromo-3-fluorophenyl)cyclopropanecarboxylic acid (5.18 g, 20.0 mmol) was suspended in dichloromethane (100 mL) and treated with a catalytic amount of N,N-dimethylformamide (3 drops) at room temperature. The reaction mixture was cooled to 0° C. with an ice/water bath. Oxalyl chloride (3.49 mL, 40.0 mmol) was added dropwise and the resulting mixture was stirred at 0° C. for 15 minutes and at room temperature for 30 minutes and then heated to reflux for 1.5 hours. An aliquot was dissolved in methanol and subjected to LCMS analysis, which indicated complete conversion to the corresponding acid chloride. The volatiles were removed under reduced pressure to yield the crude acid chloride as a white solid which was used immediately. A portion of the acid chloride (833 mg, 3.0 mmol) was dissolved in toluene and treated with triethylamine (2.1 mL, 15.0 mmol) and methylsulfonamide (1.43 g, 15.0 mmol). The resulting mixture was heated to reflux for 2 hours. The reaction was cooled to room temperature and the solvent was removed in vacuo. The residue was dissolved in ethyl acetate, washed with 1 N HCl aqueous and brine. The organic layer was dried over anhydrous MgSO4, filtered and evaporated. The crude solid was triturated with diethyl ether and filtered. Product obtained as a beige solid. Yield=439 mg (44%). Method 3, Rt 2.60 min. MS (ESI) m/z 338.4 [M+H+].
- 1-(4-bromo-3-fluorophenyl)-N-(methylsulfonyl)cyclopropane-1-carboxamide [Example 16, Step 3] (437 mg, 1.30 mmol) was dissolved in 1,4-dioxane (13 mL) and treated with potassium acetate (287 mg, 2.93 mmol) and pinacol diborane (826 mg, 3.25 mmol). The resulting mixture was degassed under N2 for 10 minutes. [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (53 mg, 0.065 mmol) was added and the resulting mixture was heated to 95° C. for 16 hours. After cooling, the reaction mixture was filtered through a pad of CELITE, rinsed with ethyl acetate and concentrated. The crude residue was purified by silica-gel chromatography, eluting with a 1:1 v/v mixture of hexanes and ethyl acetate. The product was obtained as a white solid, after trituration from diethyl ether. Yield=273 mg (55%). Method 3, Rt 2.80 min. MS (ESI) m/z 384.5 [M+H+].
- A stirring mixture of 3-[(R)-1-(o-chlorophenyl)ethoxycarbonylamino]-2-(p-bromophenyl)-4-fluoro-2H-pyrazole [Example 16, Step 2] (44 mg, 0.10 mmol), 2:1 v/v mixture of toluene and ethanol (1 mL), 2M Na2CO3 aqueous solution (333 μL) and 1-(3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-N-(methylsulfonyl)cyclopropane-1-carboxamide [Example 16, Step 4] (57 mg, 0.15 mmol) was degassed under N2 for 10 minutes and treated with Pd[Ph3P]4 (6 mg, 0.005 mmol). The resulting mixture was heated to 85° C. and stirred for 6 hours at that temperature. The reaction mixture was cooled to room temperature, extracted with ethyl acetate (50 mL) and washed with 1N HCl aqueous and brine. The organic layer was dried over anhydrous MgSO4, filtered and evaporated. The crude product was purified by preparative thin layer chromatography, eluting with a 90:10 v/v mixture of acetone and dichloromethane, respectively. Yield=8 mg (13%). Method 3, Rt 3.24 min. MS (ESI) m/z 615.2 [M+H+].
- A stirring mixture of 3-[(R)-1-Phenylethoxycarbonylamino]-2-(p-bromophenyl)-4-fluoro-2H-pyrazole [Example 3, Step 7] (37 mg, 0.092 mmol), 2:1 v/v mixture of toluene and ethanol (1 mL), 2M Na2CO3 aqueous solution (333 μL) and 1-(3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-N-(methylsulfonyl)cyclopropane-1-carboxamide [Example 16, Step 4] (57 mg, 0.15 mmol) was degassed under N2 for 10 minutes and treated with Pd[Ph3P]4 (6 mg, 0.005 mmol). The resulting mixture was heated to 85° C. and stirred for 6 hours at that temperature. The reaction mixture was cooled to room temperature, extracted with ethyl acetate (50 mL) and washed with 1N HCl aqueous and brine. The organic layer was dried over anhydrous MgSO4, filtered and evaporated. The crude product was purified by preparative thin layer chromatography, eluting with a 90:10 v/v mixture of acetone and dichloromethane, respectively. Yield=6 mg (11%). Method 3, Rt 3.34 min. MS (ESI) m/z 581.4 [M+H+].
- N-Chlorosuccinimide (155 mg, 1.16 mmol) was added to a stirring solution containing 3-[(R)-1-(o-chlorophenyl)ethoxycarbonylamino]-2-(p-bromophenyl)-2H-pyrazole [Example 16, Step 1] (486 mg, 1.16 mmol) in acetonitrile (6 mL) at room temperature. The resulting mixture was heated to 80° C. for 4 hours, after which time the reaction was deemed complete by LCMS. The reaction mixture was cooled to room temperature, concentrated in vacuo and purified directly via silica-gel column chromatography, eluting with a hexanes/ethyl acetate gradient. The product was obtained as a yellow oil, which solidified upon standing. Yield=328 mg (62%). Method 3, Rt 3.27 min. MS (ESI) m/z 455.8 [M+H+].
- A stirring mixture of 3-[(R)-1-(o-chlorophenyl)ethoxycarbonylamino]-2-(p-bromophenyl)-4-chloro-2H-pyrazole [Example 18, Step 1] (45 mg, 0.10 mmol), 2:1 v/v mixture of toluene and ethanol (1 mL), 2M Na2CO3 aqueous solution (333 μL) and 1-(3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-N-(methylsulfonyl)cyclopropane-1-carboxamide [Example 16, Step 4] (57 mg, 0.15 mmol) was degassed under N2 for 10 minutes and treated with Pd[Ph3P]4 (6 mg, 0.005 mmol). The resulting mixture was heated to 85° C. and stirred for 6 hours at that temperature. The reaction mixture was cooled to room temperature, extracted with ethyl acetate (50 mL) and washed with 1N HCl aqueous and brine. The organic layer was dried over anhydrous MgSO4, filtered and evaporated. The crude product was purified by preparative thin layer chromatography, eluting with a 90:10 v/v mixture of acetone and dichloromethane, respectively. Yield=4.8 mg (8%). Method 3, Rt 3.11 min. MS (ESI) m/z 631.7 [M+H+].
- 1-(p-Bromophenyl)cyclopropanecarboxylic acid (2.41 g, 10.0 mmol) was suspended in dichloromethane (50 mL) and treated with a catalytic amount of N,N-dimethylformamide (3 drops) at room temperature. The reaction mixture was cooled to 0° C. with an ice/water bath. Oxalyl chloride (1.75 mL, 20.0 mmol) was added dropwise and the resulting mixture was stirred at 0° C. for 15 minutes and at room temperature for 30 minutes and then heated to reflux for 1.5 hours. An aliquot was dissolved in methanol and subjected to LCMS analysis, which indicated complete conversion to the corresponding acid chloride. The volatiles were removed under reduced pressure to yield the crude acid chloride as a white solid which was used immediately. The acid chloride (2.60 g, 10.0 mmol) was dissolved in toluene (25 mL) and treated with triethylamine (7.01 mL, 50.0 mmol) and methylsulfonamide (4.75 g, 50.0 mmol). The resulting mixture was heated to reflux for 2 hours. The reaction was cooled to room temperature and the solvent was removed in vacuo. The residue was dissolved in ethyl acetate, washed with 1 N HCl aqueous and brine. The organic layer was dried over anhydrous MgSO4, filtered and evaporated. The crude solid was triturated with diisopropyl ether and filtered. Product obtained as a tan solid. Yield=997 mg (31%). Method 3, Rt 2.74 min. MS (ESI) m/z 318.3-319.8 [M+H+].
- 1-(4-bromophenyl)-N-(methylsulfonyl)cyclopropane-1-carboxamide [Example 19, Step 1] (997 mg, 3.13 mmol) was dissolved in 1,4-dioxane (30 mL) and treated with potassium acetate (690 mg, 7.04 mmol) and pinacol diborane (1.99 g, 7.83 mmol). The resulting mixture was degassed under N2 for 10 minutes. [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (128 mg, 0.157 mmol) was added and the resulting mixture was heated to 95° C. for 16 hours. After cooling, the reaction mixture was filtered through a pad of CELITE, rinsed with ethyl acetate and concentrated. The crude residue was purified by silica-gel chromatography, eluting with a hexanes and ethyl acetate gradient. The product was obtained as a white solid, after trituration from diethyl ether. Yield=1.00 g (88%). Method 3, Rt 2.95 min. MS (ESI) m/z 366.0 [M+H+].
- A stirring mixture of 3-[(R)-1-phenylethoxycarbonylamino]-2-(p-bromophenyl)-4-chloro-2H-pyrazole [Example 4, Step 1] (210 mg, 0.5 mmol), 2:1 v/v mixture of toluene and ethanol (5 mL), 2M Na2CO3 aqueous solution (1.67 mL) and N-(methylsulfonyl)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropane-1-carboxamide [Example 19, Step 2] (219 mg, 0.6 mmol) was degassed under N2 for 10 minutes and treated with Pd[Ph3P]4 (29 mg, 0.025 mmol). The resulting mixture was heated to 85° C. and stirred for 16 hours at that temperature. The reaction mixture was cooled to room temperature, extracted with ethyl acetate (50 mL) and washed with 1N HCl aqueous and brine. The organic layer was dried over anhydrous MgSO4, filtered and evaporated. The crude product was purified by silica-gel chromatography, eluting with a hexanes and ethyl acetate gradient. Product obtained as a white solid. Yield=140 mg (48%). Method 3, Rt 3.36 min. MS (ESI) m/z 579.4 [M+H+].
- A stirring mixture of 3-[(R)-1-(o-chlorophenyl)ethoxycarbonylamino]-2-(p-bromophenyl)-4-fluoro-2H-pyrazole [Example 15, Step 5] (219 mg, 0.5 mmol), 2:1 v/v mixture of toluene and ethanol (5 mL), 2M Na2CO3 aqueous solution (1.67 mL) and N-(methylsulfonyl)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropane-1-carboxamide [Example 19, Step 2] (219 mg, 0.6 mmol) was degassed under N2 for 10 minutes and treated with Pd[Ph3P]4 (29 mg, 0.025 mmol). The resulting mixture was heated to 85° C. and stirred for 16 hours at that temperature. The reaction mixture was cooled to room temperature, extracted with ethyl acetate (50 mL) and washed with 1N HCl aqueous and brine. The organic layer was dried over anhydrous MgSO4, filtered and evaporated. The crude product was purified by silica-gel chromatography, eluting with a hexanes and ethyl acetate gradient. Product obtained as a white solid. Yield=110 mg (37%). Method 3, Rt 3.21 min. MS (ESI) m/z 597.4 [M+H+].
- A stirring mixture of 3-[(R)-1-(o-chlorophenyl)ethoxycarbonylamino]-2-(p-bromophenyl)-4-fluoro-2H-pyrazole [Example 15, Step 5] (438 mg, 1.0 mmol), 2:1 v/v mixture of toluene and ethanol (10 mL), 2M Na2CO3 aqueous solution (3.3 mL) and 4-(1-cyanocyclopropyl)phenylboronic acid (243 mg, 1.3 mmol) was degassed under N2 for 10 minutes and treated with Pd[Ph3P]4 (58 mg, 0.05 mmol). The resulting mixture was heated to 85° C. and stirred for 3 hours at that temperature. The reaction mixture was cooled to room temperature, extracted with ethyl acetate (50 mL) and washed with 1N HCl aqueous and brine. The organic layer was dried over anhydrous MgSO4, filtered and evaporated. The crude product was purified by silica-gel chromatography, eluting with a hexanes and ethyl acetate gradient. Yield=403 mg (81%). Method 3, Rt 3.20 min. MS (ESI) m/z 501.7 [M+H+].
- A stirred solution containing 3-[(R)-1-(o-chlorophenyl)ethoxycarbonylamino]-2-{6-[p-(1-cyanocyclopropyl)phenyl]-3-pyridyl}-4-fluoro-2H-pyrazole [Example 21, Step 1] (50 mg, 0.10 mmol) in toluene (10 mL) was treated with dibutyltin(IV) oxide (27 mg, 0.10 mmol) and trimethylsilyl azide (36 μL, 0.27 mmol). The resulting mixture was heated to 100° C. for 16 hours and then cooled to room temperature and concentrated in vacuo. The crude product was purified by preparative thin layer chromatography, eluting with a 95:5 v/v mixture of dichloromethane and methanol, respectively. Yield=17 mg (31%). Method 3, Rt 3.29 min. MS (ESI) m/z 544.5 [M+H+].
- A stirring mixture of 3-[(R)-1-phenylethoxycarbonylamino]-2-(p-bromophenyl)-4-chloro-2H-pyrazole [Example 4, Step 1] (210 mg, 0.5 mmol), 2:1 v/v mixture of toluene and ethanol (5 mL), 2M Na2CO3 aqueous solution (1.7 mL) and 4-(1-cyanocyclopropyl)phenylboronic acid (112 mg, 0.6 mmol) was degassed under N2 for 10 minutes and treated with Pd[Ph3P]4 (29 mg, 0.025 mmol). The resulting mixture was heated to 85° C. and stirred for 3 hours at that temperature. The reaction mixture was cooled to room temperature, extracted with ethyl acetate (50 mL) and washed with 1N HCl aqueous and brine. The organic layer was dried over anhydrous MgSO4, filtered and evaporated. The crude product was purified by silica-gel chromatography, eluting with a hexanes and ethyl acetate gradient. Product obtained as a white solid. Yield=173 mg (72%). Method 3, Rt 3.36 min. MS (ESI) m/z 483.5 [M+H+].
- A stirred solution containing 3-[(R)-1-phenylethoxycarbonylamino]-4-chloro-2-[4′-(1-cyanocyclopropyl)-4-biphenylyl]-2H-pyrazole [Example 22, Step 1] (101 mg, 0.21 mmol) in toluene (1 mL) was treated with dibutyltin(IV) oxide (58 mg, 0.23 mmol) and trimethylsilyl azide (75 μL, 0.57 mmol). The resulting mixture was heated to 100° C. for 16 hours and then cooled to room temperature and concentrated in vacuo. The residue was dissolved in ethyl acetate, treated with 1 N HCl aqueous and washed with brine. The organic layer was dried over anhydrous MgSO4, filtered and evaporated. The crude product was purified by C-18 reverse phase chromatography, eluting with a water and acetonitrile+0.1% TFA gradient. Yield=39 mg (35%). Method 3, Rt 3.07 min. MS (ESI) m/z 526.1 [M+H+].
- A stirring mixture of 3-[(R)-1-(o-chlorophenyl)ethoxycarbonylamino]-2-(p-bromophenyl)-4-chloro-2H-pyrazole [Example 18, Step 1] (227 mg, 0.5 mmol), 2:1 v/v mixture of toluene and ethanol (5 mL), 2M Na2CO3 aqueous solution (1.7 mL) and 4-(1-cyanocyclopropyl)phenylboronic acid (112 mg, 0.6 mmol) was degassed under N2 for 10 minutes and treated with Pd[Ph3P]4 (29 mg, 0.025 mmol). The resulting mixture was heated to 85° C. and stirred for 3 hours at that temperature. The reaction mixture was cooled to room temperature, extracted with ethyl acetate (50 mL) and washed with 1N HCl aqueous and brine. The organic layer was dried over anhydrous MgSO4, filtered and evaporated. The crude product was purified by silica-gel chromatography, eluting with a hexanes and ethyl acetate gradient. Product obtained as a white solid. Yield=189 mg (73%). Method 3, Rt 3.48 min. MS (ESI) m/z 517.3 [M+H+].
- A stirred solution containing 3-[(R)-1-(o-chlorophenyl)ethoxycarbonylamino]-4-chloro-2-[4′-(1-cyanocyclopropyl)-4-biphenylyl]-2H-pyrazole [Example 23, Step 1] (108 mg, 0.21 mmol) in toluene (1 mL) was treated with dibutyltin(IV) oxide (58 mg, 0.23 mmol) and trimethylsilyl azide (75 μL, 0.57 mmol). The resulting mixture was heated to 100° C. for 16 hours and then cooled to room temperature and concentrated in vacuo. The residue was dissolved in ethyl acetate, treated with 1 N HCl aqueous and washed with brine. The organic layer was dried over anhydrous MgSO4, filtered and evaporated. The crude product was purified by C-18 reverse phase chromatography, eluting with a water and acetonitrile+0.1% TFA gradient. Yield=36 mg (31%). Method 3, Rt 3.18 min. MS (ESI) m/z 560.1 [M+H+].
- (R)-1-(4′-(4-chloro-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-1-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid [Example 4] (200 mg, 0.40 mmol) was co-evaporated twice with pyridine (10 mL) and dissolved in DMF (4.5 mL). The resulting solution was treated with pyridine (300 μL, 3.75 mmol) followed by dropwise addition of pentafluorophenyl trifluoroacetate (125 μL, 0.71 mmol). After 2 hours at room temperature, LCMS analysis indicates complete conversion to the corresponding pentafluorophenyl ester. The reaction mixture was diluted with ethyl acetate (30 mL) and treated with saturated NaHCO3 aqueous solution. The organic layer was separated, washed with brine, dried over anhydrous MgSO4, filtered and evaporated. The residue was taken up in DMF (4 mL) and treated with sodium hydrogen cyanamide (77 mg, 1.2 mmol) at room temperature overnight. Next morning, reaction was diluted with ethyl acetate (30 mL) and treated with saturated NaHCO3 aqueous solution. The organic layer was separated, washed with brine, dried over anhydrous MgSO4, filtered and evaporated. The product was purified by preparative thin layer chromatography, eluting with a 90:10 v/v mixture of dichloromethane and methanol, respectively. Yield=36 mg (32%). Method 3, Rt 2.84 min. MS (ESI) m/z 526.5 [M+H+].
- 1-(p-Bromophenyl)cyclopropanecarboxylic acid (2.41 g, 10.0 mmol) was suspended in dichloromethane (34 mL) and treated with a catalytic amount of N,N-dimethylformamide (2 drops) at room temperature. The reaction mixture was cooled to 0° C. with an ice/water bath. Oxalyl chloride (1.75 mL, 20.0 mmol) was added dropwise and the resulting mixture was stirred at 0° C. for 15 minutes and at room temperature for 30 minutes and then heated to reflux for 2 hours. An aliquot was dissolved in methanol and subjected to LCMS analysis, which indicated complete conversion to the corresponding acid chloride. The volatiles were removed under reduced pressure to yield the crude acid chloride as a white solid which was used immediately. The acid chloride (2.60 g, 10.0 mmol) was dissolved in DMF (30 mL) and a 10 mL aliquot of this solution was taken (3.3 mmol) and treated with sodium hydrogen cyanamide (640 mg, 10.0 mmol). The resulting mixture was stirred at room temperature overnight. The reaction was diluted with ethyl acetate, washed with 1 N HCl aqueous and brine. The organic layer was dried over anhydrous MgSO4, filtered and evaporated. The crude solid product was used in the next step without any further purification. Product obtained as a solid. Yield=650 mg (74%). Method 3, Rt 2.68 min. MS (ESI) m/z 267.3 [M+H+].
- 1-(4-bromophenyl)-N-cyanocyclopropane-1-carboxamide [Example 25, Step 1](650 mg, 2.44 mmol) was dissolved in 1,4-dioxane (12 mL), treated with bis(pinacolato)diboron (1.94 g, 7.33 mmol), KOAc (720 mg, 7.33 mmol) and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (193 mg, 0.32 mmol). The resulting mixture was heated to 100° C. overnight and then cooled to room temperature, filter through a pad of CELITE and rinsed with methanol. The filtrate was concentrated in vacuo. The crude material was purified by preparative think layer chromatography on silica gel, eluting with a 1:1 v/v mixture of hexanes and ethyl acetate. The product is a white solid. Yield=400 mg (53%). Method 3, Rt 2.86 min. MS (ESI) m/z 313.6 [M+H+].
- A stirred suspension of 3-[(R)-1-(o-chlorophenyl)ethoxycarbonylamino]-2-(p-bromophenyl)-4-chloro-2H-pyrazole [Example 18, Step 1] (127 mg, 0.28 mmol), 1,4-dioxane (3 mL), 2 M aqueous solution of Na2CO3 (630 μL) and N-cyano-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropane-1-carboxamide [Example 25, Step 2] (106 mg, 0.34 mmol) was degassed under nitrogen for 10 minutes and treated with Pd[Ph3P]4 (46 mg, 0.04 mmol). The resulting mixture was immersed in an oil bath with stirring at 95° C. for 12 hours. The reaction was cooled, transferred to a separatory funnel and diluted with ethyl acetate (50 mL). The mixture was carefully treated with 1 N aqueous HCl solution (20 mL). The organic layer was separated, washed with brine, dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude residue was purified by preparative TLC plate (1000 μm), eluting with a 9:1 v/v dichloromethane/methanol mixture. The product was obtained as a white solid. Yield=18 mg (12%). HPLC (254 nm): Method 3, Rt 3.15 min. MS (ESI) m/z 560.5 [M+H+].
- A stirred suspension of (R)-[2-(4-bromo-phenyl)-4-fluoro-2H-pyrazol-3-yl]-carbamic acid 1-(2-chloro-phenyl)-ethyl ester [Example 15, Step 5] (88 mg, 0.2 mmol), 2:1 v/v toluene/ethanol (2 mL), 2 M aqueous solution of Na2CO3 (670 μL) and 1-[4-(dihydroxyboranyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid (45 mg, 0.20 mmol) was degassed under nitrogen for 10 minutes and treated with Pd[Ph3P]4 (12 mg, 0.01 mmol). The resulting mixture was immersed in an oil bath with stirring at 90° C. for 12 hours. The reaction was cooled, transferred to a separatory funnel and diluted with ethyl acetate (50 mL). The mixture was carefully treated with 1 N aqueous HCl solution (20 mL). The organic layer was separated, washed with brine, dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude residue was purified by preparative TLC plate (1000 μm), eluting with a 1:1 v/v hexanes/ethyl acetate mixture. The product was obtained as a white solid. Yield=40 mg (37%). HPLC (254 nm): Method 3, Rt 3.14 min. MS (ESI) m/z 538.3 [M+H+].
- A stirring mixture containing (R)-1-(4′-(5-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-4-fluoro-1H-pyrazol-1-yl)-2-fluoro-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid [Example 26, step 1] (107 mg, 0.2 mmol) THF (1 mL) and N-hydroxysuccinimide (23 mg, 0.2 mmol) was treated with N,N′-dicyclohexylcarbodiimide (41 mg, 0.2 mmol) at room temperature. The resulting mixture was stirred for 3 hours, then the separated solids were filtered and the filtrate solution was added to a stirring solution of sodium hydrogen cyanamide (38 mg, 0.6 mmol) in water (1 mL). The resulting mixture was stirred for 2 days at room temperature. The reaction mixture was diluted with ethyl acetate (30 mL) and treated with 0.1 N HCl aqueous to pH ˜3. The organic layer was separated, washed with brine, dried over anhydrous MgSO4, filtered and evaporated. The crude product was purified by preparative thin layer chromatography, eluting with a 90:10 v/v mixture of dichloromethane and methanol, respectively. Yield=36 mg (32%). Method 3, Rt 3.13 min. MS (ESI) m/z 561.9 [M+H+].
- A mixture containing 2-(p-bromophenyl)-2-methylpropionic acid (66 mg, 0.27 mmol), tetrahydroxydiboron (109 mg, 1.22 mmol), KOAc (26 mg, 1.22 mmol) in ethanol (3 mL) was degassed under N2 and then treated with XPhosPdG3 (6 mg, 0.007 mmol). This mixture was heated to 80° C. for 2 hours under magnetic stirring and then cooled to room temperature. This reaction was then treated sequentially with 3-[(R)-1-(o-chlorophenyl)ethoxycarbonylamino]-2-(p-bromophenyl)-2H-pyrazole-4-carbonitrile [Example 6, Step 1] (54 mg, 0.12 mmol), 2 M K2CO3 aqueous (270 μL) and XPhosPdG3 (2 mg, 0.0023). The resulting mixture was degassed with N2 for 5 minutes and then heated to 80° C. for 16 hours. The reaction was cooled to room temperature, filtered through a pad of CELITE and rinsed with ethanol. The filtrates were concentrated in vacuo and the residue was purified by preparative thin layer chromatography, eluting with a 70:30 v/v toluene and acetone, respectively. The product was obtained as a white solid (12 mg, 19%). Method 3, Rt 3.23 min. MS (ESI) m/z 529.5 [M+H+].
- 2-(p-Bromophenyl)-2-methylpropionic acid (1.22 g, 5.0 mmol) was dissolved in methanol (20 mL), cooled to −20° C. using ice water (2 parts) and salt (1 part). To this solution, thionyl chloride (1.45 mL, 20.0 mmol) was added dropwise. After completion of addition, the reaction was stirred for 15 minutes at −20° C. and then allowed to warm to room temperature over a period of 2 hours. LCMS indicated product formation. The reaction was concentrated in vacuo and the residue was partitioned between dichloromethane and an aqueous saturated Na2CO3 solution. The organic layer was dried over anhydrous MgSO4, filtered and evaporated to yield methyl 2-(p-bromophenyl)-2-methylpropionate (0.9 g, 3.5 mmol, 70%). This material was dissolved in 1,4-dioxane (20 mL), treated with bis(pinacolato)diboron (2.69 g, 10.1 mmol), KOAc (1.03 g, 10.5 mmol) and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (328 mg, 0.44 mmol). The resulting mixture was heated to 100° C. overnight and then cooled to room temperature, filter through a pad of CELITE and rinsed with methanol. The filtrate was concentrated in vacuo. Part of the crude material was purified by preparative think layer chromatography on silica gel, eluting with hexanes. The product is a white solid. Yield=153 mg. Method 3, Rt 3.37 min. MS (ESI) m/z 305.8 [M+H+].
- A stirring mixture of 3-[(R)-1-phenylethoxycarbonylamino]-2-(p-bromophenyl)-2H-pyrazole-4-carbonitrile [Example 5, Step 1] (58 mg, 0.14 mmol), 1,4-dioxane (2 mL), 2M Na2CO3 aqueous solution (315 μL) and methyl 2-methyl-2-[p-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propionate [Example 24, Step 1] (51 mg, 0.17 mmol) was degassed under N2 for 10 minutes and treated with Pd[Ph3P]4 (23 mg, 0.02 mmol). The resulting mixture was heated to 95° C. overnight. The reaction mixture was cooled to room temperature, filtered through a pad of CELITE and rinsed with methanol. The filtrates were concentrated in vacuo and the crude residue was purified directly by preparative thin layer chromatography, eluting with 70:30 v/v mixture of hexanes and ethyl acetate, respectively. Yield=20 mg (28%). Method 3, Rt 3.17 min. MS (ESI) m/z 509.3 [M+H+].
- Methyl 2-(4′-{5-[(R)-1-phenylethoxycarbonylamino]-4-cyano-1H-pyrazol-1-yl}-4-biphenylyl)-2-methylpropionate [Example 28, Step 1] (18 mg, 0.03 mmol) was dissolved in THF (1 mL) and treated with a 1 M LiOH aqueous solution (1 mL) and the resulting mixture was stirred at room temperature overnight. Reaction progress was monitored by thin layer chromatography (30% ethyl acetate in hexanes). The reaction was treated with 1 M aqueous HCl solution (5 mL) and the product was extracted with ethyl acetate. The organic layer was dried over anhydrous MgSO4, filtered and evaporated. The crude residue was purified by preparative thin layer chromatography, eluting with a 70:30 v/v mixture of toluene and acetone, respectively. The product was obtained as a white solid. Yield=15 mg (quant.). Method 3, Rt 2.93 min. MS (ESI) m/z 495.8 [M+H+].
- Compounds of Table 1 and derivatives thereof are prepared according to procedures outlined for compounds 1-28. The heterocyclic amines or esters required to assemble the corresponding carbamates were prepared based on methods described in citations 1-19.
- Certain pyrazole substitutions are prepared following construction of the appropriate aryl pyrazole (8, Scheme 1). Direct flurorination, chlorination or trifluoromethylation provides arylbromide (9), intermediates suitable for further modification to compounds of the present invention according to procedures described for examples 1-28.
- Alternatively, Core pyrazole (8) may be prepared according to the approach depicted in Scheme 2:
- Where the requirement for RC as cyano is concerned, the corresponding core cyanopyrazole (9) is prepared according to the steps described in Scheme 3:
- Binding affinity of compounds of Formula I-III were determined based on their ability to displace tritiated lysophosphatidic acid ([3H]-LPA) from CHO cells expressing LPA1R in a protocol similar to that described in reference 17. In a 96 well format, CHO cells expressing human LPA1R [Cerep] were treated with [3H]-LPA (2 nM). Test compounds were added in increasing concentration to each well and incubated at room temperature for 90 minutes. At this time the plates were washed and the wells counted for radioactivity. Results were compared to a control in which cells were treated with [3H]-LPA in the presence of 10 μM unlabeled LPA. The specific ligand binding to the receptors was defined as the difference between the total binding and the nonspecific binding determined in the presence of an excess of unlabeled ligand. The results were expressed as a percent of control specific binding ((measured specific binding/control specific binding)×100) and as a percent inhibition of control specific binding (100-((measured specific binding/control specific binding)×100)) obtained in the presence of the test compounds. The IC50 value (concentration causing a half-maximal inhibition of control specific binding) and Hill coefficient (nH) were determined by non-linear regression analysis of the competition curve generated with mean replicate values using Hill equation curve fitting (Y=D+[(A−D)/(1+(C/C50)nH)], where Y=specific binding, D=minimum specific binding, A=maximum specific binding, C=compound concentration, C50=IC50, and nH=slope factor). This analysis was performed using a software developed at Cerep (Hill software) and validated by comparison with data generated by the commercial software SigmaPlot® 4.0 for Windows® (© 1997 by SPSS Inc.). The inhibition constant (Ki) was calculated using the Cheng Prusoff equation (Ki=IC50/(1+(L/KD)), where L=concentration of radioligand in the assay, and KD=affinity of the radioligand for the receptor). A scatchard plot was used to determine the Kd.
- Inhibition of LPA-stimulated Ca2+ flux was used to assess compound potency using FLIPR technology in a 96 well plate format. The assay buffer used was a modified Hanks Balanced Salt Solution (HBSS) where HBSS was supplemented to contain 20 mM HEPES and 2.5 mM Probenecid at pH7.4 (Millipore, GPCR Profiler®). LPA1R expressing cells (Millipore) were plated and prepared 24 hours prior to assay of test articles. Ca2+ ion flux was assessed from fluorescence of a Fluo-based No Wash Ca2+ dye. Antagonist data are generated from plates with LPA concentrations sufficient to generate 80% efficacy [EC80]. Percentage inhibition was calculated from a reduction of efficacy according to concentration of compounds of Formula I-VI. For dose responses the inhibition data was used to calculate compound IC50.
- The agonist assay was conducted on a FLIPRTETRA instrument where the test compound(s), vehicle controls, and reference agonist were added to the assay plate after a fluorescence baseline was established. The agonist assay was a total of 180 seconds and was used to assess each compound's ability to activate each GPCR assayed. Upon completion of the agonist assay, the assay plate was removed from the FLIPRTETRA and incubated at 25° C. for seven (7) minutes. After the incubation period, the assay plate was placed back in the FLIPRTETRA and the antagonist assay was initiated.
- Antagonist Assay: Using EC80 potency values determined during the agonist assay, all pre-incubated sample compound wells were challenged with EC80 concentration of reference agonist after establishment of a fluorescence baseline. The antagonist assay was conducted using the same assay plate that was used for the agonist assay. The antagonist assay was conducted on a FLIPRTETRA instrument where 9 vehicle controls and EC80 concentration of reference agonist were added to appropriate wells. The antagonist assay was a total of 180 seconds and was used to assess each compound's ability to inhibit each GPCR assayed.
- Data Processing: All assay plate data were subjected to appropriate baseline corrections. After baseline corrections were applied, maximum fluorescence values were exported and data processed to calculate percentage activation (relative to Emax reference agonist and vehicle control values), percentage inhibition (relative to EC80 and vehicle control values), and additional statistical values (i.e. Z′, percentage variation between replicate data values) to assess the quality of each plate. Where assay plate data were rejected, additional experiments were conducted. All dose response curves were generated using GraphPad Prism. The curves were fit by utilizing “Sigmoidal Dose Response (Variable Slope)” equation where the bottom parameter was fixed to “0.” Where appropriate, the top parameter was fixed to “100” to better predict potency values when a full curve was not generated by the concentrations assayed.
- Antagonist activity data for representative compounds prepared according to the synthetic methods disclosed herein are presented in Table 2.
-
TABLE 2 In vitro biological data for representative compounds of Formula I-III Unless otherwise noted, compounds that were tested had an IC50 of less than 50 μM in the LPA1R Ca2+ flux functional assay. LPA1 R LPA1 R Antagonist Example Antagonist Compound Activity Number Activity 1 A 15 A 2 A 16 A 3 A 17 A 4 A 18 A 5 A 19 A 6 A 20 A 7 A 21 C 8 A 22 A 9 A 23 C 10 A 24 C 11 A 25 C 12 A 26 A 13 A 27 A 14 A 28 A - Unless otherwise noted, compounds that were tested had an IC50 of less than 50 μM in the LPA1R Ca2+ flux functional assay. A=less than 0.3 μM; B=greater than 0.3 μM and less than 1 μM; C=greater than 1 μM and less than 50 μM; D=greater than 50 μM
-
- Menozzi G, Mosti L, Schenone P, Donnoli D, Schiariti F, Marmo E. (1990). 1-phenyl-1H-pyrazole derivatives with antiinflammatory, analgesic and antipiretic activities. Farmaco 45(2):167-86.
- Pinto D J, Orwat M J, Wang S, Fevig J M, Quan M L, Amparo E, Cacciola J, Rossi K A, Alexander R S, Smallwood A M, Luettgen J M, Liang L, Aungst B J, Wright M R, Knabb R M, Wong P C, Wexler R R, Lam P Y (2001). Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 44(4):566-78.
- Hanzlowsky A, Jelencic B, Recnik S, Svete J, Golobic A, Stanovnik B (2003). Regioselective synthesis of ethyl pyrazolecarboxylates from ethyl 3-[(dimethylamino)methylidene]pyruvate and diethyl 3-[(dimethylamino)methylidene]-2-oxosuccinate. Isolation of ethyl 4,5-dihydro-1-heteroaryl-5-hydroxy-1H-pyrazole-5-carboxylates as stable intermediates in the pyrazole ring formation. Journal of Heterocyclic Chemistry 40, 3, 487-498.
- Bell M G, Doti R A, Genin M J, Lander P A, Ma T, Manninen P R, Ochoada J M, Qu F, Stelzer L S, Stites R E, Warshawsky A M (2007). FXR Agonists, WO2007/140183, 2007, A1.
- Magalhaes, Franko N, Annunziato G, Welch M, Dolan S K, Bruno A, Mozzarelli A, Armao S, Jirgensons A, Pieroni M, Costantino G, Campanini B (2018). Discovery of novel fragments inhibiting O-acetylserine sulphhydrylase by combining scaffold hopping and ligand-based drug design. J Enzyme Inhib Med Chem 33(1):1444-1452.
- Lahm G P, Selby T P (2004). Substituted heterocyclic phthalic acid diamide arthropodicides. US2004/63738 A1.
- Guerrini G, Ciciani G, Cambi G, Bruni F, Selleri S, Besnard F, Montali M, Martini C, Ghelardini C, Galeotti N, Costanzo A (2007). Novel 3-iodo-8-ethoxypyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide as promising lead for design of alpha5-inverse agonist useful tools for therapy of mnemonic damage. Bioorg Med Chem 15(7):2573-86.
- Guerrini G, Ciciani G, Bruni F, Selleri S, Guarino C, Melani F, Montali M, Daniele S, Martini C, Ghelardini C, Norcini M, Ciattini S, Costanzo A (2010). New fluoro derivatives of the pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide system: evaluation of fluorine binding properties in the benzodiazepine site on γ-aminobutyrric acid type A (GABA(A)) receptor. Design, synthesis, biological, and molecular modeling investigation. J Med Chem 53(21):7532-48.
- Banks R E, Mohialdin-Khaffaf S N, Lal G S, Sharif I, Syvret R G (1992). 1-Alkyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane salts: a novel family of electrophilic fluorinating agents. J. Chem. Soc., Chem. Commun 8, 595-596.
- Morimoto H, Tsubogo T, Litvinas N D, Hartwig J F (2011). A broadly applicable copper reagent for trifluoromethylations and perfluoroalkylations of aryl iodides and bromides. Angew Chem Int Ed Engl 50(16):3793-8.
- Menozzi G, Mosti L, Schenone P (1987). Reaction of 2-dimethylaminomethylene-1,3-diones with dinucleophiles. VI. Synthesis of ethyl or methyl 1,5-disubstituted 1H-pyrazole-4-carboxylates. Journal of Heterocyclic Chemistry, 24, 6, 1669-1675.
- Luconi L, Rossin A, Motta A, Tuci G, Giambastiani G (2013). Group IV organometallic compounds based on dianionic “pincer” ligands: synthesis, characterization, and catalytic activity in intramolecular hydroamination reactions. Chemistry 19(15):4906-21.
- Stoermer M (1907). Justus Liebigs Annalen der Chemie, vol. 352p. 333.
- Claisen R (1894). Justus Liebigs Annalen der Chemie, vol. 278p. 295.
- Peretto I, Radaelli S, Parini C, Zandi M, Raveglia L F, Dondio G, Fontanella L, Misiano P, Bigogno C, Rizzi A, Riccardi B, Biscaioli M, Marchetti S, Puccini P, Catinella S, Rondelli I, Cenacchi V, Bolzoni P T, Caruso P, Villetti G, Facchinetti F, Del Giudice E, Moretto N, Imbimbo B P (2005). Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion. J Med Chem 48(18):5705-20.
- Huang A, Moretto A, Janz K, Lowe M, Bedard P W, Tam S, Di L, Clerin V, Sushkova N, Tchernychev B, Tsao D H, Keith J C, Shaw G D, Schaub R G, Wang Q, Kaila N (2010). Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury. J Med Chem 53(16):6003-17.
- Molloy J J, Law R P, Fyfe J W, Seath C P, Hirst D J, Watson A J. A modular synthesis of functionalised phenols enabled by controlled boron speciation. Org Biomol Chem 13(10):3093-102.
- Qian Y, Hamilton M, Sidduri A, Gabriel S, Ren Y, Peng R, Kondru R, Narayanan A, Truitt T, Hamid R, Chen Y, Zhang L, Fretland A J, Sanchez R A, Chang K C, Lucas M, Schoenfeld R C, Laine D, Fuentes M E, Stevenson C S, Budd D C (2012). Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts. J Med Chem 55(17):7920-39.
- An S, Dickens M A, Bleu T, Hallmark O G, Goetzl E J (1997). Molecular cloning of the human Edg2 protein and its identification as a functional cellular receptor for lysophosphatidic acid. Biochem Biophys Res Commun 231(3):619-22.
Claims (22)
1. A compound having the structure of Formula I
or a pharmaceutically acceptable salt thereof,
wherein RA is —CO2H, tetrazolyl, —C(═O)NH2, —C(═O)NHRB, —CONHCN, —C(═O)NHSO2RB or —C(═O)NHCH2CH2SO3H;
RB is a substituted or unsubstituted C1-C4 alkyl;
L1 is a substituted or unsubstituted saturated C1-C6 alkylene, or L1 is —CH2—,
or dimethylmethane;
A1 is N or C;
Ring A has the structure of one of:
RC is —CN, —F, —Cl, or C1-C4 fluoroalkyl;
RD is —N(RF)—C(═O)XCH(RG)—CY, wherein X is O and CY is unsubstituted phenyl or Phenyl substituted with one RH:
RE, RF and RG independently are —H or saturated C1-C4 alkyl or RE and RF independently are —H or saturated C1-C4 alkyl and one RG is saturated —C1-C4 alkyl and is taken together with the RH phenyl moiety of the Ring A RD substituent and the carbon atom to which RG and said phenyl moiety is attached to define a substituted or unsubstituted carbocycle, and the other RG, if present, is as defined for RE; and
each RH is independently absent, a halogen, or substituted or unsubstituted saturated C1-C4 alkyl.
2. The compound according to claim 1 , wherein:
RA is tetrazolyl
—C(═O)NH2, —CONHCN or —C(═O)NHSO2RB;
L1 is —CH2—,
or dimethylmethane;
in the ring
RH is absent, a halogen, or —CH3;
in the ring
A1 is C or N and RH is —H;
Ring A has the structure of
RH is absent or a halogen.
4. (canceled)
6. (canceled)
8. (canceled)
10. The compound according to claim 9 , wherein the compound is (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-carbamoylcyclopropyl)-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate.
12. The compound according to claim 11 , wherein the compound is (R)-1-(2-chlorophenyl)ethyl (4-fluoro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (4-fluoro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-chloro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (4-chloro-1-(4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, or (R)-1-(2-chlorophenyl)ethyl (4-fluoro-1-(4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate,
14. The compound according to claim 13 , wherein the compound is (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-chloro-1H-pyrazol-5-yl)carbamate or (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-chloro-1H-pyrazol-5-yl)carbamate.
16. The compound according to claim 15 wherein the compound is (R)-1-phenylethyl (4-chloro-1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-chloro-1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, or (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(cyanocarbamoyl)cyclopropyl)-2′-fluoro-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate.
17. The compound according to claim 2 wherein the compound is (R)-1-phenylethyl (4-chloro-1-(4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate.
18. The compound according to claim 1 , wherein RG is in an R or S configuration.
19. A pharmaceutical composition comprising:
the compound according to claim 1 ; and
at least one pharmaceutically acceptable excipient.
20. A method for treating a lysophosphatidic acid-dependent disease or condition in a subject in need thereof, the method comprising:
administering to the subject a therapeutically effective amount of the compound according to claim 1 .
21. The method according to claim 20 , wherein the lysophosphatidic acid-dependent disease or condition is diabetic nephropathy or nonalcoholic steatohepatitis (NASH).
22. A compound according to claim 1 , selected from the group consisting of (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-carbamoylcyclopropyl)-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-fluoro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (4-fluoro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-chloro-1-(2′-fluoro-4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (4-chloro-1-(4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (4-fluoro-1-(4′-(1-((methylsulfonyl)carbamoyl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-fluoro-1H-pyrazol-5-yl)carbamate, (R)-1-phenylethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-chloro-1H-pyrazol-5-yl)carbamate, (R)-1-(2-chlorophenyl)ethyl (1-(4′-(1-(1H-tetrazol-5-yl)cyclopropyl)-[1,1′-biphenyl]-4-yl)-4-chloro-1H-pyrazol-5-yl)carbamate, 3-[(R)-1-Phenylethoxycarbonylamino]-4-chloro-2-{4′-[1-(cyanoamino)carbonylcyclopropyl]-4-biphenylyl}-2H-pyrazole, 3-[(R)-1-(o-Chlorophenyl)ethoxycarbonylamino]-4-chloro-2-{4′-[1-(cyanoamino)carbonylcyclopropyl]-4-biphenylyl}-2H-pyrazole, and 3-[(R)-1-(o-Chlorophenyl)ethoxycarbonylamino]-2-{4′-[1-(cyanoamino)carbonylcyclopropyl]-2′-fluoro-4-biphenylyl}-4-fluoro-2H-pyrazole.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/015,289 US20230286928A1 (en) | 2013-03-15 | 2019-06-18 | Heterocyclic compounds useful in the treatment of disease |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361801426P | 2013-03-15 | 2013-03-15 | |
US201361801231P | 2013-03-15 | 2013-03-15 | |
US201361827409P | 2013-05-24 | 2013-05-24 | |
US16/010,755 US10526298B2 (en) | 2013-03-15 | 2018-06-18 | Heterocyclic compounds useful in the treatment of disease |
US18/015,289 US20230286928A1 (en) | 2013-03-15 | 2019-06-18 | Heterocyclic compounds useful in the treatment of disease |
PCT/US2019/037749 WO2019246109A1 (en) | 2018-06-18 | 2019-06-18 | Heterocyclic compounds useful in the treatment of disease |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/010,755 Continuation US10526298B2 (en) | 2013-03-15 | 2018-06-18 | Heterocyclic compounds useful in the treatment of disease |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230286928A1 true US20230286928A1 (en) | 2023-09-14 |
Family
ID=51538557
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/776,954 Active US10000459B2 (en) | 2013-03-15 | 2014-03-17 | Heterocyclic compounds useful in the treatment of disease |
US16/000,283 Active US10570103B2 (en) | 2013-03-15 | 2018-06-05 | Heterocyclic compounds useful in the treatment of disease |
US16/010,755 Active US10526298B2 (en) | 2013-03-15 | 2018-06-18 | Heterocyclic compounds useful in the treatment of disease |
US18/015,289 Pending US20230286928A1 (en) | 2013-03-15 | 2019-06-18 | Heterocyclic compounds useful in the treatment of disease |
US16/784,486 Active 2035-01-04 US11427552B2 (en) | 2013-03-15 | 2020-02-07 | Heterocyclic compounds useful in the treatment of disease |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/776,954 Active US10000459B2 (en) | 2013-03-15 | 2014-03-17 | Heterocyclic compounds useful in the treatment of disease |
US16/000,283 Active US10570103B2 (en) | 2013-03-15 | 2018-06-05 | Heterocyclic compounds useful in the treatment of disease |
US16/010,755 Active US10526298B2 (en) | 2013-03-15 | 2018-06-18 | Heterocyclic compounds useful in the treatment of disease |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/784,486 Active 2035-01-04 US11427552B2 (en) | 2013-03-15 | 2020-02-07 | Heterocyclic compounds useful in the treatment of disease |
Country Status (16)
Country | Link |
---|---|
US (5) | US10000459B2 (en) |
EP (1) | EP2988743B1 (en) |
JP (3) | JP6482086B2 (en) |
KR (1) | KR102090231B1 (en) |
CN (3) | CN105142635B (en) |
AU (3) | AU2014232383B2 (en) |
BR (2) | BR112015023267B1 (en) |
CA (1) | CA2906931C (en) |
DK (1) | DK2988743T3 (en) |
EA (1) | EA033923B1 (en) |
ES (1) | ES2855173T3 (en) |
HK (1) | HK1221167A1 (en) |
MX (2) | MX2015013303A (en) |
PT (1) | PT2988743T (en) |
SG (3) | SG11201507459YA (en) |
WO (1) | WO2014145873A2 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019246109A1 (en) * | 2018-06-18 | 2019-12-26 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
DK2988743T3 (en) * | 2013-03-15 | 2021-03-01 | Epigen Biosciences Inc | HETEROCYCLIC COMPOUNDS WHICH MAY BE USED FOR DISEASE TREATMENT |
US20180360803A1 (en) * | 2015-11-20 | 2018-12-20 | Ube Industries, Ltd. | Pharmaceutical composition for treatment or prevention of nash |
KR102292989B1 (en) * | 2017-03-29 | 2021-08-26 | 재단법인 아산사회복지재단 | Composition for preventing and treating nonalcoholic steatohepatitis by targeting S1PR4 |
EP3728222B1 (en) * | 2017-12-19 | 2023-03-29 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azines as lpa antagonists |
US11319309B2 (en) | 2017-12-19 | 2022-05-03 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azines as LPA antagonists |
ES2942767T3 (en) | 2017-12-19 | 2023-06-06 | Bristol Myers Squibb Co | Isoxazole azoles of cyclohexylic acid as LPA antagonists |
JP7274486B6 (en) | 2017-12-19 | 2024-02-15 | ブリストル-マイヤーズ スクイブ カンパニー | Triazole N-linked carbamoylcyclohexylate as an LPA antagonist |
JP7212047B2 (en) * | 2017-12-19 | 2023-01-24 | ブリストル-マイヤーズ スクイブ カンパニー | Cyclohexylate Pyrazole Azoles as LPA Antagonists |
CN112041302A (en) * | 2017-12-19 | 2020-12-04 | 百时美施贵宝公司 | Pyrazole O-linked carbamoylcyclohexanoic acids as LPA antagonists |
WO2019126099A1 (en) * | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
EA202091500A1 (en) | 2017-12-19 | 2020-09-14 | Бристол-Маерс Сквибб Компани | Pyrazole N-Bonded Carbamoylcyclohexyl Acids as LPA Antagonists |
US11180488B2 (en) | 2017-12-19 | 2021-11-23 | Bristol-Myers Squibb Company | Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists |
AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
JOP20210298A1 (en) | 2019-05-14 | 2023-01-30 | Provention Bio Inc | Methods and compositions for preventing type 1 diabetes |
US20240122934A1 (en) * | 2019-10-16 | 2024-04-18 | University Of South Florida | Compositions and methods of treatment for inhibiting capillary tube regression |
US11548871B2 (en) | 2019-11-15 | 2023-01-10 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof |
AU2021282986B2 (en) | 2020-06-03 | 2024-03-07 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
TWI838626B (en) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa receptor antagonists and uses thereof |
IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for preventing type 1 diabetes |
US20230250093A1 (en) * | 2020-07-16 | 2023-08-10 | Chiesi Farmaceutici S.P.A. | Amido cyclohexane acid derivatives as lpa receptor inhibitors |
CN116669727A (en) * | 2020-08-11 | 2023-08-29 | 唯久生物有限公司 | Triazole-pyridinyl substituted azacyclohexylacetic acid compounds as LPA receptor antagonists |
CA3218917A1 (en) | 2021-05-11 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
AU2022405082A1 (en) | 2021-12-08 | 2024-07-11 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
WO2024112895A1 (en) * | 2022-11-24 | 2024-05-30 | Lhotse Bio, Inc. | Compounds and compositions for treating conditions associated with lpa receptor activity |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO2308B1 (en) | 1999-05-31 | 2005-09-12 | اف. هوفمان- لاروش أيه جي | 5-phenyl purinidine derivatives |
TWI288136B (en) * | 2000-02-18 | 2007-10-11 | Kirin Brewery | Novel isoxazole and thiazole compounds and use thereof as drugs |
EP1364659B1 (en) | 2001-02-08 | 2009-11-11 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
CA2487315A1 (en) | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
BRPI0411221A (en) | 2003-06-11 | 2006-07-18 | Sankyo Co | compound, medicament, methods for inhibiting the production of inflammatory cytokines, and for the prevention or treatment of diseases associated with inflammatory cytokines, method for treating or alleviating fever, pain and / or inflammation, and methods for the prevention or treatment of arthritis. rheumatoid, osteoarthritis, septic disease, psoriasis, crohn's disease, ulcerative colitis, diabetes mellitus or hepatitis |
WO2005012269A1 (en) | 2003-08-05 | 2005-02-10 | Ajinomoto Co., Inc. | Novel azole compound |
US7390835B2 (en) | 2003-10-30 | 2008-06-24 | Merck & Co., Inc. | Aralkyl amines as cannabinoid receptor modulators |
PL1732892T3 (en) | 2004-03-26 | 2009-03-31 | Hoffmann La Roche | Tetrahydrocarbazoles and derivatives |
EP2522670A1 (en) | 2004-04-07 | 2012-11-14 | Takeda Pharmaceutical Company Limited | Heterocyclic CRF receptor antagonists |
AU2006261841B8 (en) * | 2005-06-27 | 2012-12-06 | Exelixis Patent Company Llc | Pyrazole based LXR modulators |
TW200803740A (en) * | 2005-12-16 | 2008-01-16 | Du Pont | 5-aryl isoxazolines for controlling invertebrate pests |
EP2096111A1 (en) | 2006-11-20 | 2009-09-02 | Japan Tobacco Inc. | Pyrazoles and use thereof as drugs |
BRPI0817844B1 (en) | 2007-10-18 | 2018-10-23 | Ihara Chemical Ind Co | 3-alkoxy-1-phenylpyrazole derivatives, pesticide, agricultural or horticultural insecticide, acaricide, nematocide and method for the control of a plague |
US20110105491A1 (en) | 2008-07-07 | 2011-05-05 | Hamed Aissaoui | Thiazolidine compounds as orexin receptor antagonists |
GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
CN102574822A (en) * | 2009-08-04 | 2012-07-11 | 阿米拉制药公司 | Compounds as lysophosphatidic acid receptor antagonists |
JP4683154B2 (en) | 2009-08-12 | 2011-05-11 | 横浜ゴム株式会社 | Refrigerant transfer hose |
GB2474120B (en) * | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
WO2011159633A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Inhalable formulations of lysophosphatdic acid receptor antagonists |
US20130253019A1 (en) | 2010-06-15 | 2013-09-26 | John Howard Hutchinson | Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye |
WO2011159635A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions |
US20120031985A1 (en) | 2010-08-09 | 2012-02-09 | Terry Lien Do | Fault tolerant appliance |
BR112013014019A2 (en) | 2010-12-07 | 2016-09-13 | Amira Pharmaceuticals Inc | lysophosphatidic acid receptor antagonists and their uses |
CN107721940A (en) | 2010-12-07 | 2018-02-23 | 阿米拉制药公司 | Polycyclic LPA1Antagonist and its use |
WO2012100436A1 (en) * | 2011-01-30 | 2012-08-02 | Curegenix Inc. | Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof |
WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
EP2744807A4 (en) * | 2011-08-15 | 2015-03-04 | Intermune Inc | Lysophosphatidic acid receptor antagonists |
WO2013070879A1 (en) | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
US20140329871A1 (en) | 2011-12-04 | 2014-11-06 | Angion Biomedica Corp. | Small molecule anti-fibrotic compounds and uses thereof |
EA201491530A1 (en) | 2012-03-20 | 2015-07-30 | Серагон Фармасьютикалс, Инк. | MODULATORS OF ESTROGEN RECEPTORS AND THEIR APPLICATION |
PE20142448A1 (en) | 2012-06-20 | 2015-01-28 | Hoffmann La Roche | N-ALKYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS |
AU2013279513A1 (en) | 2012-06-20 | 2014-10-16 | F. Hoffmann-La Roche Ag | N-aryltriazole compounds as LPAR antagonists |
CA2869602A1 (en) | 2012-06-20 | 2013-12-27 | F. Hoffmann-La Roche Ag | Substituted pyrazole compounds as lpar antagonists |
EP2940013B1 (en) | 2012-12-28 | 2018-02-21 | Ube Industries, Ltd. | Halogen-substituted heterocyclic compound |
WO2014113485A1 (en) | 2013-01-15 | 2014-07-24 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
DK2988743T3 (en) * | 2013-03-15 | 2021-03-01 | Epigen Biosciences Inc | HETEROCYCLIC COMPOUNDS WHICH MAY BE USED FOR DISEASE TREATMENT |
WO2015066456A1 (en) | 2013-10-31 | 2015-05-07 | Bristol-Myers Squibb Company | Radioligands for imaging the lpa-1 receptor |
US10023554B2 (en) | 2014-06-27 | 2018-07-17 | Ube Industries, Ltd. | Halogen-substituted heterocyclic compound salt |
-
2014
- 2014-03-17 DK DK14762555.2T patent/DK2988743T3/en active
- 2014-03-17 KR KR1020157028061A patent/KR102090231B1/en active IP Right Grant
- 2014-03-17 BR BR112015023267-1A patent/BR112015023267B1/en active IP Right Grant
- 2014-03-17 JP JP2016503448A patent/JP6482086B2/en active Active
- 2014-03-17 EA EA201591607A patent/EA033923B1/en unknown
- 2014-03-17 PT PT147625552T patent/PT2988743T/en unknown
- 2014-03-17 MX MX2015013303A patent/MX2015013303A/en unknown
- 2014-03-17 US US14/776,954 patent/US10000459B2/en active Active
- 2014-03-17 EP EP14762555.2A patent/EP2988743B1/en active Active
- 2014-03-17 AU AU2014232383A patent/AU2014232383B2/en active Active
- 2014-03-17 SG SG11201507459YA patent/SG11201507459YA/en unknown
- 2014-03-17 WO PCT/US2014/030712 patent/WO2014145873A2/en active Application Filing
- 2014-03-17 SG SG10201803833WA patent/SG10201803833WA/en unknown
- 2014-03-17 CA CA2906931A patent/CA2906931C/en active Active
- 2014-03-17 ES ES14762555T patent/ES2855173T3/en active Active
- 2014-03-17 CN CN201480015333.XA patent/CN105142635B/en active Active
-
2016
- 2016-08-05 HK HK16109390.9A patent/HK1221167A1/en unknown
-
2018
- 2018-06-05 US US16/000,283 patent/US10570103B2/en active Active
- 2018-06-18 US US16/010,755 patent/US10526298B2/en active Active
-
2019
- 2019-02-07 JP JP2019020553A patent/JP6843903B2/en active Active
- 2019-04-17 AU AU2019202731A patent/AU2019202731B2/en active Active
- 2019-06-18 MX MX2020014300A patent/MX2020014300A/en unknown
- 2019-06-18 BR BR112020025927-6A patent/BR112020025927A2/en unknown
- 2019-06-18 CN CN201980047732.7A patent/CN112424174B/en active Active
- 2019-06-18 SG SG11202012656WA patent/SG11202012656WA/en unknown
- 2019-06-18 US US18/015,289 patent/US20230286928A1/en active Pending
- 2019-06-18 CN CN202410150847.1A patent/CN118290357A/en active Pending
- 2019-06-18 AU AU2019288275A patent/AU2019288275B2/en active Active
-
2020
- 2020-02-07 US US16/784,486 patent/US11427552B2/en active Active
-
2024
- 2024-04-03 JP JP2024059851A patent/JP2024084796A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019288275B2 (en) | Heterocyclic compounds useful in the treatment of disease | |
EP2606031B1 (en) | Autotaxin inhibitors and uses thereof | |
WO2012166415A1 (en) | Heterocyclic autotaxin inhibitors and uses thereof | |
JP7467361B2 (en) | Heterocyclic compounds useful in the treatment of diseases | |
RU2818246C2 (en) | Heterocyclic compounds used in treating disease | |
NZ751063A (en) | Heterocyclic compounds useful in the treatment of disease | |
NZ712889B2 (en) | Heterocyclic compounds useful in the treatment of disease | |
NZ751063B2 (en) | Heterocyclic compounds useful in the treatment of disease | |
EA038294B1 (en) | Heterocyclic compounds useful in the treatment of diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: EPIGEN BIOSCIENCES, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BEATON, GRAHAM;TUCCI, FABIO C.;RAVULA, SATHEESH B.;AND OTHERS;SIGNING DATES FROM 20240410 TO 20240418;REEL/FRAME:067581/0284 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |